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CHAPTER 1
INTRODUCTION

Please note that part of this chapter was taken from a book chapter titled
“Intracellular Delivery Considerations for RNAi Therapeutics” published in RNA
Interference from Biology to Therapeutics, K. A. Howard, Ed., Springer, New York 2012
[1]. The authors of the book chapter include Dr. Jing Li, Prof. David Oupicky and me.
Part of this chapter was also taken from a review titled “Recent advances in delivery of
drug-nucleic acid combinations for cancer treatment” published in the Journal of
Controlled Release [2]. The authors of the review include Dr. Jing Li, Yan Wang, Prof.
David Oupicky and me. All the authors agreed with including the work in this
dissertation.

1.1

Gene Therapy

1.1.1 Overview
The U.S. Food and Drug Administration defines gene therapy as “the use of
genetic material to treat, cure, or prevent a disease or medical condition”. Ever since the
first human gene transfer was approved in 1989 [3], the past two decades had
witnessed the fast development of gene therapy from preclinical to clinical studies for a
vast majority of diseases [4]. According to the data from Journal of Gene Medicine,
more than 1,800 clinical trials have been approved worldwide (Figure 1). Although the
field of gene therapy was under intense debate after the tragic death of Jesse Gelsinger
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in 1999 in a gene therapy clinical trial, recently, the field was able to show promises with
encouraging results in both pre-clinical and clinical studies [5].

Figure 1. Number of gene therapy clinical trials approved worldwide, from 1989 to
2013. (Source: The Journal of Gene Medicine)

To date, clinical trials of gene therapy have been performed in more than 30
countries, with representatives from all five continents. The gene types transferred are
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most frequently antigens, cytokines, tumor suppressors and suicide genes, which are
generally used for cancer treatment [6]. These categories contributed to the 64.2% of
clinical trials in gene therapy against cancer (Figure 2). Other major types of genes in
use including growth factors, which were transferred in 7.5% of clinical trials and are
mostly aimed at cardiovascular diseases; deficiency genes were used in 7.9 % of trials,
which are used for the treatment of monogenic diseases. In all, gene therapy holds
promise as a revolutionary approach for the treatment of various diseases.

Figure 2. Distribution of gene therapy clinical trials categorized by countries, disease
types, gene types and clinical phases.

1.1.2 Nucleic acids for gene therapy
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Diverse genetic materials can be used in gene therapy, with the major types
including nucleic acids such as DNA coding functional genes, and RNA interference.
Plasmid DNA is a high molecular weight, double-stranded DNA construct with unique
circular structure, which is commonly found in bacteria. It is physically separate from
chromosomal DNA in cell nuclei, and can replicate independently. Artificial plasmids can
be engineered as vectors carrying specific therapeutic genes for the expression in host
cells. Examples of plasmids encoding therapeutic genes include tumor necrosis factor–
related apoptosis-inducing ligand (TRAIL) gene against renal cell carcinoma, glioma
cells and human lung cancer cells [7-9], interleukin-12 (IL-12) gene against malignant
melanoma, renal cell carcinoma as well as human ovarian cancer [10-13], and p53
gene against human osteosarcoma, restenosis and endobronchial cancer [14-16]. More
recently, minicircle DNA was developed as an effective alternative to conventional
plasmid gene vectors. Conventional plasmid DNA contains bacterial backbone with
resistance gene sequences and immunogenic motifs, which represent a potential risk
for safe clinical application. The minicircle technology removes such sequences and
demonstrates improved gene transfection efficiency [17-20]. For instance, Wu and
coworkers investigated the antitumor effect of interferon (IFN)-γ gene on human
nasopharyngeal

carcinoma

using

minicircle

DNA

[21].

IFN-γ

minicircle

DNA

demonstrated 11 times higher gene expression in nasopharyngeal carcinoma xenograft
in mice, compared with the parental plasmids. Park et al. reported the application of
minicircle DNA encoding adiponectin gene as a treatment of diet-induced obesity in
mice. This strategy achieved a sufficient blood level of adiponectin in mice, whereas the
parental plasmids showed no effect on the adiponectin expression [22].
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Antisense oligodeoxynucleotides (AON) are short single-stranded segments of
DNA that upon cellular internalization can selectively hybridize with the complementary
mRNA and induce translational arrest of the target protein [23, 24]. AON demonstrate
promise in gene therapy towards various diseases such as inherited neurodegenerative
diseases, dysregulation of hepatic lipid metabolism and cancer [25-27]. For example,
treatment with antisense oligonucleotides targeting superoxide dismutase 1 significantly
slowed disease progression in a model of amyotrophic lateral sclerosis [28].
Small interfering RNA (siRNA) is a class of double-stranded RNA molecules with
20-25 nucleotides in length. siRNA conducts its silencing function in the cytoplasm by
incorporating into RNA-induced silencing complex (RISC). RISC further pairs with the
complementary mRNA molecule and leads to the cleavage of mRNA. The process is
known as post-transcriptional gene silencing. Ever since the first discovery of siRNAmediated gene silencing in 1998 [29], siRNA has been vigorously studied in the field of
gene therapy. Therapeutics based on siRNA have emerged for the treatment of cancer,
infectious diseases, and other diseases associated with specific gene disorders [30].
Current targets in clinical trials with siRNA include apolipoprotein B (ApoB) in patients
with hypercholesterolemia [31]; vascular endothelial growth factor (VEGF) in solid
tumors, diabetic macular edema and macular degeneration; polo-like kinase 1 (PLK1) in
liver tumors [32].
Small hairpin RNA (shRNA) is a class of RNA interference (RNAi) agents with
tight hairpin turn that can be cleaved by Dicer enzyme to generate 21-23 nucleotides
long siRNA. shRNA can be introduced into host cells via plasmid vectors and further
integrated into the host genome. Unlike siRNA, shRNA is usually delivered as the
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relative gene inserted in plasmid DNA, which undergoes transcription process to form
shRNA [33]. In 2002, Xia and coworkers published the first use of shRNA expressed in
viral vector to achieve endogenous gene silencing and applied the strategy to a model
system

of

polyglutamine

diseases

and

demonstrated

reduced

polyglutamine

aggregation in cells [34]. More therapeutic strategies based on shRNA emerged
recently. Examples include clinical trials of FANGTM vaccine for the treatment of solid
tumors, which contains furin bifunctional shRNA [35]. Orally delivered shRNA against βcatenin for the treatment of familial adenomatous polyposis is currently under Phase II
study [36].
Other types of nucleic acids, such as mRNA, microRNA (miRNA) or antagomirs,
are also under investigation as suitable components for gene therapy. Although it was
generally accepted that mRNA is too unstable to be used for gene therapy, recent
advances enabled the mRNA-mediated transfection and demonstrated its advantages
as an alternative to plasmid DNA (pDNA) [37]. In addition, new members in the RNAi
therapy include miRNA and antagomirs. The miRNA is a single strand RNA generated
during endogenous transcription [38]. It is about 22 nucleotides in length, firstly
transcribed in the nucleus as long primary transcripts (pri-miRNA), which can be
processed to form mature miRNA by Dicer [39]. Depending on the level of
complementarity with mRNA, miRNA may cause mRNA cleavage or it may bind
imperfectly with the untranslated regions of mRNA, leading to translational repression.
Opposing gene regulation can be achieved by antagomirs, which are single-stranded
RNAs that can bind endogenous mature miRNA and block the function of miRNAmediated silencing [40, 41].
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1.1.3 Gene delivery vectors
Gene therapy shows promise for various diseases but its success requires
efficient gene delivery systems. There are two major classes of delivery systems: viral
vectors and synthetic nonviral vectors. Viral vectors that are capable of delivering
nucleic acids into host cells can be used for gene therapy. Due to their long natural
evolution, viruses typically exhibit higher delivery efficiency when compared with
synthetic vectors. The most frequently used viral vectors are adenovirus (Ad), adenoassociated virus (AAV), retrovirus (RV), and lentivirus (LV). Ad and AAV are commonly
used to deliver genes encoding therapeutic proteins, or encoding shRNA and miRNA.
Neither Ad nor AAV integrates into the host genome, but they maintain their transient
forms in the nucleus [42]. These virus types are able to infect both dividing and nondividing cells. Both RVs and LVs can be integrated into the host genome but the major
limitation of RV is their inability to infect non-dividing cells [43]. On the other hand, one
advantage of LVs is that they favor integration into introns of active transcriptional units,
which reduces the risk of insertional oncogenesis. Although viral vectors demonstrated
effective gene delivery efficiency and are used in gene therapy clinical trials, their major
drawbacks are safety concerns related to insertion mutagenesis and immunogenicity.
Difficulties related to production scale-up are also a concern.
Compared with viral vectors, the synthetic delivery systems have several
advantages, such as easier chemical modification, easier large-scale production and
lower biological safety concerns associated with genome manipulations and host
immunogenicity. Most studied synthetic vectors include polycations and cationic lipids.
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Polycations bind with negatively charged nucleic acids and self-assemble via
electrostatic interactions into nano-sized complexes termed polyplexes. Synthetic and
natural polycations have been explored extensively for gene delivery, including
polyethylenimine (PEI), poly(amido amine)s (PAA), cyclodextrins, and chitosan. Cationic
lipids are amphiphilic molecules with a hydrophobic tail of long hydrocarbon chains
(usually two alkyl chains) and a hydrophilic head of a charged group (e.g., quaternary
amine) [44]. Plethora of cationic lipids is commercially available. Commonly used lipids
for

gene

(DOTMA),

delivery

include

1,2-di-O-octadecenyl-3-trimethylammonium

1,2-dioleoyl-3-trimethylammonium

propane

(DOTAP),

propane

1,2-dioleoyl-3-

phosphatidylcholine (DOPC) and cholesterol [45]. Moreover, many commercial vectors
for gene delivery are cationic lipids, including Lipofectamine, RNAifect and
Oligofectamine. Upon hydration, the amphiphilic cationic lipids can spontaneously form
complexes with nucleic acid molecules termed lipoplexes, or the lipids can selfassemble into lamellar vesicular structures as liposomes that can encapsulate precondensed nucleic acids (major precondensing agents are polycationic molecules such
as polyamines and peptides with cationic amino acids) [46-49].

1.2

Combination Drug-Nucleic Acids Therapy in Cancer
As mentioned above, the major area of gene therapy application is cancer.

Although gene therapy alone showed promise in treating cancer, most successful
treatments rely on combination therapies. Heterogeneity of cancer and involvement of
multiple pathways during tumor growth, progression and metastasis means that
therapies that use only a single agent are unlikely to succeed. Most common types of
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combination approaches include combinations of surgery with chemotherapy or
radiation therapy, combinations of multiple chemotherapeutics, combinations of
chemotherapy with immunotherapy, and more recently also drug-gene combinations
[50]. The main rationale for combination therapies is to target different disease
pathways to decrease the likelihood of developing drug resistance as well as to
synergistically enhance activity of individual treatments and improve target selectivity
[51]. Novel approaches that use drug-nucleic acid combinations in cancer treatment are
described in the following sections.

1.2.1 Combining chemotherapy with nucleic acids to overcome multidrug resistance
(MDR)
Drug resistance is one of the major issues causing failure and relapse of many
tumors, which makes it a therapeutic target for combination cancer treatment. A typical
approach to overcome multi-drug resistance (MDR) is to utilize RNAi to silence the
expression of efflux transporter while at the same time giving an appropriate anticancer
drug. In many cases, MDR is highly associated with P-glycoprotein (Pgp), also known
as multidrug resistance protein 1 (MDR1). Pgp is a glycoprotein responsible for
transporting a wide variety of substances across extra- and intracellular membranes.
Importantly, Pgp is found overexpressed in various malignant tumor tissues, where it is
actively involved in pumping chemotherapy drugs out of the cells. This active role in
removal of the chemotherapeutic makes Pgp a prime target in combination approaches
to overcome MDR. Numerous studies have shown that successful inhibition of Pgp
expression by gene silencing with siRNA or AON dramatically increases the
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accumulation of chemotherapy drugs in tumors and results in improved anti-tumor
efficiency. However, efflux proteins like Pgp also play a crucial role in physiological
regulation of endogenous substrates in healthy tissues throughout the body. It is
important to control the silencing of Pgp expression specifically only in the tumor cells to
avoid side effects caused by undesirable pharmacological activity in healthy organs and
tissues [52]. Other MDR proteins such as MRP1, MRP2, BCRP and certain cell
signaling pathways also contribute to chemoresistance. For example, in ovarian cancer,
the Notch signaling pathway is a key regulator of tumor resistance to the treatment with
cisplatin. Both in vivo and in vitro evidence showed that Notch 3 overexpression
resulted in expansion of cancer stem cells and increased chemoresistance to cisplatin
[53].

1.2.2 Combining chemotherapy with nucleic acids that promote apoptosis
One hallmark of cancer is its ability to escape apoptosis [54]. Pre-cancerous cells
undergoing fatal mutations are usually eliminated from the body through apoptosis,
which is a natural self-destruct mechanism. A complex, balanced network of proapoptotic and anti-apoptotic genes regulates apoptosis. However, this often becomes
dysfunctional during tumor progression as a result of multiple gene mutations. Thus,
delivery of gene therapy to reverse the apoptotic functionality of the mutated cells
together with apoptosis-inducing chemotherapy is a possible strategy to avoid tumor
recurrence and relapse.
The tumor suppressor p53 gene is a key regulator in cell cycle and functions in
conserving genome stability. Malkin et al. demonstrated that treatment with wild-type
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p53 delivered via an adenovirus significantly increased the sensitivity of various
osteosarcoma cell lines to the chemotherapeutics cisplatin and doxorubicin (DOX) [55].
Introducing pro-apoptotic genes to cancer cells alone with the treatment of
chemotherapy also showed beneficial outcome. In the treatment of head and neck
squamous cell carcinoma, Zheng et al. demonstrated that local delivery of the TRAIL
gene by adeno-associated virus-2 (AAV-2) synergized with cisplatin chemotherapy both
in vitro and in vivo, and cisplatin pre-treatment significantly increased TRAIL-induced
apoptosis [56]. In addition to TRAIL gene therapy, Wagner et al. described the
application of a combined treatment using TNF-α gene and DOX. TNF-α is a cytokine
involved in direct killing of tumor cells and promoting tumor angiogenesis, or the
formation of new blood vessels. Multiple injections in vivo of combined TNF-α gene and
DOX therapy significantly delayed tumor growth in subcutaneous murine neuroblastoma
as well as liver metastases of human LS174T colon carcinoma [57]. In addition, another
approach to promote apoptosis is to silence anti-apoptotic genes. Examples of suitable
targets used in combination include Bcl-2 and survivin [58-60]. Bisen et al. investigated
the effect of cisplatin in combination with survivin siRNA on apoptosis in head and neck
cancer. The results confirmed that halting the function of the survivin gene through LVmediated RNAi silencing therapy significantly increased the sensitivity of cancer cells to
cisplatin-mediated apoptosis [59].

1.2.3 Other strategies in drug and nucleic acid combinations
In addition to chemosensitizing tumor cells using combinations of silencing
agents and chemotherapeutics, other widely explored strategies are the combination of
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anti-cancer drugs with nucleic acids for immunotherapy or anti-angiogenesis. For
example, in resistant 4T1 and sensitive EMT-6 syngeneic mouse breast tumor models
Kim et al. described the combined local interleukin-12 (IL-12) pDNA delivery with
systemic paclitaxel (PTX) chemotherapy. This combination therapy showed improved
inhibition of both the growth of the primary tumor as well as lung metastases compared
with untreated and monotherapy-treated controls [61]. In another example, Huang et al.
described co-delivery of VEGF siRNA and DOX using micelles composed of PEI grafted
with stearic acid. Their result showed a promising effect on anti-tumor growth in a
mouse model of human hepatocarcinoma [62].

1.3

Delivery Strategies for Drug-Nucleic Acid Combinations
Pharmacologic effects of various drug-nucleic acid combinations and the

interactions between the signaling pathways involved are complicated and not
necessarily well understood, therefore makes it difficult to optimize the delivery strategy,
timing and dosing in combination treatment. However, co-delivery of chemotherapeutics
and therapeutic nucleic acids in a single nanocarrier may offer benefits in terms of
convenience, vehicle uniformity, ratiometric drug loading and temporal drug release
[63]. Examples of proven simultaneous delivered drug-nucleic acid combinations are
summarized in Table 1.
Table 1. Co-delivery of drug-nucleic acid combinations in cancer treatment.
Nucleic acid

Drug

Target

Delivery method

Ref.

Bcl-2 siRNA

DOX

Human hepatic cancer (in vivo)

Polyplex

[64]

Bcl-2 siRNA

DOX

Rat glioma (in vivo)

Polyplex

[65]
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Bcl-2 siRNA

DOX

Human ovarian cancer (in vitro)

Silica nanoparticle

[66]

Bcl-2 siRNA

PTX

Human breast cancer (in vitro)

Polyplex

[67]

Bcl-2/MRP1 siRNA Bcl-

DOX

Human MDR cancers (in vitro)

Lipoplex

[68]

c-Myc /VEGF siRNA

DOX

Human fibrosarcoma (in vivo)

Lipid-polymer nanoparticle

[69]

c-Myc siRNA

DOX

Human fibrosarcoma (in vivo)

Lipid-polymer nanoparticle

[70]

EGFR siRNA

DSGLA lipid

Human lung carcinoma (in vivo)

Lipid-polymer nanoparticle

[71]

EGFR siRNA

SAHA

Human glioblastoma (in vitro)

Polyplex

[72]

Mcl1 siRNA

SAHA

Nasopharynx carcinoma (in vivo)

Lipoplex

[73]

Mcl1 siRNA

Mitoxantrone

Human nasopharynx carcinoma (in vivo)

Lipoplex

[74]

Mcl1 siRNA

PTX

Human nasopharynx carcinoma (in vivo)

Lipoplex

[75]

MDR-1 siRNA

DOX

Human breast carcinoma (in vivo)

Polyplex

[76]

MDR1 siRNA

DOX

Human cervical carcinoma (in vitro)

Quantum dot

[77]

MVP siRNA

DOX

Human breast cancer (in vivo)

Polyplex

[78]

P-gp siRNA

PTX

Mouse mammary gland adenocarcinoma

Polyplex

[79]

2/MDR1 siRNA

(in vivo)
P-gp siRNA

DOX

Human cervix carcinoma (in vitro)

Silica nanoparticle

[80]

Plk1 siRNA

PTX

Human breast carcinoma (in vivo)

Polyplex

[81]

Survivin shRNA

PTX

Human ovarian cancer (in vivo)

Polymer micelle

[82]

TRAIL plasmid

DOX

Human liver cancer (in vivo)

Polyplex

[83]

TRAIL plasmid

DOX

Human brain gliomas (in vivo)

polyplex

[84]

VEGF siRNA

PTX

Human prostate adenocarcinoma (in vitro)

Polyplex

[85]

VEGF siRNA

DOX

Human hepatoma (in vivo)

Polymeric micelle

[62]

DOX: doxorubicin
PTX: paclitaxel
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An interesting type of the co-delivery vectors emerging in recent years is the
carrier doubles as a nucleic acid delivery vector and a prodrug that can enhance the
therapeutic outcome of nucleic acids. A growing number of examples of such carriers
successfully combine the delivery function of vectors with pharmacologic activity.
Pluronic block copolymers are probably the best-known and most-investigated example
of such carriers. These copolymers chemosensitize MDR cancer cells through multiple
mechanisms, including inhibition of the Pgp drug efflux system [86], depletion of cellular
ATP pools [87], and dysfunction of mitochondria [88]. While most of the available
reports address the use of Pluronics for delivery of chemotherapeutics, importantly, the
copolymers can be also used to deliver nucleic acids. Namely, it has been
demonstrated that Pluronics can activate the nuclear factor kappa-light-chain-enhancer
of activated B cells (NFκB), which is a transcription factor that enhances gene
expression [89]. By introducing Pluronics into existing polyplexes, the gene delivery
efficiency can be significantly improved, without causing cytotoxicity, as a result of
increased cell uptake and nuclear transport of pDNA.
In most cases, dual-function carriers are rationally designed for specific
applications. For example, Huang et al. developed a novel cationic lipid named DSGLA
that is capable of delivering siRNA while simultaneously down-regulating the
phosphorylated extracellular signal-regulated kinase (pERK) to enhance anti-cancer
activity of the delivered siRNA [71]. The lipid, which contains guanidinyl and lysyl
headgroups, has been shown to efficiently down-regulate pERK in H460 human lung
carcinoma cells and to induce their apoptosis. Furthermore, a significant enhancement
in tumor growth inhibition was observed in a mouse model of lung tumors after
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intravenous (i.v.) administration of DSGLA/siRNA lipoplexes containing EGFR siRNA.
In addition to the use of lipoplexes as a dual-function vector, Rice et al. designed
a type of novel cationic polypeptide capable of incorporating peptides with an intrinsic
proteasome inhibitory function in order to improve transfection activity of plasmid DNA
[90]. Proteasomes are important cellular enzymes responsible for the degradation of a
variety of proteins. Inhibition of proteasomes has been shown to enhance transfection
efficiency. Interestingly, in human hepatocellular carcinoma HepG2 cells, Rice et al.
incorporated a tripeptide aldehyde proteasome inhibitor into the C-terminal end of a
cationic gene delivery peptide (Cys-Trp-Lys18), and the resulting carrier showed
elevated gene expression. Rice et al. note that using peptides with a proteasome
inhibitory function as the carrier for pDNA delivery is more beneficial than concurrent
treatment with pDNA polyplexes and free proteasome inhibitors. Thus, introducing
intrinsic proteasome inhibitory activity has shown potential to boost the efficiency of anticancer gene therapy.
We have recently reported synthesis of biodegradable polycations that can
function dually as gene delivery vectors and as antagonists of the CXCR4 chemokine
receptor [91]. As a result of CXCR4 inhibition, the synthesized polycations were able to
block the invasion of cancer cells, while simultaneously mediating efficient transfection
in vitro. Evidence shows that the chemokine receptor CXCR4 and its cognate ligand
SDF-1 (CXCL12) play critical roles in tumor invasion and metastasis. Likewise, many
clinical studies have revealed that CXCR4-positive tumors metastasize to distant sites
with high levels of SDF-1. Blocking the CXCR4/SDF-1 axis either by CXCR4
antagonists or by siRNA silencing of the CXCR4 gene has been shown to be capable of
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preventing metastasis [92]. Such dual-function delivery vectors are expected to
enhance anti-metastatic efficacy in a variety of cancer gene therapy methods.

1.4

Polyamine Pathway in Cancer
Years of research in the field of cancer treatment promoted the elucidation of the

molecular basis of cancer, and led to the identification of valuable therapeutic targets
[93]. One typical example is the polyamine pathway, which is generally up-regulated in
cancer and therefore holds promise for the chemotherapy and chemoprevention.

1.4.1 Natural polyamines and their biological functions
Natural polyamines, including spermine (SPM), spermidine (SPD) and their
diamine precursor putrescine (PUT), are alkylamines that exist in all eukaryotes [94-96].
In 1678, SPM and SPD were first discovered by Leeuwenhoek in human semen [97].
Later in 1885, Brieger reported the discovery of PUT [98]. These polyamines are
essential for cell growth, differentiation, survival and mammalian development [99]. In
general, the intracellular concentration of all polyamines is in millimolar range and most
of the polyamines exist in the form bound to nucleic acids (DNA, RNA) or other
negatively charged molecules, such as proteins and phospholipids [100, 101]. The
majority of polyamines exists as polyamine-RNA complexes, thus influencing protein
synthesis [102]. It is generally believed that polyamines exhibit its main function in
supporting cell growth and cell survival at the transcriptional, translational and posttranslational levels, through the regulation of gene expression, free-radical scavenging,
ion-channel regulation and maintenance of chromatin structure [103]. The dynamic
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balancing of polyamine levels inside the cells is important for maintaining the healthy
status of the cells, and the intracellular polyamine concentration is strictly regulated
through the biosynthesis, catabolism pathway, cell uptake and efflux [94]. Dysregulation
of polyamine levels is usually associated with various diseases, as the polyamine
depletion leads to inhibition of cell growth and accelerates aging [104], while increased
level of polyamines is associated with hyper-proliferative diseases such as cancer [105].
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Figure 3. The polyamine pathway. Ornithine, the precursor for polyamine synthesis,
is the product of arginine generated from urea cycle. Ornithine is converted to PUT by
ornithine decarboxylase (ODC). PUT is then converted to higher molecular weight
SPD by addition of propyl amine. The process is catalyzed by SPD synthase. SPD
can be further converted to SPM by SPM synthase. Notably, the product of propyl
amine involved in the synthesis of SPD and SPM is generated from the
decarboxylation of S-adenosylmethionine (AdoMet) by S-adenosylmethionine
decarboxylase (AdoMetDC). Catabolism of SPD and SPM is mediated by three major
enzymes: spermine/spermidine N1-acetyltransferase (SSAT); polyamine oxidase
(APAO) and spermine oxidase (SMO). SMO can oxidize SPM to form SPD; SSAT
catalyzes the acetylation of SPM and SPD to form the N1-acetyl-SPM or N1-acetylSPD, respectively. Acetylated polyamine product can be further exported out of the
cell, or it can be oxidized by APAO to form the precursor polyamine (PUT or SPD).

1.4.2 Polyamine biosynthesis
Polyamines can be imported from extracellular resources, such as directly from
food, or generated by gut bacteria [106], although the mechanism of cellular polyamine
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uptake is not yet fully characterized. On the other hand, endogenous polyamines are
generated from the biosynthesis pathway. As shown in Figure 3, the first rate-limiting
enzyme in the polyamine biosynthesis pathway is ODC, which catalyzes the conversion
of ornithine to PUT. Ornithine, the substrate for ODC is an amino acid intermediate in
the urea cycle generated from arginine by arginase [107]. In mammals, ODC has a very
short half-life around 10 min, and it is one of the best-characterized proteins that is
subjected to ubiquitin-independent degradation process [96]. The degradation of ODC is
mediated by ODC antizyme, and the process is negatively regulated by the feedback
loop of polyamine products [108].
The second rate-limiting step in the polyamine synthesis is the decarboxylation of
AdoMet by AdoMetDC to generate the amino propyl donor (decarboxylated AdoMet) for
the synthesis of SPD and SPM. SPD is synthesized from PUT by incorporating the
aminopropyl moiety from decarboxylated AdoMet, and the reaction is catalyzed by SPD
synthase. SPM is synthesized in presence of SPM synthase by aminopropylation to the
aminobutyl end of SPD [109].

1.4.3 Polyamine catabolism
Several enzymes, such as SMO, SSAT and APAO, mediate the catabolism of
polyamines. SSAT is a rate-limiting enzyme in the catabolic pathway. It catalyzes the
N1-acetylation of SPD and SPM, by transferring the acetyl group from acetyl coenzyme
A. SSAT is a highly inducible enzyme, and its expression can be regulated by a variety
of stimuli such as polyamine levels, hormones, toxins, drugs, cytokines and stress
pathways [110]. Oppositely, APAO is constitutively expressed in most tissues with its
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high activity and slow turnover rate [111]. SMO specifically oxidizes SPM. It is also
highly inducible by a variety of stress stimuli, and is often up-regulated during cellular
stress such as inflammation, cell differentiation and DNA damage [112].
SPD and SPM can be acetylated by SSAT and further exported out of the cells.
Alternatively, the acetylated products from SPD and SPM are also subjected to
oxidation by APAO, which leads to the formation of lower molecular weight polyamines
(PUT or SPD), as well as the product of 3-acetylaminopropanal and hydrogen peroxide
(H2O2). In contrast to the function of APAO, which oxidizes the acetylated product of
SPD and SPM, SMO catalyzes the oxidation of unsubstituted SPM to SPD, and
releases 3-aminopropanal and H2O2. It is also worth noting that reaction with APAO and
SMO in the polyamine pathway causes oxidative stress to the cell by generating H2O2
and aldehydes. The production of reactive oxygen species (ROS) together with
increases in acetylated polyamines and the enzyme activities are reported to be
responsible for apoptosis and ROS damage to the host cells [113, 114].

1.4.4 Polyamine regulation in cancer
Considering the essential role of polyamine pathway in cell growth and
development, it is not surprising to find that occurrence of cancer usually correlates with
dysregulation of polyamine pathway. Indeed, higher expression of natural polyamines,
elevated activity of the polyamine synthesis enzymes or reduced activity of polyamine
catabolism are normally found in various cancers, including breast, prostate, renal,
colorectal, pancreatic, hepatocellular carcinoma, lung and brain cancers [115].
Moreover, SPD and SPM are acetylated when they are accumulated in excess amount
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during carcinogenesis, therefore the urinary acetylated SPD and SPM has become a
sensitive marker for human cancers [100].
In 1968, Russell et al. first showed that increased ODC activity was associated
with sarcomas and hepatomas [116]. ODC is a transcriptional target of the oncogene cMyc and Ras [117], and it is shown to be overexpressed in gastric cancer [118], breast
cancer [119], lymphoma [120], non-small-cell lung cancer [121] and prostate cancer
[122]. Deng et al. examined the expression of ODC in breast cancer tissues and four
breast cancer cell lines, and found that ODC was upregulated in all breast cancer
tissues and cell lines compared with non-tumor tissue and normal breast epithelial cells
[123]. They also demonstrated that down-regulation of ODC expression with antisense
ODC resulted in suppression of cancer proliferation and cell cycle arrest. More
significantly, O’Brien and coworkers were able to demonstrate that overexpression of
ODC is sufficient for the promotion of skin tumor [124]. They developed the ODC
transgenic mice model for skin tumorigenesis experiment. Results showed much higher
sensitivity of the transgenic mice to develop skin tumors with a single administration of
carcinogen, compared with the normal control mice. Similarly, AdoMetDC, the second
rate-limiting enzyme in the biosynthesis pathway of polyamine has also been reported
to be up-regulated in certain types of cancer [125]. Ravanko et al. proved that
AdoMetDC alone is sufficient for the transformation of NIH 3T3 cells into highly invasive
tumors in nude mice [126]. Furthermore, the inhibition of AdoMetDC by small molecule
inhibitor SAM486A led to the suppression of breast cancer invasiveness both in vitro
and in vivo [127]. Other enzymes involved in the polyamine biosynthesis such as SPM
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and SPD synthases are constitutively expressed in the cells, and are considered to be
less relevant to the tumorigenesis in human [128].
Additionally, dysregulation of enzymes in polyamine catabolism also contributes
to the tumorigenesis. Increased activity of SMO is often observed in inflammationassociated tumors. In this case, production of ROS by SMO is directly linked with DNA
damage and activation of inflammation cytokines. Chronic inflammation with sustained
elevation of ROS produced by SMO increases the risk of tumorigenesis [112]. For
example, development of prostate cancer is considered to be associated with
inflammation [129]. This statement is supported by Goodwin et al. that significantly
higher expression of SMO is observed in tissue samples of prostate cancer patients
[130]. Another interesting example is that certain infection events that lead to the upregulation of SMO activity will later contribute to the carcinogenesis. Xu et al. reported
that Helicobacter pylori, a human gastric pathogen, could up-regulate the enzyme
activity of SMO, thus causing the production of ROS and consequently, result in
mutagenic DNA damage that may contribute to the development of gastric cancer [131].
It is also worth mentioning that SMO seems to play an opposite role in the development
of breast cancer. Report showed that SMO activity is much lower in the tumor tissue
samples than in the normal tissue samples from breast cancer patients [132]. This result
is in good correspondence with another report that decreased APAO activity was
observed in breast cancer tissues [133]. Possible explanation for the decreased activity
of polyamine catabolic enzymes in breast cancer is that lower expression of SMO and
APAO leads to reduced amount of ROS in the local tumor tissue, thus promotes the
survival of tumor cells [112]. The role of SSAT enzyme in tumorigenesis is also
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complicated

and

requires

more

investigation.

Mouse

model

with

systemic

overexpression of SSAT demonstrated resistance to the development of skin cancer
after being challenged by carcinogen [134]. However, local induction of SSAT
expression in the mice skin resulted in accelerated tumor progression [135]. Elevated
SSAT was observed in tumor tissue from breast cancer patients [133]. In contrast, in the
case of human colon cancer or other gastrointestinal cancers that are associated with
Ki-ras oncogene, SSAT activity was suppressed by Ki-ras, which resulted in
suppression of polyamine catabolism and elevated polyamine content [136].
In all, dysregulation of enzymes involved in the polyamine pathway results in
accumulation of polyamines, which promotes tumorigenesis and tumor progression.
Elevated polyamine levels are reported to enhance the malignant potential of cancer
cells and decrease anti-tumor immunity [137]. Alteration in the polyamine pathway is
also associated with poor prognosis of certain cancers [138]. Therefore, targeting the
polyamine pathway holds great potential in cancer chemotherapy and chemoprevention
[139].

1.4.5 Targeting polyamine pathway in cancer
Realizing the importance of polyamine pathway in cancer, extensive effort has
been made to develop therapeutic agents against the polyamine metabolism. Earlier
work starting from 1970s was mainly focusing on developing inhibitors of polyamine
biosynthesis enzymes. Structures of representative inhibitors are shown in Figure 4.
Methylglyoxal bis(guanylhydrazone) (MGBG), a drug used for treatment of leukemia,
was demonstrated to be a competitive inhibitor for AdoMetDC by Williams-Ashman et
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al. in 1972 [140]. Treatment with MGBG leads to the depletion of SPM and SPD,
however, accumulation of excess PUT was observed [141]. Although in vitro results
showed that MGBG treatment led to cell growth inhibition, clinical use of this drug is
limited by the significant toxicity to mitochondria [142]. Based on the structure of MGBG,
researchers later developed other AdoMetDC inhibitors, such as SAM486A, with
reduced mitochondrial toxicity [143]. Unfortunately, no clinical benefit was shown in
Phase I and Phase II studies [144, 145].

Figure 4. Representative inhibitors for polyamine metabolic enzymes. DFMO is an
irreversible inhibitor for ODC; MGBG is a competitive inhibitor for AdoMetDC; SAM486A
is a competitive inhibitor for AdoMetDC with lower mitochondrial toxicity than MGBG;
MDL 72527 is an enzyme-activated inhibitor for APAO, which can also inhibit SMO.
Modified from [101].
One of the most well-known inhibitors for polyamine biosynthesis is
difluoromethylornithine (DFMO), an irreversible inhibitor of ODC that binds to the active
site of this enzyme [146, 147]. Results from in vitro studies showed that treatment of
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cells with DFMO led to depletion of PUT and SPD, but the level of SPM often remained
less affected [148]. Generally, DFMO leads to cytostatic growth inhibition, rather than
cytotoxic effect towards cancer cells. Clinical trials demonstrated that DFMO was
ineffective as a single chemotherapy agent against several tumor models, including
gliomas, melanomas, breast and prostate cancers [101]. Possible explanation for the
disappointing result is that DFMO is poorly transported into the cell thus limiting the
ODC inhibition and polyamine depletion effect. Additionally, activation of compensatory
mechanism in polyamine pathway and incomplete depletion of SPM after the treatment
with DFMO may also compromise the treatment outcome [149]. ODC inhibitors with
higher potency were also synthesized, however, no significant advantage in clinical
studies was shown so far [150]. Furthermore, inhibitors targeting the SPM and SPD
synthase were also explored as chemotherapy agent. For example, S-adenosyl-3-thio1,8-diaminooctane was synthesized as a specific inhibitor of SPD synthase. A similar
analogue, S-adenosyl-1,12-diamino-3-thio-9-azadodecane was developed as inhibitor
for SPM synthase. However, both inhibitors demonstrated limited effect on cell growth
inhibition [151, 152]. Also worth mentioning are inhibitors developed for targeting other
enzymes such as APAO. Although APAO was thought to be constitutively expressed in
the cells, thus having less importance as a therapeutic target, recent developments in
inhibiting APAO activity showed promising cell killing effect towards cancer cells [149].
The most successful inhibitor for APAO is N1,N4-bis(2,3-butadienyl)-1,4-butanediamine
(MDL 72527), which is also considered an inhibitor for SMO. MDL 72527 has shown
toxic effect towards leukemia cells and appears to be effective when combined with
DFMO in in vivo cancer models [128, 149].
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As discussed above, initial efforts of developing anti-cancer reagent based on the
inhibition of polyamine biosynthesis enzymes yielded limited clinical success. The
ineffectiveness of the inhibitors targeting biosynthesis of polyamines is partially due to
the incomplete depletion of all the natural polyamines. In recent years, more emphasis
has been put on developing polyamine analogues that are capable of competing with
natural polyamines for the transport, biosynthesis and catabolism. Theoretically, ideal
polyamine analogues would possess the following features: (i) capable of competing
with natural polyamines for the polyamine transport system thus reducing the import of
natural polyamines; (ii) despite the structural similarity with natural polyamines, the
analogues should not have the same biological functions as natural polyamines; (iii)
intracellular accumulation of the polyamine analogues should act as a feedback to the
polyamine metabolism, resulting in down-regulation of polyamine biosynthesis and upregulation of catabolism [103].
Synthesis of polyamine analogues that met the above criteria was first attempted
by Bergeron and coworkers in 1988 [153]. Since then, considerable amount of
polyamine analogues mimicking the structures of SPD and SPM was synthesized and
tested over the past 20 years. The analogues can be grouped into the following
categories based on the chemical structure: symmetrically substituted bis(alkyl)
polyamine analogues; asymmetrically substituted analogues; conformationally restricted
analogues; oligoamines and macrocyclic analogues [154]. Representative examples of
polyamine analogues are shown in Figure 5. Among the most successful of the
developed polyamine analogues is N1,N11–bisethylnorspermine (BENSpm). BENSpm
has shown promising antitumor activity against a wide range of cancers, including
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melanomas, ovarian, breast, and pancreatic cancers [155-158]. BENSpm induces
SSAT, down-regulates ODC and AdoMetDC [159], and ultimately causes cell growth
inhibition and apoptosis [160-162]. The mechanism of action as well as preclinical and
clinical outcomes of BENSpm will be discussed in detail in the following section. In
addition,

asymmetrical

polyamine

analogues

N1-propargyl-N11-ethylnorspermine

(PENSpm) and N1-cyclopropyl-methyl-N11-ethylnorspermine (CPENSpm) possess
similar backbone as BENSpm and also showed significant anti-proliferation activity and
SSAT induction. The similar antitumor effect of asymmetrical analogues with BENSpm
demonstrates that active functional moieties could be linked to the same polyamine
backbone, which may offer potential targeting capability [103]. Synthesis of
conformational restricted analogues also generated encouraging results. Most
promising agents in this group are CGC-11047 and CGC-11093, which are derivatives
of N1,N12-bisethylspermine (BESpm) and N1,N14-bisethylhomospermine (BEHSpm),
respectively. CGC-11047 and CGC-11093 showed increased anti-proliferative activity
and reduced nonspecific toxicity compared with the parent compounds [101]. Notably,
despite the structural similarities, CGC-11047 and CGC-11093 showed discrepancy in
the profile of regulating polyamine catabolic enzymes. CGC-11047 significantly induced
SSAT and SMO, whereas CGC-11093 showed little effect on the expression of both
enzymes [103]. The fact that both compounds are active anti-cancer agents implied the
complexity of the mechanism for polyamine regulation and indicated the diverse
influences of polyamine analogues on polyamine pathway, other than affecting the
enzyme activities.
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Synthesis of oligoamines as effective antitumor agents is guided by the
hypothesis that increased number of amines in the polyamine analogue contributes to
increased affinity for DNA. The interactions between the polyamine analogue and
nucleic acids in the cancer cells are then responsible for the antiproliferative effect
[163]. For example, CGC-11144 is a representative oligoamine with significant
antitumor activity. CGC-11144 demonstrated growth inhibition in a panel of prostate
cancer cells, and showed antitumor effect in vivo in a breast cancer model [164]. CGC11144 showed broad effect on cellular functions. Treatment with CGC-11144 not only
leads to decrease in all three natural polyamines and inhibition of ODC activity, but also
results in multiple genetic changes such as activation of caspase 3 and suppression of
the expression of estrogen receptor [165]. Another unique class of polyamine analogues
is macrocyclic polyamine. Unlike other polyamine analogues that generally target the
polyamine pathways, macrocyclic polyamines exhibit its antitumor function through
other mechanisms such as DNA cleavage and depletion of ATP. Representative
molecule from this subset of compounds, such as CGC-11199, demonstrated antitumor
activity in human prostate cancer. However, the mechanism of action is considered less
relevant with the polyamine regulation [166].
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Figure 5. Examples of polyamine analogues with antitumor activity. (a) Symmetrically
substituted polyamine analogues; (b) asymmetrically substituted polyamines; (c)
conformational restricted polyamine analogues; (d) oligoamines and (e) macrocyclic
polyamine.
1.4.6 BENSpm as anticancer drug targeting polyamine pathway
As discussed above, BENSpm is one of the most successful antitumor agents
developed in the field of polyamine research. BENSpm mimics the structure of SPM, but
differs from SPM in that the terminal primary amines of BENSpm are modified with ethyl
groups, thus preventing the oxidation by multiple oxidases such as APAO. BENSpm
exhibits multiple functions in the regulation of intracellular polyamines. It is shown that
BENSpm can highly induce the activity of catabolic enzyme SSAT. It also induces SMO
and downregulates both ODC and AdoMetDC [164]. Unlike single enzyme inhibitors,
BENSpm demonstrates complete depletion of all three natural polyamines and shows
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significant antitumor activity in vitro [165]. Using a transgenic model of primary fibroblast
derived from transgenic mice overexpressing SSAT, Alhonen et al. demonstrated that
the growth inhibition effect of BENSpm was largely dependent on the depletion of
polyamine pools, and the massive induction of SSAT activity mainly happened at the
post-transcription level [167, 168]. It was also reported that BENSpm is a potent inducer
of SMO, especially in non-small-cell lung cancers [169]. Investigations in BENSpmtreated SK-MEL-28 human melanoma cells revealed that BENSpm caused depletion of
intracellular polyamine pools and triggered G1 phase cell cycle arrest. Besides the
effect on cell growth inhibition, BENSpm also induced apoptosis in the melanoma cells
by activating the mitogen-activated protein kinase (MAPK) pathway, inducing cellular
oxidative stress and activating the mitochondrial apoptotic pathway [113, 170]. BENSpm
is also reported to exhibit gene regulation functions. Shah et al showed that BENSpm
downregulated the gene expression of two transcription factors: NFκB and estrogen
receptor-alpha in breast cancer cells, and resulted in apoptosis in the tested MCF-7
breast cancer cell line [171].

Table 2. Applications of BENSpm in cancer therapy.
Treatment

Model

Cancer type

Effect

Ref.

BENSpm

in vitro

Breast tissue explants

↑SSAT

[172]

BENSpm

in vitro

L56Br-C1 breast cancer cells

↑SSAT;
Apoptosis;
↓
proliferation; ↑caspase-3 and 9

Cell

[173]

BENSpm

in vitro

MALME-3M melanoma cells

↑p53-p21WAF1/CIP1-Rb;
cycle arrest

cell

[158,
174]

BENSpm

in vitro

MCF-7 breast cancer cells

G1 cell cycle arrest; ↑p53 and p21
expression; Cell growth inhibition and
apoptosis

[160]

BENSpm

in vitro

MCF-7, L56Br-C1 and HCC1937 breast

Polyamine depletion; DNA strand

[175]

G1
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cancer cells

breakage
↑SSAT and SMO; Growth inhibition;
↓ODC; Polyamine depletion

[176]

Panc-1 and BxPC-3 pancreatic cancer
cells and xenograft mice model

↑SSAT;

[177,
178]

BENSpm

in vitro

MDA-MB-231, Hs578t,
breast cancer cells

BENSpm

in vitro

MCF-7,

T47D

↓ODC

and

AdoMetDC;

↓polyamine pool; antiproliferation; in
vivo antitumor effect

BENSpm

in vitro

SH-SY5Y neuroblastoma cells

Polyamine depletion; cell growth
inhibition and apoptosis; ↑survivin

[179]

BENSpm

in vitro

SK-BR-3, MCF-7, L56Br-C1 and HCC1937
breast cancer cells

Polyamine depletion; Cell growth
inhibition; Regulation of cell cycle

[180]

BENSpm

in vitro

SK-MEL-28 melanoma cells

↑SSAT

[113]

and

ROS;

Apoptosis;

↑caspase-3 and 9; cytochrome c
release
BENSpm

in vitro

SK-MEL-28, MALME-3M, A375 and LOX
melanoma cells

↑SSAT;
inhibition;
proteins;
pathway

Apoptosis

and

growth

↓survivin and
Activation
of

ML-IAP
MAPK

[170,
181]

BENSpm

in vitro

U87, LN229 glioblastoma cells

↑SSAT;
↑Cell
apoptosis
and
detachment; Inhibition of mTORmediated protein synthesis

[182,
183]

BENSpm

in vitro and
in vivo

AT3.1, AT6.1, AT6.3, DU145, DuPro-1 and
TSU-Pr1 prostate cancer cells; DU145,
DuPro-1 and PC-3 xenograft mouse model

Cytotoxicity; Tumor growth inhibition

[184]

BENSpm

in vitro and
in vivo

PC-3, TSU-pr1, DU-145, and JCA-1
prostate cancer cells; DU-145 xenograft
mouse model

↑SSAT; ↓ODC; ↓Polyamines; Tumor
growth inhibition

[185]

BENSpm

in vitro and
in vivo

U87, LN229 glioblastoma
intracerebral mouse model

↑SSAT and ROS; Prolonged survival
of tumor-bearing mice

[186]

BENSpm

in vivo

A121 ovarian carcinoma, A549 lung
cancer, MALME-3M melanoma, and SH-1
melanoma xenografts mice model

Tumor regression

[187,
188]

BENSpm

in vivo

BL13 bladder carcinoma xenograft mouse
model

Tumor regression

[189]

BENSpm

in vivo

PANUT-3 and MALME-3M
xenograft mice model

melanoma

↑SSAT in tumor tissue; polyamine
depletion in tumor; antitumor activity

[190]

BENSpm

in vivo

Transgenic mouse model with neu/erb-B2
overexpression

↑SSAT; ↓number of tumor; ↓tumor
volume

[191]

BENSpm

Phase I
trial

Advanced solid tumors patients

Central nervous system toxicity

[192,
193]

BENSpm

Phase I
trial

Hepatocellular carcinoma patients

Dose well tolerated in patients; Lack
of efficiency

[194]

BENSpm

Phase I
trial

Non-small cell lung cancer patients

MTD was 185 mg/m for 5 days;
Gastrointestinal toxicity

[195]

BENSpm

Phase II
trial

Metastatic breast cancer patients

Dose well tolerated in patients; Lack
of efficiency

[196]

cells;

U87

2

BENSpm
2ME

and

in vitro

MCF-7 breast cancer cells

Synergism; Polyamine depletion; Cell
apoptosis

[197]

BENSpm
5-FU

with

in vitro

HCT116 colon carcinoma cells

↑SSAT; ↑Apoptosis; ↓Polyamines;
Synergism

[198]

BENSpm

with

in vitro

MCF-7, Hs578t, T47D and MDA-MB-231

Strong synergism; ↑SSAT and SMO;

[199]
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5-FU or PTX

breast cancer cells

Cytotoxicity

BENSpm
cisplatin

with

in vitro and
in vivo

L1210 leukemia cells and B16F1
melanoma cells; L1210 and B16F10 mice
model

Cytotoxicity; ↑ Lifespan

[200]

BENSpm
OXP

with

in vitro

A2780 ovarian cancer cells

↑Strong
synergism;
↑SSAT;
Polyamine depletion; Cell growth
inhibtion and cytotoxicity

[201,
202]

BENSpm with
OXP and 5-FU

in vitro

HCT-116 colorectal cancer cells

Polyamine depletion; ↑SSAT and
SMO; ↓cell resistance

[203,
204]

5-FU: 5-fluorouracil
PTX: paclitaxel
OXP: oxaliplatin
2ME: 2-Methoxyestradiol

BENSpm demonstrated promising antitumor effect in both in vitro and in vivo
models of a variety of cancers. Application of BENSpm in preclinical and clinical cancer
therapy is summarized in Table 2. For in vitro studies, BENSpm showed promising
outcome as antitumor agent towards glioblastoma U87 and LN229 cells [182],
neuroblastoma SH-SY5Y cells, breast cancer MDA-MB-231 and MCF-7 cells [176], SKMEL-28 human melanoma cells [113] and human prostate cancer PC-3, TSU-pr1, DU145, and JCA-1cell lines [185]. More significantly, several studies pointed out the
effectiveness of BENSpm for in vivo antitumor therapy. For example, BENSpm
significantly inhibited tumor growth of breast cancer MDA-MB-231 xenografts mouse
model, following the treatment schedule of 5 times each week (100 mg/kg for each
dose) for constitutively 4 weeks [199]. In a FVB/NTgN transgenic mouse model with
neu/erb-B2 oncogene overexpression, treatment with 20 mg/kg BENSpm once a week
for 10 weeks resulted in a 40% reduction in the average number of tumors per mouse
[191]. Similarly, significant antitumor efficacy was also observed in in vivo mouse
models including bladder BL13 carcinoma, SH-1 melanoma, MALME-3M melanoma,
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A549 lung adenocarcinoma, A121 ovarian carcinoma, pancreatic Panc-1 and BxPC-3
adenocarcinoma xenografts [178, 187, 189].
Because of the promising results from in vitro and in vivo studies, BENSpm was
evaluated as a single agent with antitumor activity in phase I and phase II clinical trials.
In a phase I clinical trial, BENSpm was tested in patients with advanced hepatocellular
carcinoma [194]. Although the drug was relatively well tolerated at 75 mg/m2 by i.v.
injection every other weekday for two weeks in a 28-day cycle, BENSpm failed to
demonstrated effectiveness against the disease and was not recommended for further
evaluation as a monotherapy agent. In another phase I study, BENSpm was
administered in patients with non-small cell lung cancer but, again, no significant
disease response was observed [195]. Another phase I trial was designed to determine
the maximum tolerated dose (MTD) and dose-limiting toxicities of BENSpm. The results
demonstrated significant central nervous system toxicity at dose levels above 94
mg/m2/day, and BENSpm was not recommended for phase II study [192]. The only
reported phase II study used BENSpm in patients with metastatic breast cancer. Again,
the results yielded no clinical activity, with all patients showing disease progression by 4
months [196].
Although as a single agent BENSpm did not show satisfactory clinical outcome,
recent studies demonstrated that it could be beneficial to combine BENSpm with other
chemotherapy drugs. For example, BENSpm act synergistically in combination with
platinum drugs, such as oxaliplatin and cisplatin in A2780 human ovarian carcinoma
cells [202]. More importantly, BENSpm was tested in combination with six standard
chemotherapy agents in a panel of four human breast cancer cell lines. The most
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promising combinations were BENSpm with 5-fluorouracil or paclitaxel in human breast
cancer cell lines MDA-MB-231 and MCF-7 [199]. In all, encouraging preclinical results
support the continuing evaluation of BENSpm in combination chemotherapy and
chemoprevention.

1.5

Prodrugs

1.5.1 Definition and advantages
Depending on the final application, modifications of the parent drug molecules to
produce corresponding prodrugs may offer additional advantages over the free drug
alone. Prodrugs are chemically modified drug molecules that are inactive or less active
than the parent drug. However, after in vivo administration, prodrugs will undergo
enzymatic metabolism or chemical transformation to release the active parent drug and
exert its desired pharmacological effect [205]. Prodrug strategy can be used to improve
the drug absorption, distribution, metabolism and elimination (ADME). In chemotherapy,
designing prodrugs also helps to improve the tumor selectivity and to minimize the offtarget toxicity [206]. In general, a prodrug is composed of three components: (1) the
active drug molecule; (2) degradable linker bridging the drug and the rest part of the
prodrug named “promoiety”; (3) the promoiety that enabled the prodrug with additional
properties such as improved solubility, targeting and decreased toxicity [206].
In the design of a successful prodrug, the chemical linker needs to be carefully
selected. Theoretically, the linker should self-immolate or cleave at the pharmacological
site of action [207]. The linker should be either enzymatically degradable or stimuliresponsive to the disease-related environment such as changes in pH and redox
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potential. Commonly used linkers include esters, carbamates, carbonates, and amides.
More recently, a variety of self-immolative linkers were developed with improved
degradation kinetics. Common prodrug linkers and proposed degradation mechanisms
are summarized in Scheme 1.
Ester prodrugs are the most widely used because esters are degraded easily by
ubiquitous plasma esterases or chemical hydrolysis. Synthesis of ester prodrugs is
straightforward, with the required carboxylic acid and hydroxyl groups often existing in
drug backbones. Ester prodrugs can be readily cleaved in the blood, liver and other
organs to release the functional drug molecule [208]. The most important esterases are
carboxylesterase,

acetylcholinesterase,

butyrylcholinesterase,

paraoxonase,

and

arylesterase [208]. These enzymes are widely distributed throughout the body, thus
rendering the ester prodrug quite labile in vivo. One major problem associated with the
ester prodrug is the difficulty in controlling the site of prodrug conversion. Because of
the ubiquitous existence of esterases, it is hard to predict the rate and the site of
hydrolysis, and further, the pharmacological outcomes. Carbonates and carbamates are
enzymatically more stable compared with hydroxyl esters. The degradation of these
types of prodrugs is mediated by selective carboxylesterase.
Another type of commonly used prodrug strategy is amide. Although amide bond
can be hydrolyzed by carboxylesterases, peptidases or proteases [205], it is generally
more stable than the corresponding esters and carbamates. In fact, amide prodrugs
exhibit high enzymatic stability in vivo, with the observation that amide prodrugs can be
stable in the plasma for several days [207]. Therefore, the application of amide prodrugs
is limited to designing specific enzyme-cleavable amides for improved targeting [209].
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Scheme 1. Structures of common linkers used in prodrug conjugations and the
proposed release mechanisms (R1 and R2 stand for either the drug molecule or the
promoiety). Modified from [210-212].
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In addition, other types of linkers include hydrazones, oximes, and disulfides.
Each linker endows the prodrug with different environmental responsive properties. For
example, hydrazone prodrugs are pH sensitive, with the degradation that takes place at
pH < 5. Thus this type of prodrug is expected to be cleaved in the acidic endosome and
lysosome compartments [213]. Disulfide prodrugs are redox responsive molecules and
the reduction-triggered drug release is favored in tumor tissues with elevated levels of
intracellular reducing agents like glutathione (GSH), thus improving the targeting in
chemotherapy [214].

1.5.2 Prodrugs of amine drugs
Although prodrug strategy is widely used and accounts for approximately 10% of
all the marketed medicine globally [215], application of such strategy in amine drugs is
limited by the high stability of amide bonds. As we discussed above in the polyamine
pathway section, polyamine analogues like BENSpm offer great therapeutic potential in
cancer treatment. Conversion of this type of amine drug molecules into prodrug would
be beneficial in the following aspects: (1) masking the amine groups, which are highly
ionized at physiological conditions improves the lipophilicity of the drug and promotes
the passive diffusion of the drug through membrane barriers; (2) temporary protection of
the amine functional groups reduces the tendency to undergo first-pass metabolism; (3)
careful selection of the promoiety of the prodrug enables the tissue targeting of amine
drug, especially for targeting the tumor site.
Besides the amide and carbamate bond, self-immolative linker strategies are
utilized in designing amine prodrugs with improved degradation profile. One interesting
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approach is to use 4-azidobenzylcarbamate as the modification strategy for amine
drugs [216]. The 4-azidobenzylcarbamate was shown to undergo rapid reduction in the
presence of reducing molecule such as dithiothreitol (DTT), and the reduction product 4aminobenzylcarbamate triggers immediate cascade degradation to release the
functional amine drug [210]. Additionally, disulfide reduction-triggered self-immolative
systems are also under vigorous investigation. Valhov et al. reported the disulfidetriggered linker system based on dithiobenzyl carbamate (Scheme 1). Following the
disulfide reduction by GSH, this linker system will undergo thioquinone-methide 1,6elimination and further release the amine free drug [211]. Another interesting approach
is to use simple dithioethyl carbamate linker that can undergo 2-mercaptoethanol 1,2elimination [212]. Activation of this prodrug contains two steps, first is the reduction of
disulfide, and then the electronic rearrangement of the reduction product resulting in
self-fragmentation of the remaining linker and release of the active amine drug. During
the 1,2-elimination process, an intermediate of thiirane is generated from intramolecular
cyclization (Scheme 1), which is further hydrolyzed to form the 2-mercaptoethanol [211].
In all, this type of self-immolative linker offers feasible solution for designing amine
prodrugs. Furthermore, advanced modifications such as to incorporate space hindering
moieties to the linker systems allow for easy control of the drug release rate.

1.5.3 Polymeric prodrug conjugates in chemotherapy
Depending on the types of promoieties, prodrugs can be categorized as targeting
ligand-conjugated prodrugs, stimuli-responsive prodrugs, double prodrugs, membrane
transporter-conjugated prodrugs, and polymeric prodrugs [206, 207, 217]. Among these,

39
polymeric prodrugs draw increasing attention in the field of chemotherapy. In general,
the most prominent advantage of polymeric prodrugs is that they allow for passive
targeting to the tumor site. Due to the rapid growth and elevated angiogenesis of the
tumor tissue, the blood vessels associated with the tumor are usually poorly developed
and thus facilitate leakage of macromolecular drugs to the tumor tissue. In addition,
tumor tissues usually lack effective lymphatic drainage systems, thus increasing the
accumulation of macromolecules in the tumor site. This phenomenon is known as the
enhanced permeability and retention (EPR) effect [218]. One successful prodrug
designed to utilize this advantage was PK1: N-(2-hydroxypropyl)methacrylamide
(HPMA)-DOX prodrug with a peptide linker [219]. Phase I clinical trial showed that the
polymeric prodrug can significantly decrease the DOX dose-limiting toxicities, with no
sign of cardiotoxicity observed in patients at the DOX equivalent dose of 1680 mg/m2. In
another study, the influence of molecular weight of HPMA in the HPMA-DOX conjugates
was evaluated. Results showed that DOX prodrug with higher molecular weight HPMA
(~1000 kDa) has 28 fold longer blood half-life, with concomitant enhancement in tumor
accumulation and significant higher efficacy in tumor inhibition, compared with the free
DOX [220].
Polymeric prodrug conjugates are generally much larger in size than the parent
drug, which leads to reduced urinary excretion, prolonged circulation half-life and
modified biodistribution profile. The most commonly used polymer for this purpose is
poly(ethylene glycol) (PEG). PEG is a water-soluble, nontoxic polymer that is approved
by FDA in several products for in vivo administration [221]. Several PEGylated prodrugs
are already on the market and more are undergoing clinical trials. NKTR-102, for
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instance, is a PEGylated irinotecan prodrug that is currently in phase 3 clinical trial for
patients

with

metastatic

breast

cancer.

NKTR-102

demonstrated

significant

enhancement in antitumor activity and reduced hematopoietic toxicity compared with
parent irinotecan [222].
More complex systems, such as liposome-encapsulated polymeric prodrugs,
self-assembled polymer-drug nanoparticles and micelles, are also developed with
increased half-life and promising antitumor activity [223, 224]. One representative
example is the design of folate receptor-targeted lipid nanoparticle formulation for PTXcholesterol prodrug [225]. PTX has poor aqueous solubility and limited lipid solubility.
Cholesterol was first conjugated to PTX to form the prodrug with improved lipophilicity.
The prodrug was then incorporated into a lipid nanoparticle, which also contained folate
as a tumor targeting ligand. This PTX nanoparticle showed prolonged systemic
circulation and exhibited excellent colloidal stability. Treatment with this novel
formulation in mouse xenograft tumor model showed significantly greater tumor growth
inhibition and prolonged animal survival. In all, incorporating polymer based prodrug
strategy into chemotherapy offers great potential for cancer treatment.

1.6

Conclusions
As described above, gene therapy in combination with chemotherapy has shown

significant promise in cancer treatment. However, current chemo drugs used in drugnucleic acids combinations are merely limited to several candidates such as PTX and
DOX. To further utilize the possible synergism by targeting various cellular pathways in
cancer, identification of novel drug-gene pairs is of great need. Considering the
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importance of polyamine pathway in cancer development, it is of great interest to
identify effective drug targets in this pathway for combination therapy. Identification of
synergistic therapeutic agents will be discussed in Chapter 2.
Furthermore, from the point of view of delivery systems, advances in the field of
drug-nucleic acid combination require efficient delivery strategies for both chemotherapy
drug and nucleic acids. It would be beneficial to design dual delivery systems for such
applications. Considering the effectiveness of polymer-based delivery systems in
nucleic acid delivery, and the possible advantages of designing polymeric prodrugs, it is
favorable to design a dual delivery system that combines the prodrug functionality and
gene delivery capability. The design of such dual delivery platforms will be the major
topic of Chapter 3, 4 and 5.
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CHAPTER 2
IDENTIFICATION OF SYNERGISTIC EFFECT OF BENSPM WITH OTHER
THERAPEUTIC AGENTS

2.1 Introduction
As discussed in Chapter 1, BENSpm is one of the most successful polyamine
analogues developed to target polyamine pathway [188, 226]. The general mechanism
of action of BENSpm is to up-regulate metabolism enzymes SSAT and SMO, while at
the same time, down-regulate biosynthesis enzyme ODC. BENSpm depletes all natural
polyamines (SPM, SPD and PUT) and leads to apoptosis and cell growth inhibition in a
wide range of cancers [158, 176, 177, 180, 182]. Recent advances in polyamine
research reveal that BENSpm can act synergistically with various chemotherapy drugs
[197, 227], thus providing the rationale for us to expand the knowledge of BENSpm
synergism with other kinds of therapeutic agents.

2.1.1. Tumor necrosis factor-related apoptosis-inducing ligand (TRAIL)
One promising candidate in combination cancer therapy is called TRAIL, which is
a therapeutic protein from the TNF family. In human, there are five TRAIL receptors:
DR4, DR5, DcR1, DcR2 and osteoprotegerin (OPG) [228]. DR4 and DR5 are the death
receptors capable of inducing apoptosis, while the other three are decoy receptors to
antagonize apoptosis by competing for ligand binding. TRAIL is attractive in cancer
treatment because transformed cells are generally more sensitive to TRAIL-induced
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apoptosis, compared with normal cells. One possible explanation for TRAIL selectivity is
that TRAIL's death receptors (DR4 and DR5) are mainly expressed in transformed cells
while its decoy receptors (DcR1, DcR2 and OPG) are expressed in normal cells [229],
which renders the cancer cells more sensitive to TRAIL treatment. Recombinant human
TRAIL protein (rhTRAIL) was tested as a single anti-cancer agent in phase I clinical trial
in advanced cancer patients and demonstrated no apparent toxicity [230]. In another
phase I clinical trial, rhTRAIL was tested in combination with rituximab, an anti-CD20
antibody, in non-Hodgkin lymphoma patients, which yielded 2 complete and 1 partial
response in patients [231, 232].

Although a recent phase II study demonstrated

unsatisfactory outcome in non-small-cell lung cancer patients by combination treatment
of rhTRAIL with three different chemotherapy drugs (paclitaxel, carboplatin and
bevacizumab), most recent preclinical and clinical studies of TRAIL are still focusing on
combination strategies [231]. Preclinical studies revealed that some cancer cells are
able to gain resistance to TRAIL after repeated exposure [233]. Therefore it would be
more efficient to administer TRAlL in combination with other chemotherapy agents,
which may sensitize the cells to TRAIL treatment and minimize the possibility of
resistance. Although it has been reported that combining TRAIL with various drugs such
as kinase inhibitors, histone deacetylase inhibitors and genotoxic drugs is beneficial
[234], combination of TRAIL with agents targeting polyamine pathway has never been
explored.

2.1.2. RNAi targets
RNAi targets are also being extensively studied in combination therapy. We are
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mainly focusing on three popular RNAi targets, Akt-2, Poly (ADP-ribose) polymerase
(PARP) and survivin, due to their active role in cancer. Akt-2 gene is known as a
putative oncogene encoding a serine/threonine-protein kinase. It belongs to the
PI3K/AKT/mTOR signaling pathway and plays an important role in balancing cell
survival and apoptosis. Reports showed that this gene is amplified in human breast
cancer cells, human ductal pancreatic cancers and human ovarian carcinoma cell lines
[235-238]. Overexpression of Akt-2 is associated with up-regulation of metastasis in
breast cancer [239, 240]. Therefore Akt-2 is expected to be a good target for RNAi
therapy,

especially

in

the

treatment

of

metastatic

cancer

cells

with

Akt-2

overexpression. PARP is a protein involved in DNA repair process. It helps to maintain
cell survival and overexpression of PARP is observed in different cancers such as
breast cancer, ovarian cancer, colon cancer and melanoma [241]. Inhibition of PARP
using either siRNA or small molecule inhibitors has shown promising therapeutic effect
for breast/ovarian cancer treatment [242-245], thus rendered PARP as a promising
therapeutic target. Survivin is known to negatively control cell apoptosis pathway by
inhibiting caspase activation. It is highly expressed in different cancer cells such as
breast cancer and colon cancer [246, 247]. Silencing of survivin gene by RNAi is
reported to effectively suppress tumor growth [248, 249]. To date, all the three targets
are being vigorously investigated in combination with chemotherapy drugs [250-255],
thus attracts our attention to test them in combination with polyamine analogue
BENSpm.

2.1.3. Evaluation of combination effect
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In order to evaluate the combination effect of BENSpm with the above-mentioned
therapeutic agents, it is necessary to use a suitable statistical method. We employed
the Chou-Talalay method for quantification of synergism [256, 257]. This method is
based on the median-effect equation, which is a unified general theory to describe the
dose-effect relationships:

fa ⎛ D ⎞
=
fu ⎜⎝ Dm ⎟⎠

m

(1)

Where fa and fu are the fractions of cell population that are affected or unaffected,
respectively. Therefore, (fa + fu) equals 1 by definition. D is the dose used to achieve the
certain effect, and Dm is the required dose to achieve median effect (IC50 in the case of
cell killing). Depending on the value of m, the median-effect equation described various
relationships between dose and response: m = 1 indicates hyperbolic dose response; m
> 1 indicates sigmoidal and m < 1 indicates flat sigmoidal dose response curve [258].
When applied to multiple drugs, for example, the combinations of two drugs (D1
and D2) with mutually exclusive drug effect, the drug-effect equation can be derived in
the following form:
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Where (fa)1,2 is the fraction of population effect in combination of the two drugs; (fa)1 and
(fa)2 are the fractions of affected cell population in the presence of single drug D1 and
D2, respectively. Detailed description of how the equation was derived was published
by Chou et al. in 1981 [259]. Based on this equation, Chou and Talalay later introduced
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the combination index (CI) for quantitative evaluation of synergism between two drugs,
where the CI value was defined as:

CI =

(D ) + (D )
(D ) (D )
1

x 1

2

x 2

(3)

The value of (Dx)1 and (Dx)2 indicates the doses of drug D1 or D2 alone to achieve a
certain effect x, respectively. (D)1 and (D)2 are the doses of drug D1 and D2 in
combination to achieve the same effect. CI < 1, = 1, and > 1 indicate synergism,
additive effect, and antagonism, respectively. The isobologram, a 2-dimensional
diagram showing varying concentrations of two drugs that resulted in constant effect, is
usually used to demonstrate the combination effect (Figure 6a) [260]. To achieve a
certain cell killing effect, for example 50% cell killing, doses of drug D1 and D2 used in
combination can be plotted on the isobologram as a point (x,y), where the x and ycoordinates indicate the respective doses of both drugs. When single drug is used, the
doses can be plotted on the axes where y = (IC50)1 and x = (IC50)2. The line connecting
these two points is the line of additivity. Synergism, additive effect, or antagonism is
indicated when the doses used in combination (x,y) are located below, on, or above the
line, respectively. Normalizing the x- and y-axis by dividing the value of drug D1 and D2
doses in combination by the constant of single drug dose to achieve the same effect
generates the normalized isobologram, where the sum of the x and y-coordinates
indicates the CI value (Figure 6b) [261]. It can be observed from this graph that smaller
CI value indicates stronger synergism. The opposite applies to antagonism, where the
larger the CI value is, the stronger antagonism is indicated. In fact, CI value can be
categorized as follows: CI < 0.1 very strong synergism; 0.1-0.3 strong synergism; 0.3-
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0.7

synergism;

0.7-0.9

moderate/slight

synergism;

0.9-1.1

additive;

1.1-1.45

slight/moderate antagonism; 1.45-3.3 antagonism; 3.3-10 strong antagonism; CI > 10
very strong antagonism [261]. In addition to CI, another important parameter that can be
obtained from the median effect/CI model is the dose-reduction index (DRI), which is
defined as:

(D )
(DRI ) = (D )

x 1

1

1

(4)

DRI indicates how many fold the dose of each drug in combination can be reduced,
compared with the doses of each drug alone [261]. In summary, CI and DRI values
allow the quantitative determination of synergistic effect between two agents. This
model will be used in our study of agents that synergize with BENSpm in cancer
therapy.

Figure 6. Isobologram of IC50. (a) A typical isobologram for two drugs with the doses
indicated at x- and y-axis. (b) Normalized isobologram of two drugs with the doses
normalized as the ratio compared with IC50 of single drugs. Modified from [261].
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2.2 Materials and Methods
2.2.1 Materials
Trypsin-like enzyme (TrypLE Express) was purchased from Gibco (Invitrogen,
Carlsbad, CA). Fetal bovine serum (FBS), Dulbecco’s phosphate buffered saline (PBS),
RPMI 1640 Medium and Penicillin-Streptomycin were purchased from Thermo Scientific
(Logan, UT). Recombinant human TRAIL/Apo2L protein was purchased from
PeproTech (Rocky Hill, NJ). Negative control siRNA (ON-TARGET plus Non-targeting
siRNA #1) was purchased from Dharmacon (Lafayette, CO). SignalSilence® siRNAs:
Akt-2, survivin, and PARP with the corresponding antibodies: Akt-2 rabbit mAb, survivin
mouse mAb and PARP rabbit mAb were from Cell Signaling Technology (Beverly, MA).
Lipofectamine™ RNAiMAX transfection reagent was purchased from Invitrogen (Grand
Island, NY). N,N'-Bis(3-aminopropyl)-1,3-propanediamine (norspermine) and di-tertbutyl dicarbonate (Boc2O) were from Alfa Aesar (Ward Hill, MA). Triethylamine (TEA)
was purchased from Acros Organic (Fair Lawn, NJ). Sodium hydride (NaH, 60%
suspension in oil) and magnesium sulfate (MgSO4) were from Sigma-Aldrich (St. Louis,
MO). All other reagents and chemicals were obtained from Fisher Scientific or VWR
International unless otherwise noted.

2.2.2 Synthesis of BENSpm
1

H NMR spectra were recorded on Mercury-400 MHz Spectrometer and chemical

shifts (δ) were expressed in ppm. BENSpm was synthesized following published
procedure via three step reaction [155]:
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Boc-protected norspermine. Briefly, norspermine (6.16 g, 32.7 mmol) and TEA
(16.6 g, 101.2 g/mol, 164 mmol) were dissolved in 200 mL methanol. Boc2O (32.3 g,
148 mmol) was dissolved in 80 mL methanol in dropping funnel and then add to the
solution of norspermine and TEA as the rate of 1 drop/sec. Reaction was kept overnight
in water bath at room temperature. Thin layer chromatography (TLC) was used to
monitor the reaction till completion (hexane: ethyl acetate = 2: 1, Rf = 1/3). Methanol
was then completely removed in vacuo. Product was further run through silica gel
column for purification (hexane: ethyl acetate = 3: 1, column size = 1000 mL, yield =
95%).
Alkylation of Boc-protected norspermine. Boc-protected norspermine (19.26 g, 33
mmol) and iodoethane (20.4 g, 10.5 mL, 131 mmol) were dissolved in dry DMF/THF (1:
4, 350 mL), to which solution NaH (4.8 g, 198 mmol, equals to 8 g 60% oil dispersion)
was carefully added. Reaction was kept in ice bath during NaH addition and then moved
to room temperature and stirred overnight. TLC was used to verify the completion of
reaction (hexane: ethyl acetate = 2: 1, Rf = 0.4). Water was then added to the reaction
mixture dropwise to consume the excess of NaH (50 mL DW). The reaction mixture was
then extracted with hexane. Hexane layer was then washed with saturated sodium
chloride (140 mL) and dried with MgSO4. Solution was concentrated on rotary
evaporator and purified by silica gel column (hexane: ethyl acetate = 3: 1, column size =
1000 mL) to give the Boc-protected BENSpm.
Boc deprotection. Boc-protected BENSpm (20.6 g, 32 mmol, 640 g/mol) was
dissolved in 200 mL isopropanol. HCl solution in isopropanol (6 N HCl, 26 mL) was
added. The reaction mixture was refluxed overnight. White solid formed during the
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reaction. The reaction mixture was then kept at -20 °C to facilitate the precipitation. The
solid was then filtered and dried in vacuum. Solid was suspended in 150 mL methanol
with 13 mL HCl (6 N in isopropanol) added. The mixture was refluxed for an additional 6
h and the solid was filtered and dried to give BENSpm (HCl salt, 390 g/mol, 11.47g,
yield 91.9%): NMR (400 MHz, D2O) δ 1.28 (t, 6H), 2.07-2.18 (m, 6H), 3.09-3.21 (m,
16H).

2.2.3 Cell culture
MCF-7 human breast adenocarcinoma cells were cultured in RPMI medium with
10% FBS. MDA-MB-231 human breast cancer cells were cultured in RPMI with 10%
FBS and 1% penicillin/streptomycin. All cells were cultured at 37 °C in incubator with
5% CO2.

2.2.4 Transfection of siRNAs and Western blotting analysis
Transfection

was

done

using

Lipofectamine™

RNAiMAX

following

manufacturer’s instructions. Briefly, MDA-MB-231 cells were seeded in 6-well plate at a
density of 300,000 cells/well, and were allowed to attach overnight. For each well,
appropriate amount of siRNA (36 pmol, final concentration 10 nM) was diluted in 300 µL
RPMI (without FBS), and in another tube, 6 µL of Lipofectamine™ RNAiMAX was
diluted in 300 µL RPMI (without FBS). The two solutions were then mixed and incubated
at room temperature for 20 min to allow lipoplexes formation. The lipoplexes were
added dropwise onto the cells (600 µL lipoplexes solution to 3 mL medium per well).
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After 48 h incubation, cells were lysed and diluted with 4× NuPAGE® LDS sample buffer
(Invitrogen). Collected cell lysates were then homogenized by sonication and the
supernatants were loaded for polyacrylamide gel electrophoresis (PAGE) and
electroblotted to nitrocellulose using the Mini Trans-Blot® system (Bio-Rad), as
previously described [262]. Blots were developed using Immobilon Western
Chemiluminescent HRP Substrate (Millipore) and were imaged using FUJIFILM
Luminescence Image Analyzer LAS-1000plus.

2.2.5 Cytotoxicity assay
MDA-MB-231 cells were treated with increasing concentration of TRAIL,
BENSpm, or BENSpm in combinations with Akt-2, survivin and PARP siRNAs for a
required time length for the drug action. Concentrations of siRNAs were 10 nM in each
well, which was delivered with Lipofectamine™ RNAiMAX using the same formulation
as for the Western blot assay. For the combination of BENSpm and TRAIL, MDA-MB231 and MCF-7 cells were incubated in 200 µL medium per well in 96-well plate with
increasing concentration of BENSpm, TRAIL or their combinations. Medium was
replaced once at 48 h with fresh medium containing the same concentration of the
respective agents.
At the end of the treatment, drug-containing medium was aspirated and replaced
by a mixture of 100 µL serum-free media and 20 µL of MTS reagent (CellTiter 96®
AQueous Non-Radioactive Cell Proliferation Assay, Promega). After 2 h incubation, the
absorbance was measured at a wavelength of 490 nm using Synergy 2 Microplate
Reader (BioTek). The relative cell viability (%) was calculated as [A]sample/[A]untreated ×
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100%. The IC50 were calculated as the drug concentration that inhibits growth of 50% of
cells relative to untreated cells using GraphPad Prism [263].

2.2.6 Analysis of synergistic effect of BENSpm and TRAIL combination
The median effect/CI model was used to determine synergy of the combination
treatment of BENSpm with TRAIL. The fraction of killed cells (fa) was determined by
MTS assay described above (fa= 1- cell viability%). Results were analyzed by
CompuSyn software (ComboSyn, Inc. Paramus, NJ) for the CI and DRI values to
quantitatively determine the synergism of BENSpm and TRAIL combination [261].

2.3 Results and Discussion

Scheme 2. The synthesis route of BENSpm.
2.3.1 Synthesis of BENSpm
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BENSpm was synthesized by selective alkylation of Boc-protected norspermine
at the primary amine ends (Scheme 2). The structure of BENSpm and complete
deprotection of Boc were confirmed by 1H NMR (Figure 7). Compared with the parent
norspermine, the primary amines are alkylated with ethyl groups in BENSpm. This
prevents oxidation by multiple amine oxidases in the cells and prolongs the duration of
BENSpm activity in targeting the polyamine pathway in cells [103]. The synthesized
BENSpm (HCl salt) was used for the following studies.

Figure 7. 1H-NMR spectra of BENSpm (HCl salt).
2.3.2 Combination effect of BENSpm and TRAIL with siRNAs
Western blot analysis verified that transfection of Akt-2, survivin and PARP
siRNAs all resulted in significant knockdown of the corresponding proteins in MDA-MB231 cells after 48 h incubation (Figure 8a). Since the required time length for BENSpm
drug action is 120 h [199], cytotoxicity of BENSpm in combination with siRNAs was
tested in the 120 h time frame. As shown in Figure 8b, where the points on y-axis
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indicated the cell viability followed siRNAs treatment alone (as concentration of
BENSpm equals zero), 120 h transfection with siRNAs resulted in significant cell killing.
However, the cytotoxicity was predominantly associated with the delivery system, since
significant cytotoxicity was observed not only in functional siRNAs treat cells, but also in
control siRNA (ctrl siRNA) group (cell viability of 52% in ctrl siRNA group vs. ~33-36% in
functional siRNAs groups). Cytotoxicity of combination of BENSpm with the functional
siRNAs was not significantly different from BENSpm and ctrl siRNA co-treatment. It
could be concluded that, although the pro-survival proteins Akt-2, survivin and PARP
can be efficiently depleted by siRNA transfection, it did not necessarily sensitize the
breast cancer cells towards BENSpm-related growth inhibition. The somewhat
disappointing result from siRNA combinations demonstrated the complexity of drugcombination effect, and synergism need to be experimentally identified on a case-bycase basis.

Figure 8. Combination of Akt-2, survivin and PARP siRNAs with BENSpm in MDAMB-231 cells. (a) Western blot analysis of MDA-MB-231 cells treated with 10 nM
survivin, PARP or Akt-2 siRNAs. β-actin is used as a loading control.(b) Combination
of siRNAs with BENSpm for 120 h in MDA-MB-231 cells. Results were expressed as
mean cell viability% ± SD (n=4).
2.3.3 Combination effect of BENSpm with TRAIL
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In order to determine the combination effect of BENSpm and TRAIL, a constant
molar ratio of BENSpm and TRAIL which equals to the ratio of their IC50
(BENSpm:TRAIL 14,700:1) was used in combination for MDA-MB-231 cells. For MCF-7
cell line, which is more resistant to TRAIL treatment, a constant concentration of TRAIL
(35 ng/mL) was used in combination. Four to six doses were used in serial dilutions
covering the activity range of BENSpm and TRAIL. The CI value and DRI value were
calculated by the Chou-Talalay method using CompuSyn software [264]. As shown in
Figure 9, we first tested whether the parent BENSpm enhances activity of the TRAIL
protein in triple-negative breast cancer cells MDA-MB-231. The observed CI values
were <0.04 across the entire studied fa range, indicating a very strong synergy between
BENSpm and TRAIL. We then expand the combination to another type of breast cancer
cell, the estrogen-dependent MCF-7 cell line. As shown in Figure 10, less potent but still
strong synergy between BENSpm and TRAIL was found also in the MCF-7 cell.

Figure 9. Synergistic activity of BENSpm and TRAIL in MDA-MB-231 cells. (a)
Cytotoxicity of increasing concentration of TRAIL, BENSpm or their combination for
120 h. Cell viability was measured by MTS assay (n=3-4). (b) CI value and DRI
calculated for each dose of BENSpm and TRAIL in combination using CalcuSyn
software.

56
In addition, the calculated DRIs range for TRAIL treatment were 59-283 and 2.56.3 respectively, in MDA-MB-231 cells and MCF-7 cells. The result that ~280-fold dose
reduction for TRAIL protein could be achieved when combined with BENSpm in MDAMB-231 cells is especially promising for the application of nonviral gene delivery. As
gene delivery is hampered by the low transfection efficiency, this finding provides the
rationale for designing BENSpm based gene delivery system to deliver therapeutic
genes (e.g., TRAIL), and enhanced treatment outcome is expected through the
combination.

Figure 10. Synergistic activity of BENSpm and TRAIL in MCF-7 cells. (a) Cytotoxicity
of increasing concentration of BENSpm alone or in combination with TRAIL (35
ng/ml) was measured by MTS assay (n=3-4). (b) CI value and DRI calculated for
each dose of BENSpm and TRAIL in combination using CalcuSyn software.
2.4 Conclusions
As a proof-of-concept, we test the combination effect of BENSpm with several
therapeutic agents. Firstly, combination of BENSpm with functional siRNAs did not
show beneficial outcome over the BENSpm combination with negative control siRNA,
indicating no synergistic effect of BENSpm combined siRNA treatment in breast cancer
MDA-MB-231 cells. However, we later identified strong synergistic combination of
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BENSpm with potential therapeutic gene product TRAIL. For both cell lines tested,
which are representative estrogen-dependent and triple-negative breast cancers,
BENSpm and TRAIL combination demonstrated strong synergism and offers potential
advantages to reduce the required treatment dose. Because the synergism is obtained
regardless of the cell line sensitivity to TRAIL, this combination strategy offers additional
benefits to overcome drug resistance in chemotherapy. In all, this finding inspired us for
the attempt to develop BENSpm-based delivery system for the co-delivery of genes and
BENSpm drug, which may further boost the therapeutic effect of the cargo genes.
Design of the dual delivery systems will be further discussed in the following chapters.
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CHAPTER 3
SYNTHESIS OF BISETHYLNORSPERMINE LIPID PRODRUG AS GENE DELIVERY
VECTOR TARGETING POLYAMINE METABOLISM IN BREAST CANCER

Please note that the content of this chapter was published in Molecular
Pharmaceutics [265]. As the second author of the study, I performed particle size and
zeta potential measurements, cytotoxicity assays in MDA-MB-231 cells (cytotoxicity in
MCF-7 cells were measured by Dr. C. Wu, the fifth author), luciferase transfection in
MDA-MB-231 cells (transfection in B16F10 cells and MCF-7 cells were performed by
Dr. Q. Zhou, the fourth author), SSAT assay and analysis of the combination treatment.
The first author Dr. Y. Dong performed the synthesis and chemical characterization of
the lipids. Dr. J. Li, the third author, performed agarose gel retardation assay and
ethidium bromide exclusion assay. All the authors agreed with including their work in
this dissertation.

3.1

Introduction
Successful implementation of novel gene therapy protocols requires the

development of strategies to effectively deliver nucleic acids to disease targets. Cationic
lipids and polymers continue to gain strength as viable alternatives to viral delivery
vectors. However, progress in the development of these vectors continues to be
hampered by their low transfection activity and toxicity of the cationic molecules. The
classical biomaterial design paradigm: “preparing vectors that are biodegradable into
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nontoxic low-molecular weight byproducts” yielded many cationic lipids and polymers
with acceptable toxicity. Although the toxicity can be decreased to some extent by using
biodegradable molecules, amplifying transfection activity is the more difficult problem to
solve because it involves complex delivery across multiple barriers. One way to
overcome the low transfection is to combine a therapeutic gene with traditional smallmolecule drugs that enhance the gene’s therapeutic activity [266, 267]. Such drug/gene
combination therapies can be accomplished by a simple combination of gene therapy
protocols with existing drugs. Alternatively, synthetic gene delivery vectors can be
designed that not only deliver a gene but also augment the activity of the gene by
exerting their own pharmacologic effect.
There are a growing number of successful examples of drug and gene delivery
vectors that combine the delivery function with a pharmacologic activity. For example,
Prof. Huang’s group developed a novel cationic lipid capable of delivering siRNA while
simultaneously enhancing siRNA antitumor effect by down-regulating pERK [71].
Pluronic copolymers have been shown to chemosensitize multidrug resistant cancers by
inhibiting P-glycoprotein and decreasing cellular ATP pools [88]. Peptides with intrinsic
proteasome inhibitory function have been shown to deliver and enhance transfection
activity of plasmid DNA [90]. Cyclodextrins, widely used as excipients and as parts of
drug delivery vectors, have been shown to have activity in the treatment of a lysosomal
storage disorder [268].
Natural polyamines SPD, SPM, and their diamine precursor PUT are essential
factors for growth of eukaryotic cells. We have recently proposed dually functioning
cationic gene delivery vectors based on polyamine analogues [269]. These agents
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exploit the self-regulatory nature of the metabolism of cellular polyamines and have
multiple targets in the polyamine pathway. Polyamine metabolism is frequently
dysregulated in cancer and other hyper-proliferative diseases [101]. The polyamine
pathway is a distal downstream target for a number of oncogenes, and inhibition of
polyamine synthesis disrupts the action of those genes [101, 270, 271]. All these factors
make polyamine analogues attractive building blocks in the design of delivery vectors
that can not only deliver a therapeutic gene but also augment the activity of the gene by
exerting their own pharmacologic effect. The goal of this study was to develop
biodegradable lipid prodrug based on the polyamine analogue BENSpm that can
function dually as gene delivery vector and, after intracellular degradation, as active
pharmacologic agent that synergistically augments the activity of a therapeutic gene in
cancer. We have also tested the hypothesis that the synthesized lipid BENSpm prodrug
will enhance activity of TRAIL in breast cancer.

3.2

Materials and Methods

3.2.1. Materials
Dioctadecylamine, 4-mercaptobenzoic acid, lithium aluminium hydride, HOBt (1hydroxybenzotriazole),

1-(3-N,N-dimethylaminopropyl)-3-ethylcarbodiimide

hydrochloride (EDCI), 3,3’-dithiodipropionic acid, zinc powder, carbomethoxysulfenyl
chloride, p-nitrophenyl chloroformate, trifluoroacetic acid (TFA), dithiothreitol (DTT),
hydroxylamine monochloride, spermidine, and ethidium bromide (EtBr) were purchased
from Sigma-Aldrich (St. Louis, MO). [14C]-Acetyl-CoA was purchased from PerkinElmer
(Waltham, MA). Biodegradable scintillation cocktails (Bio-Safe NA™ for non-aqueous
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samples, Bio-Safe II™ for aqueous samples) were purchased from RPI Corp. (Mount
Prospect, IL). Trypsin-like enzyme (TrypLE Express) was purchased from InvitrogenGibco (Carlsbad, CA). RPMI 1640 Medium, Dulbecco’s Modified Eagle’s Medium
(DMEM), fetal bovine serum (FBS), and Dulbecco’s phosphate buffered saline (PBS)
were purchased from Thermo Scientific-Hyclone (Logan, UT). Plasmid DNA, gWizTM
high-expression luciferase, containing luciferase reporter gene was from Aldevron
(Fargo, ND). Luciferase assay system with reporter lysis buffer was purchased from
Promega (Madision, WI). Recombinant human TRAIL/Apo2L protein was purchased
from PeproTech (Rocky Hill, NJ).

LipoBEN was synthesized as described in our

previous publication [269]. All other reagents and solvents were purchased from
commercial suppliers and were used without further purification unless otherwise stated.

3.2.2. Synthesis
NMR spectra were recorded on a Varian FT-NMR Unity-300, Mercury-400 or
Mercury-500 MHz spectrometer. Chemical shifts (δ) are expressed in ppm and are
internally referenced (0.00 ppm for TMS for 1H NMR and 77.0 ppm for CDCl3 for

13

C

NMR). Mass spectra were recorded on a Waters ZQ2000 single quadrupole mass
spectrometer using an electrospray ionization source.
Synthesis of 3. A suspension of 3,3′-dithiodipropionic acid 2 (105 mg, 0.5 mmol)
and HOBt (203 mg, 1.5 mmol) in anhydrous CHCl3 (30 mL) was added to the solution of
EDCI (233 mg, 1.5 mmol) in anhydrous CHCl3 (10 mL) at 0 °C, followed by addition of
the mixture of TEA (152 g, 0.21 mL, 1.5 mmol) and dioctadecylamine 1 (522 mg, 1
mmol) in CHCl3 (10 mL). The resulting mixture was stirred at room temperature for 12 h,
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when it turned to a clear solution. The reaction mixture was then partitioned with water
(15 mL) at 0 °C. The organic layer was separated, and the water layer was extracted
with CHCl3 (3 × 10 mL). Combined organic layers were washed with brine, dried over
anhydrous Na2SO4, and evaporated under vacuum to give the crude product. The
residue was dry-loaded to a silica gel column, and separation (eluent: CHCl3/ethyl
acetate 4:1) gave the product 3 (0.58 g, 95%) as a white solid. Rf 0.85 (CHCl3). Mp 3839 °C. 1H NMR (400 MHz, CDCl3): δ 3.29 (bt, J = 7.8 Hz, 4H), 3.22 (bt, J = 7.6 Hz, 4H),
2.96 (t, J = 7.0 Hz, 4H), 2.73 (t, J = 7.4 Hz, 4H), 1.55-1.50 (m, 8H), 1.26 (bs, 112H),
0.88 (t, J = 6.6 Hz, 12H).

13

C NMR (100 MHz, CDCl3): 170.2, 47.9, 46.0, 33.5, 32.7,

31.9, 29.65, 29.60 (m), 29.55, 29.51, 29.4, 29.3, 29.1, 27.7, 27.0, 26.9, 22.6, 14.0. ESI
MS (m/z): calcd for C78H156N2O2S2 [M + H]+ 1218.16, found 1217.99; [M + Li]+ 1224.17,
found 1224.00; [M + K]+ 1256.12, found 1255.96.
Synthesis of 4. The synthesis of 4 followed previous publication [272]. To a
solution of 3 (0.55 g, 0.79 mmol) in acetic acid (10 mL) was added zinc powder (0.51 g,
7.9 mmol) at 0 °C. The mixture was refluxed for 40 min and monitored by TLC (viewed
by UV and stained by DTNB). The mixture was filtered over Celite and washed with
CHCl3. The obtained organic solution was evaporated under vacuum. The residue was
flushed with nitrogen to remove excess acetic acid. The white solid was dissolved in
CHCl3 (10 mL) and washed with water to neutrality. The combined organic layers were
then washed with brine, dried over anhydrous Na2SO4, and concentrated under
vacuum. The residue was purified by silica gel column (eluent: CHCl3/ethyl acetate 4:1)
to give the product 4 (0.55 g, 100%) as a white solid. Rf 0.52 (CHCl3). Mp 44-45 °C. 1H
NMR (400 MHz, CDCl3): δ 3.30 (bt, J = 7.8Hz, 2H), 3.20 (bt, J = 7.8 Hz, 2H), 2.80 (bq,
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J1 = 7.6 Hz, 2H), 2.63 (t, J = 6.6 Hz, 4H), 1.72 (t, J = 8.4 Hz), 1.53 (m, 4H), 1.26 (bs,
56H), 0.88 (t, J = 7.0 Hz, 6H). 13C NMR (100 MHz, CDCl3): 169.9, 47.7, 45.9, 37.0, 31.8,
29.60, 29.56 (m), 29.5, 29.4, 29.3, 29.2, 28.9, 27.7, 26.9, 26.8, 22.6, 20.2, 13.9. ESI MS
(m/z): calcd for C39H79NOS [M + H]+ 610.59, found 610.51; [M + Li]+ 616.60, found
616.52; [M + K]+ 648.55, found 648.47.
Synthesis of 5. The solution of 4 (0.53 g, 0.87 mmol) in methanol (5 mL) was
added dropwise to a solution of carbomethoxysulfenyl chloride (0.11 g, 0.87 mmol) in
methanol (10 mL) and CHCl3 (20 mL) at 0 °C. The mixture was stirred for 30 min at 0
°C, then allowed to reach room temperature, and after 4 h evaporated under vacuum.
The obtained residue was dissolved in CHCl3 (10 mL) and purified on silica (CHCl3/ethyl
acetate 4:1). Pure product 5 was obtained as colorless oil, which turned to a white solid
when kept in a freezer (0.55 g, 90%). Rf 0.39 (CHCl3). Mp 36-37 °C. 1H NMR (400 MHz,
CDCl3): δ 3.88 (s, 3H), 3.29 (bt, J = 7.8 Hz, 2H), 3.20 (bt, J = 7.8 Hz, 2H), 3.01 (t, J =
7.2 Hz, 2H), 2.72 (t, J = 7.0 Hz, 4H), 1.52 (m, 4H), 1.26 (bs, 56H), 0.88 (t, J = 7.0 Hz,
6H). 13C NMR (100 MHz, CDCl3): 170.1, 169.7, 55.2, 47.8, 46.0, 35.1, 32.7, 31.9, 29.63,
29.59, 29.52 (m), 29.5, 29.3, 29.2, 29.0, 27.7, 26.9, 26.8, 22.6, 20.2, 14.0. ESI MS
(m/z): calcd for C41H81NO3S2 [M + H]+ 700.57, found 700.57; [M + Na]+ 722.55, found
722.54; [M + Li]+ 706.58, found 706.58; [M + K]+ 738.52, found 738.51.
Synthesis of 6. A solution of 4-mercaptobenzoic acid (0.77 g, 5 mmol) in dry
THF (10 mL) was added dropwise to a suspension of lithium aluminum hydride (0.57 g,
15 mmol) in dry THF (10 mL) under nitrogen at 0 °C [273]. The mixture was stirred
overnight at room temperature. Water (5 mL) was added, followed by aqueous HCl (1
N, 5 mL) at 0 °C, and the mixture was stirred for 5 min. The solution was extracted with
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diethyl ether (3 × 10 mL). The organic layer was washed with H2O (20 mL) and brine (10
mL), dried over anhydrous Na2SO4, and then concentrated under vacuum at room
temperature. The residue was purified by a short silica gel column to give the product as
a white solid (0.56 g, 80%). Rf 0.28 (hexane: EA 2: 1) Mp 49-51 °C. 1H NMR (400 MHz,
CDCl3): δ 7.26-7.20 (m, 4H), 4.60 (s, 2H), 3.45 (s, 1H), 2.00 (bs, 1H).

13

C NMR (100

MHz, CDCl3): 138.3, 129.9, 129.5, 127.8, 64.7.
Synthesis of 7. A solution of 6 (0.32 g, 2.28 mmol) in CH3OH/CHCl3 (5 mL/10
mL) was added to a solution of 5 (0.53 g, 0.76 mmol) in CH3OH (5 mL) at 0 °C under
nitrogen. The mixture was stirred for 1 h at 0 °C and then warmed to room temperature.
After 3 days, the mixture was evaporated and the obtained residue was dissolved by
CHCl3 and purified by a short silica gel column (hexane/ethyl acetate 3:1). Compound 7
was obtained as colorless oil, which turned to a white solid in the freezer (0.42 g, 75%).
Rf 0.38 (hexane/ethyl acetate 3: 1). Mp 40-41 °C. 1H NMR (400 MHz, CDCl3): δ 7.47 (d,
J = 8.4 Hz, 2H), 7.28 (d, J = 8.4 Hz, 2H), 4.61 (s, 2H), 3.35 (bs, 1H), 3.24 (bt, J = 7.6
Hz, 2H), 3.10 (bt, J = 7.8 Hz, 2H), 2.96 (t, J = 7.0 Hz, 2H), 2.66 (t, J = 7.2 Hz, 2H), 1.47
(m, 4H), 1.26 (bs, 56H), 0.88 (t, J = 7.0 Hz, 6H).
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C NMR (100 MHz, CDCl3): 170.1,

140.2, 135.9, 127.6, 127.4, 64.1, 47.8, 46.0, 34.0, 32.4, 31.8, 29.58, 29.54, 29.47 (m),
29.4, 29.3, 29.2 (m), 28.9, 27.6, 26.9, 26.7, 22.6, 14.0. ESI MS (m/z): calcd for
C46H85NO2S2 [M + H]+ 748.60, found 748.61; [M + Na]+ 770.59, found 770.60; [M + Li]+
754.62, found 754.63; [M + K]+ 786.57, found 786.59.
Synthesis of 8. p-Nitrophenyl chloroformate (0.23 g, 1.12 mmol) was added to a
solution of 7 (0.42 g, 0.56 mmol) in anhydrous CHCl3 at 0 °C under nitrogen, followed
by TEA (0.234 mL, 1.68 mmol). The mixture was stirred for 30 min and then warmed to
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room temperature. After stirring for 24 h, the mixture was evaporated and the obtained
residue was dissolved in CHCl3 and purified by a short silica gel column (hexane/ethyl
acetate 5:1). Recrystallization from ethyl acetate gave the pure product 8 as a white
solid (0.36 g, 70%). Rf 0.37 (hexane/ethyl acetate 5:1). Mp 52-53 °C. 1H NMR (400
MHz, CDCl3): δ 8.27 (d, J = 8.8 Hz, 2H), 7.58 (d, J = 8.8 Hz, 2H), 7.41− 7.37 (m, 4H),
5.27 (s, 2H), 3.28 (bt, J = 7.8 Hz, 2H), 3.14 (bt, J = 7.8 Hz, 2H), 3.04 (t, J = 7.0 Hz, 2H),
2.71 (t, J = 6.8 Hz, 2H), 1.48 (m, 4H), 1.26 (bs, 56H), 0.88 (t, J = 6.6 Hz, 6H).

13

C NMR

(100 MHz, CDCl3): 169.9, 155.4, 152.4, 145.4, 138.7, 132.6, 129.4, 127.2, 125.2, 121.7,
70.3, 47.8, 46.1, 34.2, 32.5, 31.9, 29.66, 29.62, 29.6 (m), 29.4, 29.3, 29.0, 27.7, 27.0,
26.8, 22.6, 14.1. ESI MS (m/z): calcd for C53H88N2O6S2 [M + H]+ 913.62, found 913.72;
[M + Na]+ 935.60, found 935.69; [M + Li]+ 919.62, found 919.74.
Synthesis of Lipo-SS-BEN. BENSpm·4HBr (0.705 g, 1.25 mmol) was stirred with
solid sodium hydroxide (1.0 g, 25 mmol) in anhydrous CHCl3 (20 mL) for 3 h at room
temperature. Anhydrous Na2SO4 (1.0 g) was added, and the mixture was stirred for
another 30 min. Filtration and washing with CHCl3 (10 mL) gave a solution that
contained free base BENSpm (1.25 mmol). The obtained BENSpm solution in CHCl3
was cooled downed to 0 °C, and a solution of 8 (0.23 g, 0.25 mmol) in anhydrous CHCl3
(15 mL) was added dropwise under nitrogen. After addition, the reaction mixture was
stirred at 0 °C for 2 h to reach completion based on TLC. The reaction mixture was
purified by a short silica gel column (methanol/ethyl acetate 1: 1) to remove pnitrophenol, followed by elution with CH2Cl2/CH3OH/sat. NH3 (25: 10: 0.5). The collected
eluent containing product was neutralized with 5 M acetic acid to pH 7.4. Evaporation
under reduced pressure at 25 °C gave a solid residue. Residual ammonium acetate was
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removed under vacuum at room temperature to give the product as acetate salt (0.36 g,
70%, kept at -40 °C). Rf 0.46 (CH2Cl2/CH3OH/sat. NH3 25:10:1). Mp 36-40 °C. 1H NMR
(400 MHz, CDCl3/CD3OD 10:1): δ 7.54 (d, J = 8.0 Hz, 2H), 7.32 (d, J = 8.0 Hz, 2H), 5.09
(s, 2H), 3.36 (m, 6H), 3.22 (bt, 2H), 2.99 (t, J = 6.4 Hz, 2H), 2.85 (m, 4H), 2.76 (m, 6H),
1.95 (s, 3H), 1.79 (bm, 4H), 1.51 (bm, 4H), 1.26 (bs, 59H), 1.14 (t, J = 6.8 Hz, 3H), 0.88
(t, J = 6.6 Hz, 6H).

13

C NMR (100 MHz, CDCl3): 177.3, 170.0, 137.2, 135.2, 128.8,

127.4, 66.0, 47.9, 46.1, 34.1, 32.6, 31.9, 29.7, 29.6 (m), 29.4, 29.3, 29.0, 27.7, 27.0,
26.9, 25.2, 24.1, 23.2, 22.6, 14.1. ESI MS (m/z): calcd for C60H115N5O3S2 [M + H]+
1018.85, found 1018.89; [M + 2H]2+ 509.93, found 510.23; [M+Li]+ 1024.86, found
1024.94.
Synthesis of 9. Boc2O (0.2 g, 0.92 mmol) was added to a solution of Lipo-SSBEN (0.11 g, 0.11 mmol) in anhydrous CHCl3 (5 mL) at 0 °C under nitrogen. The
mixture was stirred for 1 h at 0 °C and then warmed to room temperature. After stirring
for 12 h, the mixture was purified by a short silica gel column to give pure product 9 as
colorless oil (0.11 g, 75%). Rf 0.30 (hexane/ethyl acetate 5: 1). 1H NMR (400 MHz,
CDCl3): δ 7.52 (d, J = 8.4 Hz, 2H), 7.30 (d, J = 8.0 Hz, 2H), 5.09 (s, 2H), 3.30-3.10 (m,
22H), 3.02 (t, J = 6.8 Hz, 2H), 2.72 (t, J = 6.8 Hz, 2H), 1.74 (m, 6H), 1.49-1.45 (muls,
31H), 1.26 (bs, 56H), 1.09 (t, J = 6.8 Hz, 2H), 0.88 (t, J = 7.0 Hz, 6H).

13

C NMR (100

MHz, CDCl3): 170.1, 155.8, 155.4, 152.4, 145.3, 138.6, 132.6, 129.4, 127.2, 125.2,
121.7, 70.3, 47.8, 46.1, 34.2, 32.5, 31.9, 29.66, 29.62, 29.6 (m), 29.4, 29.3, 29.0, 27.7,
27.0, 26.8, 22.6, 14.1. ESI MS (m/z): calcd for C75H139N5O9S2 [M + Na]+ 1340.99, found
1341.42; [M + 2Na]2+ 681.99, found 682.54; [M + K]+ 1356.96, found 1357.39.
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3.2.3. EtBr exclusion assay
The ability of the cationic lipids to condense DNA was determined by measuring
changes in EtBr/DNA fluorescence. DNA solution at a concentration of 20 µg/mL was
mixed with EtBr (1 µg/mL), and fluorescence was measured and set to 100% using
λexc/λem 540/590 nm. Fluorescence readings were taken following a stepwise addition of
the lipid solution prepared in 10 mM HEPES pH 7.4, and the condensation curve for
each lipid was constructed.

3.2.4. Agarose gel retardation assay
The condensation ability of the lipids and the redox stability of the lipoplexes
were examined by agarose gel electrophoresis. Lipid/DNA complexes were formed at
specified N/P ratios and incubated with or without 20 mM GSH and with or without
increasing concentration of heparin for 30 min. Samples were loaded onto a 0.8%
agarose gel containing 0.5 µg/mL EtBr and run for 60 min at 120 V in 0.5× TBE running
buffer. The gel was visualized under UV illumination on a Gel Logic 100 imaging
system.

3.2.5. Particle size and zeta potential measurement
The hydrodynamic diameters and zeta potentials of lipid/DNA complexes
prepared in 10 mM HEPES (pH 7.4) were determined using ZetaPlus Particle Size and
Zeta Potential analyzer (Brookhaven Instruments) (Table 4). Lipid/DNA complexes were
formed at specified N/P ratios and incubated for 30 min. Scattered light was detected at
90° angle and 25 °C.
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3.2.6. Cell lines
B16F10 mouse melanoma cells were cultured in DMEM supplemented with 10%
FBS. MCF-7 human breast adenocarcinoma cells were cultured in RPMI medium with
10% FBS. MDA-MB-231 breast cancer cells were cultured in RPMI with 10% FBS and
1% penicillin/streptomycin. All cells were cultured at 37 °C in incubator with 5% CO2.

3.2.7. Cell viability assay
Cytotoxicity of the cationic lipids in human breast cancer cell lines MCF-7 and
MDA-MB-231 was determined by MTS assay using CellTiter 96® Aqueous Cell
Proliferation Assay Kit (Promega). 4,000 cells were seeded in a 96-well plate and
allowed to attach overnight, culturing medium was then removed and replaced with 200
µL of medium with increasing concentration of the relative drug. Medium was replaced
every 48 h with fresh medium containing the same concentration of the respective drug.
After 120 h treatment, cell viability was determined by MTS assay according to
manufacturer’s protocol. The results are expressed as mean percentage cell viability
relative to untreated cells ± SEM (n = 4-8). IC50 values were calculated using Prism 5
(Graphpad Software, Inc.) using sigmoidal nonlinear regression.

3.2.8. Luciferase transfection
Complexes were prepared by adding a predetermined amount of cationic lipids to
the solution of plasmid DNA in 10 mM HEPES pH 7.4 to achieve a final DNA
concentration of 32 µg/mL and N: P ratios of 2, 4, 8, 16, 32. Mass of 325 per one
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phosphate group of DNA was assumed in the calculations. All transfection studies were
performed in 96-well plates or 48-well plates with cells plated 24 h before transfection at
the seeding density of 12,000 cells/well (for 96-well plate) and 50,000 cells/well (for 48well plate). The cells were incubated with DNA complexes for 3 h in 150 µL of medium
without FBS at 2 µg DNA/mL. Luciferase expression was measured after 24 h and
expressed as mean relative light units (RLU) per mg of cellular protein measured by the
bicinchoninic acid (BCA) assay ± SD of quadruplicate samples.

3.2.9. SSAT assay
Enzymatic activity of SSAT in MDA-MB-231 cells was determined using [14C]Acetyl-CoA substrate as previously described [274, 275]. In brief, cells were harvested
after the treatment with BENSpm, LipoBEN and Lipo-SS-BEN at the doses of the
relative IC50 values, and resuspended in SSAT breaking buffer (5 M HEPES, 1 M DTT,
PH 7.2) at 2×107 cells/mL and centrifuged at 14,000 rpm for 15 min at 4 °C. 25 µL of the
supernatant was used to obtain total cellular protein concentration using BCA protein
assay reagent (Pierce, Thermo Scientific). Another 20 µL of each sample was mixed
with reaction mixture (10 µL 0.5 M HEPES, pH 7.8, 5 µL 30 mM spermidine, 0.5 µL
[14C]-Acetyl-CoA, 14.5 µL ddH2O) and incubated in 37 °C water bath for 5 min. 20 µL
0.5 M hydroxylamine was then added to each sample. Reaction was stopped by boiling
the samples for 3 min. 50 µL of each sample was then pipetted to p81 Whatman filter,
and put into wash system with continuous water flow for 30 min and suspended in
Biosafe counting fluid. Each sample was counted for 1 min using 1209 Rackbeta liquid
scintillation counter (PerkinElmer).
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3.2.10.

Analysis of the combination treatment with TRAIL

The median effect/combination index model was used to determine synergy of
the combination treatments of the cationic lipids with TRAIL. Cells were treated for 120
h with increasing concentration of TRAIL, LipoBEN, Lipo-SS-BEN, or their combinations
at a constant molar ratio equal to the ratio of their IC50. The following molar ratios were
used: Lipo-SS-BEN: TRAIL 1,372: 1; and Lipo-SS-BEN: TRAIL 19,600: 1. Cell viability
was measured by MTS assay as described above. Results were analyzed by
CompuSyn software (ComboSyn, Inc. Paramus, NJ) to quantitatively determine whether
the combination treatment was synergistic [261].

Figure 11. Structure of BENSpm and its lipid derivatives.
3.3

Results and Discussion
We have previously proposed that BENSpm can serve as a suitable building

block of cationic lipids and polymers that can function dually as gene delivery vectors
and active pharmacologic agents targeting dysregulated polyamine metabolism in
cancer. To that end, we reported synthesis of a lipid derivative of BENSpm (LipoBEN,
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Figure 11) and demonstrated its ability to deliver genes in vitro [269]. The cytotoxic
effects of BENSpm result, in part, from inducing polyamine catabolic enzymes such as
SSAT. Here we measured whether the SSAT inducing capability is preserved in
LipoBEN by measuring SSAT activity in human breast cancer cells MDA-MB-231
(Figure 12). The results show that modification of BENSpm with the lipid moiety results
in the loss of its SSAT-inducing activity. This result motivated the present study and
provided a strong rationale for adopting a prodrug approach to the synthesis of
BENSpm-based gene delivery vectors.

Figure 12. SSAT induction by BENSpm and its lipid derivatives. MDA-MB-231 cells
were treated with IC50 dose of indicated sample for 72 h. Results are shown as mean
pmol of N1-acetylspermidine/mg of protein/min ± SD, n=3. One-way ANOVA with
Tukey’s multiple comparison test (p < 0.05 untreated vs BENSpm, untreated vs LipoSS-BEN, and LipoBEN vs Lipo-SS-BEN).

3.3.1. Synthesis of Lipo-SS-BEN prodrug
We have considered multiple prodrug strategies in our approach. Ester prodrugs
are widely used in drug design because of easy degradation by ubiquitous plasma
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esterases or chemical hydrolysis. Prodrug strategies for amine drugs like BENSpm,
however, are limited by the high stability of amide bonds. For dual-functioning BENSpmbased gene delivery vectors, spatiotemporal considerations of the prodrug activation
were crucial. Successful gene delivery requires the delivery vector to remain intact until
the DNA is transported into the target cell. Therefore, enzymatically activated amine
prodrug approaches, such as carbamates and N-acyloxyalkyl derivatives, in which
activation typically occurs in the plasma, were not considered suitable. Other strategies
that limit prodrug activation to intracellular enzymes, such as peptide spacers activated
by lysosomal cathepsins [276], were excluded because of the unfavorable intracellular
location of the activation (lysosomal activation and release of DNA is considered
premature). Functional groups like β-aminoketones, N-Mannich bases, and enaminones
offer easy nonenzymatic hydrolytic transformation of amine drugs from their prodrug
forms [277-279]. The possible ways to control spatiotemporal localization of the
activation in these approaches are limited. However, it is well established that disulfide
reduction is localized predominantly to the cytoplasm and nucleus, which is highly
beneficial for gene delivery [262, 280-284]. Based on these considerations, we selected
reducible dithiobenzyl carbamate linker [285, 286] to synthesize Lipo-SS-BEN prodrug
that can be activated by intracellular thiolysis of the disulfide bond (Scheme 3).
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Scheme 3. Mechanism of thiolytic activation of Lipo-SS-BEN.
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Scheme 4. Synthesis of Lipo-SS-BEN prodrug.
The target compound Lipo-SS-BEN was synthesized using a six step synthesis,
depicted in Scheme 4. Despite the four amines in BENSpm, a single product Lipo-SSBEN was detected by ESI-MS and TLC. ESI-MS of the reaction mixture gave the
expected m/z 1018.97 and 510.26 peaks, corresponding to m/z (M + H)+ and (M + 2H)2+
of Lipo-SS-BEN (Figure 13a). Excess BENSpm (MW 244.26) was seen at m/z (M + H)+
and (M + 2H)2+ 245.47 and 123.33 in Figure 13a. Purification of Lipo-SS-BEN was
confronted with difficulties caused by easy decomposition during drying due to
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susceptibility to disulfide-disulfide exchange reactions. Purification of the reaction
mixture by silica gel chromatography gave the expected Lipo-SS-BEN in the eluent.
Isolated Lipo-SS-BEN was neutralized with 5 M acetic acid and the solvent was
removed to give the desired compound as acetate salt mixed with ammonium acetate.
The ammonium acetate could be removed slowly under reduced pressure but some
decomposition was still observed (Figure 13b, c).
Finally, we confirmed that, due to steric effects, it was the terminal and not the
internal amine of BENSpm that was substituted in Lipo-SS-BEN. The purified Lipo-SSBEN was reacted with Boc2O to give fully Boc-protected compound 9 (Scheme 5).
Reductive degradation of 9 with DTT gave tri-Boc-protected BENSpm 10. The 1H NMR
and

13

C NMR of compound 10 were found to agree with the known NMR spectra of

3,7,11-tri-Boc BENSpm reported in our previous study [269]. This result confirmed that
the location of BENSpm substitution in Lipo-SS-BEN shown in Figure 11 and Scheme 4
is correct. We have also attempted synthesis of Lipo-SS-BEN by reaction of 8 with 10,
but this approach failed due to decomposition of compound 9 during Boc deprotection
with TFA.
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Figure 13. ESI-MS and 1H NMR spectra of Lipo-SS-BEN prodrug. (a) ESI-MS of
unpurified Lipo-SS-BEN after reaction of 8 with BENSpm. (b) ESI-MS of Lipo-SS-BEN
after purification. (c) 1H NMR of Lipo-SS-BEN in CDCl3.
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Scheme 5. Synthesis and degradation of compound 9.

Figure 14. ESI-MS after reductive degradation of Lipo-SS-BEN.
3.3.2. Reductive release of BENSpm from Lipo-SS-BEN and restoration of SSAT
inducing activity
Intracellular reduction or thiolytic breakage of the disulfide in Lipo-SS-BEN by
GSH is expected to lead to an unstable p-mercaptobenzyl urethane intermediate,
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followed by a breakdown via 1,6-elimination and decarboxylation, and ultimately result
in the regeneration of the original BENSpm molecule and a GSH-conjugated lipid [287,
288]. For success of our approach, it was necessary to verify that Lipo-SS-BEN is
transformed to free BENSpm following cleavage of the disulfide bond. Lipo-SS-BEN
was therefore treated with excess of a strong reducing agent (100 mM DTT) in PBS at
37 °C, and progress of the reaction was monitored by TLC and ESI-MS for 24 h. The
TLC showed complete disappearance of Lipo-SS-BEN after 10 min of treatment with
DTT and appearance of a mixture of intermediates that disappeared after 4 h (not
shown). ESI-MS analysis shown in Figure 14 confirmed the TLC results by showing
complete decomposition of Lipo-SS-BEN and release of BENSpm as indicated by the
disappearance of the peak at 1018 and appearance of the peak at 632.64,
corresponding to m/z [M + Na]+ of regenerated compound 4 (MW 609.58) and the
peaks of free BENSpm shown at m/z (M + H)+ and (M + 2H)2+ at 245.47 and 123.33.
The activation of the Lipo-SS-BEN prodrug and release of functional BENSpm was
subsequently confirmed in MDA-MB-231 cells by demonstrating restored SSATinducing activity when compared with nondegradable LipoBEN (Figure 12). This result
clearly suggests that the dithiobenzyl carbamate linker is cleaved in the intracellular
environment and that BENSpm is released in its active form.
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Table 3. Cytotoxicity of TRAIL, BENSpm and its derivatives in MDA-MB-231.

a

Sample

IC50 a µM

BENSpm

91.4 ± 37.6

Lipo-SS-BEN

21.4 ± 2.9

LipoBEN

6.84 ± 0.69

TRAIL

0.0051 ± 0.2

IC50 values were determined by MTS assay after 120 h treatment

3.3.3. Decreased toxicity of Lipo-SS-BEN and synergistic enhancement of TRAIL
activity
Toxicity of cationic vectors is a major concern in their use in gene delivery. We
expected that degradability of Lipo-SS-BEN will not only restore BENSpm activity as
shown above but also will result in decreased toxicity of the lipid. We measured the
toxicity using MTS assay in MDA-MB-231 cells (Table 3). The results confirmed that
Lipo-SS-BEN is significantly less toxic than the nondegradable LipoBEN. Similar results
were observed also in MCF-7 cells, where LipoBEN showed IC50 = 1.40 ± 0.40 µM while
Lipo-SS-BEN showed decreased toxicity with IC50 = 17.2 ± 1.9 µM. Our results confirm
previous studies that cationic lipids and polymers degradable by intracellular disulfide
reduction exhibit reduced toxicity compared to nondegradable analogues [289-291]. The
fact that Lipo-SS-BEN had lower IC50 than the parent BENSpm is a reflection of the
general toxicity of cationic lipids and not a result of enhanced antiproliferative activity of
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BENSpm as suggested by similar SSAT-inducing activity of Lipo-SS-BEN and BENSpm
(Figure 12).

Figure 15. Effect of (a) Lipo-SS-BEN or (b) LipoBEN on antiproliferative activity of
TRAIL in MDA-MB-231 cells and the calculated CI value for combination of TRAIL
with (c) Lipo-SS-BEN or (d) LipoBEN.
The main objective of this study was to design BENSpm-based lipids capable of
functioning dually as (i) gene delivery vectors and (ii) active anticancer agents targeting
dysregulated polyamine metabolism in cancer. As described in Chapter 2, BENSpm
showed strong synergistic effect with TRAIL in MDA-MB-231 cells. Thus it was
important to investigate if the Lipo-SS-BEN prodrug retained the synergism with TRAIL.
To allow determination of synergy using the Chou-Talalay method, all TRAIL
combination experiments were performed at constant BENSpm lipid: TRAIL ratios
(Figure 15) determined from the ratios of the IC50 values of the individual agents. Four
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doses were used in serial dilutions covering the activity range of LipoBEN, Lipo-SSBEN, and TRAIL, and the fraction of killed cells (fa) was determined by MTS assay. CI
value was calculated by the Chou-Talalay method using CompuSyn software [264]. As
described in Chapter 2, the parent BENSpm enhances activity of the TRAIL protein in
triple-negative breast cancer cells MDA-MB-231, with CI values less than 0.04 across
the entire studied fa range. We then evaluated whether the enhancing effect of BENSpm
on TRAIL activity is preserved in Lipo-SS-BEN (Figure 15a and c). Combination
treatment with Lipo-SS-BEN and TRAIL was indeed more effective than either of the
agents alone, but the calculated CI values were higher than in the case of
BENSpm/TRAIL combination, indicating a weaker synergism and a simple additive
effect at lower fa range. A similar outcome was obtained when the cells were treated
with LipoBEN/TRAIL combination (Figure 15b and d). We hypothesize that the transition
from a strong synergism in BENSpm/TRAIL treatment to a weaker synergism and even
more additive effect of the BENSpm lipids is the result of nonspecific toxicity associated
with the cationic lipids and not a specific effect of BENSpm on polyamine metabolism.
The effect of the nonspecific lipid toxicity is prominent even in Lipo-SS-BEN despite its
degradability. We propose that, in order to take full advantage of the BENSpm/TRAIL
synergism that is based on a specific mechanism of action of BENSpm on the
polyamine metabolism, toxicity of the BENSpm-based delivery vectors will have to be
decreased even beyond the decrease achieved with Lipo-SS-BEN.
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Table 4. Hydrodynamic diameter and zeta potential of Lipo-SS-BEN/DNA (N/P 20)
and LipoBEN/DNA (N/P 8) complexes.
Sample

Size (nm)

Zeta (mV)

Lipo-SS-BEN

98.6 ± 0.9

30.9 ± 3.1

LipoBEN

86.2 ± 0.8

41.0 ± 1.1

3.3.4. Evaluation of DNA complexes of Lipo-SS-BEN.
The ability to efficiently deliver genes is an important requirement for the dually
functioning BENSpm-based delivery vectors. We have therefore conducted preliminary
studies to determine their ability to deliver reporter gene in vitro. We first confirmed the
ability of LipoBEN and Lipo-SS-BEN to condense DNA using EtBr exclusion assay
(Figure 16a). Both Lipo-SS-BEN and LipoBEN efficiently condensed DNA, while the
parent BENSpm showed poor condensation ability with only 20% decrease in
fluorescence intensity at N/P 8. LipoBEN showed a more efficient DNA condensing
ability as indicated by the fact that full DNA condensation was achieved at N/P < 2,
while N/P 5 was required in the case of Lipo-SS-BEN.
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Figure 16. DNA condensation and reduction-triggered DNA release from Lipo-SSBEN complexes. (a) DNA condensation by BENSpm, LipoBEN and Lipo-SS-BEN
assessed by EtBr exclusion assay. (b) Effect of disulfide reduction on susceptibility of
Lipo-SS-BEN/DNA complexes to polyelectrolyte exchange reactions with heparin.
LipoBEN/DNA (N/P 8) and Lipo-SS-BEN (N/P 20) were treated with increasing
concentration of heparin either alone or in combination with 20 mM GSH.
We expect that the intracellular cleavage of the disulfide bond in Lipo-SS-BEN
should be mediated by thiol/disulfide exchange reactions with small redox molecules
like GSH. The reduction is expected not only to release the active form of BENSpm but
also to facilitate release of the DNA from Lipo-SS-BEN/DNA complexes. Cellular GSH is
predominantly present in the cytoplasm (1-11 mM), which is also the principal site of
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GSH biosynthesis [292-294]. However, nuclear GSH concentrations are typically even
higher and can reach up to 20 mM [295-297]. As shown above, the reduction of the
disulfide bond in Lipo-SS-BEN resulted in the release of BENSpm. The effect of
disulfide reduction on the DNA release was investigated by incubating Lipo-SSBEN/DNA and control LipoBEN/DNA complexes with 20 mM GSH and by analyzing the
concentration of heparin required to destabilize the complexes and release free DNA
(Figure 16b). The control nonreducible LipoBEN/DNA complexes were stable in the
absence of GSH up to 100 µg/mL heparin. At heparin concentrations 100 µg/mL and
above, signs of free DNA were observed but most of the DNA was confined to the start
of the gel. In the reducing environment of 20 mM GSH, first signs of DNA release from
the LipoBEN/DNA complexes were observed at 80 µg/mL heparin. Strong
responsiveness to reducing conditions was observed for Lipo-SS-BEN/DNA complexes,
suggesting that the employed prodrug strategy not only results in the release of an
active form of BENSpm but also facilitates DNA release from the complexes. We predict
that the fact that cancer cells often exhibit elevated levels of GSH will further increase
the effectiveness of the thiolytically activated gene delivery vector [282]. No DNA
release was observed in oxidizing conditions up to 120 µg/mL heparin, while only 40
µg/mL heparin was required to cause DNA release in the reducing conditions of 20 mM
GSH.
Initial transfection activity of the BENSpm-based DNA complexes was
determined in a panel of three cell lines using luciferase reporter plasmid (Figure 17).
DOTAP/DNA complexes were used as controls. DNA complexes of the nondegradable
LipoBEN showed consistently higher transfection activity than bioreducible Lipo-SS-
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BEN/DNA complexes in all three cell lines. As expected, transfection of BENSpm/DNA
complexes was several orders magnitude lower than transfection of any of the BENSpm
lipid complexes across all tested N/P ratios. Overall, transfection of the Lipo-SS-BEN
complexes showed a stronger dependence on the N/P ratio, in particular in the B16F10
and MDA-MB-231 cells. Between the lowest and highest tested N/P ratio, the
transfection of Lipo-SS-BEN complexes increased 192-, 15-, and 6,760-fold in the
B16F10, MCF-7, and MDA-MB-231 cells, respectively. For comparison, the
corresponding increases for LipoBEN complexes were 4-, 6-, and 270-fold. The strong
N/P dependence is likely the result of premature disulfide breakage in Lipo-SS-BEN. It
suggests that Lipo-SS-BEN may be partly degraded already before cell uptake by
extracellular thiols, thus requiring larger lipid excess to achieve comparable transfection
as LipoBEN complexes. Differences among the three cell lines are likely the result of
different amounts of secreted thiols from different cells as suggested previously [298].
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Figure 17. Transfection activity of BENSpm and its lipid derivatives in (a) B16F10
cells, (b) MCF-7 cells, and (c) MDA-MB-231 cells. Results are expressed as
luciferase expression in RLU/mg of protein (mean ± SD, n=4).
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3.4

Conclusions
We described synthesis of degradable BENSpm prodrug capable of functioning

dually as a gene delivery vector and an active anticancer agent targeting dysregulated
polyamine metabolism in cancer. The used dithiobenzyl carbamate linker in the LipoSS-BEN prodrug is cleavable by thiolysis, which leads to the release of free BENSpm
and restoration of SSAT-inducing activity of BENSpm. BENSpm demonstrated a strong
synergy with TRAIL in triple negative breast cancer cells MDA-MB-231. Although LipoSS-BEN also enhanced TRAIL activity, the results were confounded by nonspecific
lipid-related toxicity that diminished the synergistic enhancement that originated in the
specific mechanism of action of BENSpm on the polyamine pathway.
In conclusion, we demonstrated that BENSpm could serve as a suitable building
block for the design of gene delivery vectors with dual functionality. However, in order to
take full advantage of the synergism based on BENSpm, general toxicity associated
with the lipid delivery vector will have to be further decreased, even beyond the
reduction achieved with Lipo-SS-BEN. Another drawback of the Lipo-SS-BEN is the
instability of the lipid vector in extracellular environment, as demonstrated by decreased
transfection efficiency compared with LipoBEN. In all, this approach shines light on our
future endeavor towards reduced vector toxicity and more stable linker system of the
prodrug design.
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CHAPTER 4
DENDRITIC POLYGLYCEROL WITH POLYAMINE SHELL AS A POTENTIAL
MACROMOLECULAR PRODRUG AND GENE DELIVERY VECTOR

4.1

Introduction
In Chapter 3, we have synthesized biodegradable lipid prodrug (Lipo-SS-BEN)

based on BENSpm using thiolytically sensitive dithiobenzyl carbamate linker [265, 269].
We have demonstrated that Lipo-SS-BEN can fulfill its function as a gene delivery
vector while at the same time exhibit anticancer effect after intracellular cleavage of the
dithiobenzyl carbamate linker and release of BENSpm. However, toxicity caused by the
cationic lipid combined with extracellular instability of the linker hindered further
development of the system.
In order to address the problems with toxicity and linker stability, we have chosen
dendritic polyglycerol (PG) as a safe component onto which to conjugate BENSpm. PG
is a dendritic polyol that exhibits thermal and oxidative stability, high water solubility and
negligible toxicity at cellular level [299, 300]. It can be synthesized by a simple one-step
ring-opening polymerization, which allows for large-scale production. The presence of a
large number of surface functional groups (64 surface hydroxyls for PG with molecular
weight 5 kDa) renders PG ideal for surface functionalization [301, 302]. Our previous
studies with BENSpm-based gene delivery vectors suggested that BENSpm has to be
released from the vector in order to exert its full therapeutic effect via modulation of the
polyamine pathway in cancer cells [265]. Selection of a biodegradable linker therefore
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became critical for the success of BENSpm-based gene delivery vectors with dual
functionality.

Instead of the dithiobenzyl carbamate linker cleavable by disulfide

reduction with glutathione described in Chapter 3, we have chosen a carbamate linker
cleavable by hydrolysis to conjugate BENSpm to PG. Carbamates are widely used in
the design of amine-containing prodrugs because of an easy enzymatic cleavage or
hydrolysis of the bond [210, 302-304]. Moreover, a recent report suggested that
conjugates of PG with oligoamines similar to BENSpm could be enzymatically cleaved
by the action of lipases [302]. Thus, we proposed to design BENSpm-conjugated PG
prodrug via carbamate linkage (PG-BEN), which we expected to be beneficial for both
BENSpm release and gene delivery functions.

4.2

Materials and Methods

4.2.1. Materials
Plasmid DNA containing luciferase reporter gene (gWiz-Luc) was from Aldevron
(Fargo, ND). Dulbecco’s Modified Eagle Medium (DMEM), Dulbecco’s Phosphate
Buffered Saline (PBS), RPMI 1640 Medium, Fetal Bovine Serum (FBS) and RNase A
(10 mg/mL) were from Thermo Scientific (Waltham, MA). Eagle's Minimum Essential
Medium (EMEM) was from Corning (Manassas, VA). MDA-MB-231-luc2 cells and
B16F10-luc2 cells stably transfected with firefly luciferase gene (luc2) were purchased
from Caliper (Hopkinton, MA). HepG2 cell line and B16F10 cell line were purchased
from American Type Culture Collection (ATCC; Manassas, VA). MDA-MB-231 cell line
was a kind gift from Dr. Jing Li, Karmanos Cancer Institute (Detroit, MI). Anti-luciferase
siRNA (pGL4) (antisense sequence 5′-GAAGUGCUCGUCCUCGUCCUU-3′) and
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negative control siRNA (ON-TARGET plus Non-targeting siRNA #1) were purchased
from Dharmacon (Lafayette, CO). Dendritic PG (5 kDa) was purchased from Johannes
Gutenberg-Universität Mainz, Germany. Lipofectamine™ RNAiMAX transfection
reagent was purchased from Invitrogen (Grand Island, NY). Norspermine, phenyl
chloroformate (99%), and heptafluorobutyric acid (HFBA) were from Alfa Aesar (Ward
Hill, MA). Pyridine (DriSolv®, anhydrous) was from EMD Millipore (Billerica, MA). 4(Dimethylamino)-pyridine (DMAP) and benzoylated dialysis tubing (nominal molecular
weight cut-off 2,000 Da) were from Sigma-Aldrich (St. Louis, MO). Hydrogen chloride
(5-6 N solution in 2-propanol) was from Acros Organics (Fair Lawn, NJ). All other
reagents and chemicals were obtained from Fisher Scientific or VWR International
unless otherwise noted.

4.2.2. Cell culture
B16F10 mouse melanoma cells were cultured in DMEM supplemented with 10%
FBS. MDA-MB-231 human breast cancer cells and B16F10-luc2 cells were cultured in
RPMI supplemented with 10% FBS. HepG2 cells and MDA-MB-231-luc2 cells were
cultured in EMEM supplemented with 10% FBS. All cells were kept at 37 °C in incubator
with 5% CO2.

4.2.3. Polymer analysis
NMR spectra were recorded on Mercury-400 MHz Spectrometer and chemical
shifts (δ) were expressed in ppm. IR spectra were recorded using JASCO FT/IR 4200
spectrometer (Easton, MD). Weight-average molecular weight (Mw) and polydispersity
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index (PDI) of polymers were determined by Size Exclusion Chromatography (SEC)
using Viscotek GPCmax chromatography system equipped with a refractive index
detector and a light scattering detector. The columns used were single-pore AquaGelTM
columns (cat# PAA-202 and PAA-203, PolyAnalytik, London, ON, Canada). OmniSEC
software was used for chromatographic data processing. Sodium acetate buffer (0.3 M,
pH 5) was used as the mobile phase at a flow rate of 0.3 mL/min. Amine content in the
PG derivatives was determined by elemental analysis of C, H, N, Cl (Atlantic Microlabs
Inc., Norcross, GA). The chemical formula of PG was assumed to be (C3H5O2)n-(OH)64
for the calculation of amine content in PG-BEN, norspermine-conjugated PG (PG-Nor)
and amine-terminated PG (PG-NH2) using the results of elemental analysis.

4.2.4. Synthesis of PG derivatives
Synthesis of PG phenyl carbonate and PG-NH2. PG phenyl carbonate and PGNH2 were synthesized following published procedures [302, 305]. PG (5 kDa, 1 g, 13.5
mmol OH-groups) was dissolved in 8 mL anhydrous pyridine and added dropwise into
phenyl chloroformate (2.44 g, 15.6 mmol) solution in 20 mL pyridine. The reaction
mixture was stirred for 16 h in ice bath. Additional chloroform and water were added at
the end of the reaction until the formed solid product was dissolved. The organic layer
was extracted three times with chloroform and then dried with MgSO4. The solution was
then concentrated and dialyzed against chloroform to give the PG phenyl carbonate
(2.71 g, yield 93.1%).
PG-NH2 was synthesized by a conversion of hydroxyl groups to amine groups
following published procedure [302, 305]. Briefly, PG (5.2 g, 70.72 mmol OH-groups)
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was dissolved in pyridine (40 mL), and a solution of methanesulfonyl chloride (9.3 g,
81.3 mmol) in pyridine (7 mL) was added dropwise. The reaction mixture was kept in ice
bath and stirred for 16 h. Excess amount of ice was then added to the reaction mixture
until a yellow solid precipitated. The solid product was washed with water three times,
dissolved

and

dialyzed

against

acetone

to

give

a

brown

product

of

PG

methanesulfonate ester (8.94 g, yield = 83.5%). PG methanesulfonate ester (8.94 g,
59.05 mmol methanesulfonate groups) was dissolved in DMF (100 mL) and NaN3
(17.93 g, 275.84 mmol) was added. The suspension was then kept at 60 °C for 3 days.
The reaction mixture was filtered and the yellowish filtrate was concentrated by rotary
evaporator. The raw product was then dissolved and dialyzed against CHCl3 to give the
final product of PG-N3 (5.75 g, yield = 99%).
PG-N3 (5.75 g, 58.54 mmol N3-group) was dissolved in THF (60 mL) and
triphenylphosphine (PPh3, 15.34 g, 58.54 mmol) and H2O (5 mL) were added. The
reaction mixture was kept stirring for 16 h while 50 mL of water was added dropwise
during the reaction. The mixture was then concentrated by rotary evaporation, followed
by extraction with CHCl3. The aqueous layer was concentrated to dryness by rotary
evaporator, then dissolved and dialyzed against methanol to give a brown viscous PGNH2 (3.94 g, 93%). 1H-NMR (400 MHz, MeOD): δ = 3.3-3.8 (m, CH and CH2 of PG),
2.52-3.18 (m, -CH2-NH2 of PG).
Synthesis of PG-BEN and PG-Nor. Solution of 200 mg PG phenyl carbonate
(0.93 mmol phenyl carbonate group) in pyridine (15 mL) was added dropwise to a
mixture of BENSpm (1.5 g, 6.14 mmol) or norspermine (1.75 g, 9.3 mmol) and DMAP
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(1.1 mg, 0.009 mmol) in pyridine (10 mL) at 0 °C. The reaction mixture was then kept
under reflux for 2 days. Solvent was removed by rotary evaporator and the concentrate
was dialyzed against methanol to give the final product PG-BEN (230 mg, yield 67.6%)
or PG-Nor (130 mg, yield 50.3 %). Free amine groups on PG-BEN and PG-Nor were
then converted into HCl salt by first dissolving PG-BEN or PG-Nor in ethanol and then
precipitating out the corresponding salt by adding HCl (1.2 eq., 5-6 N HCl in 2propanol). The precipitate was then washed three times with ethanol and dried in
vacuum to afford the final product PG-BEN.HCl and PG-Nor.HCl. 1H-NMR (400 MHz,
D2O) of PG-BEN: δ = 1.17 (a1, CH3-CH2-NH-), 1.29 (a2, CH3-CH2-N-(COO-PG)-), 1.602.22 (c1,c2, -CH2-CH2-NH-), 2.90-3.47 (b1,b2, -CH2-NH-), 2.89-4.03(PG). 1H-NMR (400
MHz, D2O) of PG-Nor: δ = 1.91 (a1, -CH2-CH2-NH-COO-), 2.11 (a2, -CH2-CH2-NH-),
2.94-3.70 (b1, b2, -CH2-NH-), 2.94-4.33 (m, CH and CH2 of PG).

4.2.5. Buffering capacity
Buffering capacity of the synthesized PG derivatives was determined by acidbase titration as previously described (Chen et al., 2009). Briefly, 6 mL solution of each
PG derivatives (10 mM total amine concentration) was adjusted to pH 4.0 by 1M HCl,
and then the solution was titrated to pH 11.0 using 0.1 M NaOH and 1M NaOH. The pH
after each addition of NaOH was recorded by pH meter (Fisher Science EducationTM,
Fisher Scientific, Pittsburgh, PA).

4.2.6. EtBr exclusion assay
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The ability of the polycations to condense gWiz-Luc DNA or negative control
siRNA into polyplexes was determined by EtBr exclusion assay by measuring the
changes in EtBr/DNA or EtBr/siRNA fluorescence. DNA and siRNA solutions at a
concentration of 20 µg/mL in 10 mM HEPES buffer (pH 7.4) were mixed with EtBr (1
µg/mL) and fluorescence was measured and set to 100% using an excitation
wavelength of 540 nm and an emission wavelength of 590 nm. Fluorescence readings
were taken following a stepwise addition of PG derivatives solution, and the
condensation curve for each PG derivative was constructed. PEI (25 kDa, branched)
was used as positive control.

4.2.7. Agarose gel retardation assay
Twenty µL polyplexes of PG derivatives or PEI with 20 µg/mL gWiz-Luc DNA at
different N/P ratios (0.5, 1, 2, 4, 8, 16) were loaded onto 0.8% agarose gel containing
0.5 µg/mL EtBr. Samples were run for 60 min at 120V in 0.5× TBE running buffer. For
siRNA polyplexes, 20 µL polyplexes of PG derivatives or PEI with 20 µg/mL negative
control siRNA at different N/P ratios (0.25, 0.5, 1, 2, 4, 8) were loaded onto 2% agarose
gel containing 0.5 µg/mL EtBr and run for 30 min at 75V. The gels were visualized
under UV illumination on a KODAK Gel Logic 100 Imaging System.

4.2.8. Particle size and zeta potential of polyplexes
Hydrodynamic diameters and zeta potentials of PG derivatives/DNA polyplexes
were determined using ZetaPlus Particle Size and Zeta Potential analyzer (Brookhaven
Instruments). Scattered light was detected at 90° angle and 25 °C. Polyplexes were

95
prepared at desired N/P ratios (4, 8, 16, 32) by adding a pre-determined amount of
polycation to the solution of plasmid DNA in 10 mM HEPES (pH 7.4) to achieve a final
DNA concentration of 20 µg/mL (300 µL). For PG derivatives/siRNA polyplexes,
optimized N/P ratio in transfection experiment was used (N/P ratios: PG-BEN/siRNA 7,
PG-Nor/siRNA 10, PG-NH2/siRNA 24). The polyplexes were incubated for 30 min at
room temperature and then diluted to 1.5 mL for size and zeta potential measurement.
Mass of 325 per one phosphate group of nucleic acid was used in the calculations.

4.2.9. Atomic force microscopy
For atomic force microscopy (AFM), DNA polyplexes of PG derivatives and PEI
were prepared at N/P ratio of 16 with DNA concentration of 20 µg/mL in 10 mM HEPES
buffer (pH 7.4). AFM images were acquired by Nanoimaging Core Facility (College of
Pharmacy, University of Nebraska Medical Center).

4.2.10.

Heparin displacement assay for siRNA polyplexes

The relative stability of PG derivatives/siRNA polyplexes was tested by
measuring siRNA release from the polyplexes in the presence of heparin. All siRNA
polyplexes were prepared at w/w ratio of 7 at siRNA concentration of 20 µg/mL.
Polyplexes were allowed to stabilize for 25 min and then the polyplex solutions were
incubated with heparin for 10 min at different concentrations (0, 10, 20, 40, 80, 160, 240
µg/mL). Samples were then loaded onto 2% agarose gel and run for 45 min at 75 V.
The gel was visualized by a KODAK Gel Logic 100 Imaging System.
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4.2.11.

RNase digestion assay for siRNA polyplexes

siRNA polyplexes of PG derivatives were incubated with increasing amount of
RNase A for 30 min at 37 °C. Polyplexes were prepared as described in heparin
displacement assay. To inactivate the RNase, samples were further incubated for 30
min at 70 °C. Heparin (240 µg/mL) was then added to each sample for complete release
of intact siRNA from the polyplexes. Twenty µL sample was loaded onto 2% agarose
gel containing 0.5 µg/mL EtBr and run for 30 min at 75 V. The gel was visualized using
a KODAK Gel Logic 100 Imaging System.

4.2.12.

Transfection

All DNA transfections were conducted in 48-well plates. Cells were seeded at a
density of 40,000 cells/well 24 h prior to transfection. On the day of transfection, cells
were incubated with the polyplexes (2.35 µg/mL DNA) in media containing 10% FBS.
After 4 h incubation, polyplexes were completely removed and the cells were
maintained in complete culture medium for 24 h prior to measuring luciferase
expression. The medium was discarded and the cells were lysed in 100 µL of 0.5× cell
culture lysis reagent buffer (Promega, Madison, WI) for 30 min. To measure the
luciferase content, 100 µL of 0.5 mM luciferin solution was automatically injected into
each well of 20 µL of cell lysate and the luminescence was integrated over 10 s using
Synergy 2 Microplate Reader (BioTek). Total cellular protein in the cell lysate was
determined by the bicinchoninic acid (BCA) protein assay using calibration curve
constructed with standard bovine serum albumin solutions (Pierce, Rockford, IL).
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Transfection activity was expressed as relative light units (RLU)/mg cellular protein ±
SD of triplicate samples.
For siRNA transfection, B16F10-luc2 cells and MDA-MB-231-luc2 cells were
seeded at a density of 40,000 cells/well or 50,000 cells/well, respectively, in 48-well
plates one day before transfection. Polyplexes and positive control Lipofectamine
RNAiMAX lipoplexes were formed in serum-free Eagle's Minimum Essential Medium
(EMEM) medium (for MDA-MB-231-luc2 cells) and RPMI medium (for B16F10-luc2
cells). PG derivatives and siRNA were mixed at w/w 7 and incubated at room
temperature for 20 min before use. Transfections were conducted with 100 nM siRNA
for the polyplexes and 10 nM siRNA for the control RNAiMAX lipoplexes. The cells were
incubated at 37 °C for 48 h and lysed for assaying luciferase activity. Transfection
activity was expressed as the percentage of luciferase expression of untreated cells.

4.2.13.

Cytotoxicity

Toxicity of polycations was evaluated by MTS assay. The cells were seeded in
96-well microplates at a density of 10,000 cells/well. After 24 h, culture medium was
replaced by 200 µL of serial dilutions of a polymer in medium with 10% FBS and the
cells were incubated for 24 h. Polymer solutions were aspirated and replaced by a
mixture of 100 µL serum-free media and 20 µL of MTS reagent (CellTiter 96® AQueous
Non-Radioactive Cell Proliferation Assay, Promega). After 2 h incubation (MDA-MB-231
cells) or 1.5 h incubation (B16F10 and HepG2 cells), the absorbance was measured at
a wavelength of 490 nm. The relative cell viability (%) was calculated as
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[A]sample/[A]untreated × 100%. The IC50 were calculated as the polymer concentration that
inhibits growth of 50% of cells relative to untreated cells using GraphPad Prism [263].

4.2.14.

Polyamine analysis by LC-MS/MS

Intracellular levels of polyamines were quantified using AQUITY UPLC TQD
system (Waters, MA) with IntelliStart program built in Masslynx 4.1 software. Ten µg/mL
of BENSpm, SPM, SPD, and PUT were dissolved in water: acetonitrile (1: 1) and
detected in MRM mode using positive electrospray ionization (ESI+): m/z (parent >
daughter) 245.24 > 143.10 for BENSpm; 203.14 > 129.14 for SPM; 146.10 > 112.05 for
SPD and 89.09 > 71.95 for PUT. Chromatographic separation was performed using
ACQUITY UPLC BEH C18 Column (2.1 x 50 mm, 1.7 µm). A gradient solvent system
consisting of 0.2% HFBA in water (solution A) and 0.2% HFBA in acetonitrile (solution
B) was used and the gradient was increased from 5 to 95% of B over 5 min at a flow
rate of 0.2 mL/min [306]. The polyamines eluted at the following elution times: 2.55 min
(BENSpm), 2.44 min (SPM), 2.29 min (SPD) and 1.98 min (PUT). Standard curve for
each polyamine was linear within the concentration range from 16 ng/mL to 2 µg/mL
(correlation coefficient r2 > 0.96 for all). MDA-MB-231 cells were treated with 2.5 µg/mL
BENSpm, 6 µg/mL PG-BEN (equiv. amount of 2.5 µg/mL BENSpm) for 72 h and then
lysed in 5% perchloric acid at a concentration of 5×106 cells/mL. The supernatant of the
cell lysate was then used for LC-MS/MS detection of polyamine levels.

4.2.15.

PG-BEN degradation
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BENSpm release from PG-BEN was monitored by both LC-MS/MS and SEC.
LC-MS/MS analysis for BENSpm content in cell lysate was conducted following 72 h
treatment of MDA-MB-231 with 2.5 µg/mL BENSpm or 6 µg/mL PG-BEN. PG-BEN
degradation was also evaluated at extreme conditions following incubation for 48 h at
90 °C in 0.1 M HCl or 0.1 M NaOH solution. Changes in SEC chromatograms of
BENSpm and PG-BEN were monitored using conditions described in earlier section
(4.2.2).

Scheme 6. Synthesis of PG-BEN, PG-Nor

4.3

Results and Discussion

4.3.1 Synthesis and characterization of PG derivatives
PG-BEN and PG-Nor were synthesized following a modified published procedure
for the synthesis of PG-oligoamine conjugates (Scheme 6) [302]. Surface hydroxyl
groups of PG were first activated using phenyl chloroformate to form PG phenyl
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carbonate. This activated form of PG was then reacted with amine groups of BENSpm
and norspermine to form PG-BEN and PG-Nor. Because both BENSpm and
norspermine have four reactive amines in their structure, there was a possibility of
intermolecular cross-linking between multiple PG molecules. Our goal was to minimize
the extent of any cross-linking reactions. We have thus used a large excess of BENSpm
and norspermine in the reaction. The use of excess polyamine also allowed us to
maximize the content of polyamines per PG molecule because of the decreased
likelihood that one BENSpm or norspermine molecule would react with multiple
hydroxyls in a single PG molecule. PG-NH2 was synthesized as a control polymer for
this study, by conversion of the PG surface hydroxyl groups to primary amines (Scheme
7).

Scheme 7. Synthesis of PG-NH2
The FT-IR analysis qualitatively verified successful conjugation of the polyamines
to PG (Figure 18a and b). The signal in the IR spectrum of PG-BEN and PG-Nor at
1730-1690 cm-1 (C=O stretch) indicated the presence of carbonyl bonds. The signal of
PG-BEN, PG-Nor and PG-NH2 at 1650-1515 cm-1 (N-H bend) confirmed the presence
of amine groups. These results confirmed that BENSpm and norspermine were
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successfully conjugated to the surface of PG via carbamate linkage.

Figure 18. Characterization of PG derivatives. (a) FT-IR spectra of PG-BEN (blue)
and PG-Nor (green). (b) FT-IR spectra of PG-NH2 (blue) and PG (green). (c) Size
exclusion chromatographs.
SEC was used to confirm that no crosslinking occurred during conjugation of
BENSpm and norspermine to PG (Figure 18c). The determined molecular weights were
nearly identical for PG-BEN (12.9 kDa) and PG-Nor (13.0 kDa) and represented an
almost 4 kDa increase over the parent PG. Narrow PDI and absence of a peak or a
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shoulder at lower retention volumes indicated that no significant crosslinking occurred in
either of the conjugation reactions.
Table 5. Characterization of the synthesized PG derivatives.
Polymer

Number of Nor or
BEN per PG

% of modified PG
hydroxyls

PG-NH2

--

92%

PG-Nor

27

42%

PG-BEN

23

36%

We then used elemental analysis (C, H, N, Cl) to determine the amine content in
the synthesized PG derivatives. Based on the elemental analysis, we calculated that on
average, there were 23 BENSpm molecules and 27 norspermine molecules attached to
a single PG molecule (Table 5). These results correspond to 36% and 42% modified PG
hydroxyls, respectively. In comparison, direct conversion of the hydroxyls to primary
amines in PG-NH2 resulted in 92% hydroxyl conversion (Table 5). Steric hindrance is
the most likely explanation for the lower conjugation efficiency in case of BENSpm and
norspermine. We then used NMR to analyze whether BENSpm and norspermine were
attached to PG via a single amine or via multiple amines on a single polyamine
molecule (Figure 19). Taking advantage of the differences in NMR shifts of the terminal
methyl in BENSpm after conjugation to PG, we observed that the integral intensities of
a1 and a2 were nearly equal (a1: a2 1.00: 1.03). Based on the assumption that
BENSpm conjugation to PG mainly occurred at the terminal amine groups, the ratio of
a1: a2 suggests that on average, only one terminal amine of BENSpm was attached to
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PG. Because of insufficient NMR signal separation, our analysis could not determine
whether any non-terminal secondary amines in BENSpm participated in the conjugation
to PG. Similar analysis for PG-Nor using signals of the methylenes in β position to the
terminal primary amines, led to similar conclusion as suggested by the ratio of the a1:
a2 = 1.95: 1.00 (Figure 19).
Strong buffering capacity of polyamine gene delivery vectors has been
recognized as an important factor for intracellular trafficking of polyplexes, such as to
enhance endosomal escape and to avoid the trafficking to degradative lysosomes[307,
308]. Although the correlation between buffering capacity and enhanced transgene
activity is under debate [309, 310], buffering capacity of polyamine vector remains an
important property for gene delivery. Here, we measured the buffering capacities of PG
derivatives in comparison with PEI (Figure 20). The results of titration curves showed
that, at the pH range between 5.0 to 7.4 that corresponds to the extracellular
environment and endosomal environment, the buffering capacity of PG-BEN and PGNor is stronger than PG-NH2 and PEI. One explanation is that there are different types
of amines in the different PG derivatives and PEI (pKa secondary amine < primary
amine), and the protonation of an amine group electrostatically suppresses the
protonation of neighboring amines [311], thus leads to the different pattern of titration
curves between each PG derivatives and PEI.
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Figure 19. 1H-NMR spectra of PG-BEN (upper panel) and PG-Nor (lower panel).
PG peak: CH and CH2 in PG backbone.
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Figure 20. Acid-base titration curves of PG derivatives.
4.3.2 DNA/siRNA condensation and polyplex characterization
All the synthesized PG derivatives were able to condense DNA as documented
by the results of the EtBr exclusion assay and agarose gel electrophoresis (Figure 21a
and b). PG-BEN and PG-Nor were comparably efficient and condensed DNA at N/P
ratios above 1. Control PEI required higher N/P ratios to fully condense DNA (N/P > 2),
as did PG-NH2 (N/P > 4). The strong DNA condensing ability of PG-BEN and PG-Nor
are the result of high surface density of amines in the conjugates. As expected from the
ability to condense DNA, all PG derivatives form positively charged polyplexes (Figure
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21d). The polyplexes were smaller than 110 nm at all studied N/P ratios as measured
by dynamic light scattering (Figure 21c).

Figure 21. Physicochemical characterization of DNA polyplexes of PG derivatives.
DNA condensation by (a) EtBr exclusion and (b) agarose gel eletrophoresis of PG
derivatives and PEI polyplexes in 10 mM HEPES (pH 7.4); and dependence of (b)
hydrodynamic particle size and (c) zeta potential of the polyplexes on different N/P
ratios.
AFM was used to study the morphology of the DNA polyplexes. As shown in
Figure 22, all polyplexes of PG derivatives were imaged at a constant N/P ratio of 16.
PG-Nor/DNA polyplexes showed the most uniform particle sizes around 60-70 nm, with
all the polyplexes spherical and homogeneously distributed. Similar result was also
observed for PG-BEN/DNA polyplexes, where spherical particles were observed with
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sizes around 50-80 nm. Interestingly, one PG-BEN/DNA polyplex showed DNA release
on the surface of the particle (indicated by arrow head in Figure 22), demonstrating the
need for higher N/P ratio of PG-BEN to achieve complete DNA condensation. PGNH2/DNA polyplexes showed different morphology than PG-BEN and PG-Nor
polyplexes, with DNA release observed for almost all particles. This result indicated the
ineffectiveness of PG-NH2 to condense DNA even at N/P ratio of 16. DNA release was
also observed from some PEI polyplexes, while the majority of PEI polyplexes were
spherical particles with sizes around 40-70 nm. The fact that smaller sizes of polyplexes
were observed from AFM than from dynamic light scattering (DLS) is a normal
phenomenon that can be explained by the difference of the techniques: in DLS
measurement, small polyplexes with weak scattering could be masked by the strong
scattering from bigger polyplex aggregates, therefore DLS yielded higher value of
particle size than AFM [312].
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Figure 22. AFM images of different DNA polyplexes. All polyplexes were prepared at a
N/P ratio of 16. Arrow heads indicate plasmid DNA released from the polyplexes.
Oppositely, although all the PG derivatives were able to sufficiently bind siRNA at
lower N/P ratios (N/P ≥ 1 for PG-BEN and PG-Nor; N/P > 2 for PEI and PG-NH2) as
shown in EtBr exclusion assay and agarose gel retardation assay (Figure 23a and b),
the PG/siRNA polyplexes showed much larger distribution in size and very small
positive charge, with zeta potential lower than 10 mV for all polyplexes (Figure 23c and
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d). The siRNA polyplexes were further analyzed by heparin replacement assay and
RNase digestion assay (Figure 24). As shown in Figure 24 (upper panel), PGNor/siRNA polyplexes were the most stable, with dissociation occurred at heparin
concentration of 160 µg/mL, which is 8-fold the amount of siRNA presented in the
polyplexes. PG-BEN and PG-NH2 polyplexes showed similar stability, with partial
release of the siRNA occurred at heparin concentration of 80 µg/mL. These results
indicated strong interactions between siRNA and all PG derivatives. However, result
from RNase digestion assay showed an opposite trend (Figure 24, lower panel) that
PG-NH2 provided better protection for siRNA against RNase A, with complete siRNA
degradation occurred at RNase concentration higher than 200 µg/mL. On the other
hand, PG-BEN and PG-Nor showed lower protection ability against RNase A, with the
complete siRNA degradation observed at RNase concentration higher than 40 µg/mL.
This result suggests that, opposite to the ineffectiveness of condensing DNA, PGNH2/siRNA polyplexes may result in improved knockdown efficiency of the cargo siRNA
compared with PG-BEN and PG-Nor polyplexes, due to the improved protection against
RNase. These results indicates that, due to the structural difference of siRNA such as
lower charge density and higher stiffness compared with DNA [313], PG-BEN and PGNor may not be able to fully condense siRNA molecules in comparison with forming
DNA polyplexes.
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Figure 23. Physicochemical characterization of siRNA polyplexes of PG derivatives.
(a) EtBr exclusion assay in 10 mM HEPES (pH 7.4); (b) agarose gel retardation
assay of siRNA polyplexes at different N/P ratios; (c) hydrodynamic particle size and
(d) zeta potential of the polyplexes at fixed N/P ratio (PG-BEN/siRNA 7, PGNor/siRNA 10, PG-NH2/siRNA 24).
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Figure 24. Agarose gel electrophoresis of siRNA polyplexes against heparin
displacement (upper panel) and recovery of intact siRNA from the polyplexes
challenged with RNase A (lower panel). Free siRNA and siRNA treated with RNase A
(10 µg/mL) were loaded as references.

4.3.3 Transfection
Transfection activity of the PG-BEN and PG-Nor polyplexes was first measured
in the presence of 10% FBS in B16F10 cells using luciferase reporter plasmid (Figure
25a). The PG-BEN and PG-Nor polyplexes showed consistently higher transfection
activity than PG-NH2 polyplexes. The transfection efficiency of PG-BEN and PG-Nor
polyplexes was fully comparable or better than that of the control PEI polyplexes. These
results demonstrate that the drug-based PG-BEN conjugate can protect DNA in the
presence of serum and facilitate DNA delivery to cells, thus fulfilling its intended function
as a gene delivery vector.
Even though PG-BEN and PG-Nor were highly efficient in DNA transfection, they
exhibited poor ability to deliver siRNA (Figure 25b and c). Both PG-BEN and PG-Nor
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polyplexes with siRNA mediated only negligible levels of silencing (~11%) of the
luciferase gene in MDA-MB-231-Luc2 cells. In contrast, PG-NH2 which demonstrated
only low DNA transfection was highly active at delivery of siRNA. The levels of
luciferase silencing by PG-NH2 approached levels of a specialized commercial siRNA
transfection reagent LipofectamineTM RNAiMAX. This result confirms finding of many
previous studies, which show that the properties that make for an efficient DNA delivery
agent, are not necessarily the same as those for efficient siRNA delivery agent. It is
likely that it is the lower binding affinity of PG-NH2 to nucleic acids as suggested by the
requirement for higher N/P ratios to condense DNA (Figure 21a) that is beneficial for
siRNA delivery. In contrast, the affinity may not be sufficient to protect DNA and mediate
intracellular DNA transport into nucleus [314, 315].

113

Figure 25. Transfection activity of polyplexes. (a) Luciferase gene transfection in
B16F10 cells measured 24 h after 4 h incubation of cells with the DNA polyplexes in
10% FBS. Results are shown as mean relative light unit (RLU)/mg protein ± SD (n=3).
siRNA silencing of luciferase expression in (b) B16F10-Luc2 cells and (c) MDA-MB231-Luc2 cells stably expressing the luciferase gene. Results are expressed as
percentage of (RLU)/mg protein ± SD (n=4) compared with untreated cells.

4.3.4 Cytotoxicity
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The cytotoxicity of PG-BEN, PG-Nor and PG-NH2 was tested in MDA-MB-231,
B16F10 and HepG2 cells (Figure 26). HepG2 cells have been established as a reliable
predictor of human hepatotoxicity and are thus widely used for in vitro cytotoxicity
testing [316-318]. Because of the anticancer activity of BENSpm, we have tested
whether its presence in PG-BEN imparts selective toxicity towards cancer cells by
measuring toxicity also in MDA-MB-231 and B16F10 cancer cells. Indeed, PG-BEN was
11-times more toxic towards MDA-MB-231 cancer cells and 3.4-times more toxic
towards B16F10 cancer cells than towards HepG2 cells, as determined from the ratios
of the respective IC50 values. In contrast, control PEI showed almost no selective
toxicity towards the two cancer cell lines with its IC50 ratios between 1.2 and 1.3. PGNor and PG-NH2 demonstrated intermediate selectivity with IC50 ratios of 5.2 and 6.1 in
MDA-MB-231 and 2.7 and 1.5 in B16F10, respectively.
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Figure 26. Toxicity of PG-BEN and PG-Nor. IC50 values in MDA-MB-231, B16F10
and HepG2 cells determined by MTS assay expressed in (a) µg/mL of the polycation
and (b) µM amino groups. (c) Summary of the results from (a) and (b).

Toxicity of polycations is strongly dependent on the number of protonated
amines. It is thus informative to compare toxicity IC50 values also in terms of molar
concentrations of amines. While PG-BEN is 7.3-times less toxic than PEI and similarly,
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PG-Nor and PG-NH2 show about 3-times lower toxicity than PEI when measured in
µg/mL, when expressed in terms of molarity of the amines, the picture changes
substantially (Figure 26b). In such case, PEI becomes the least toxic among the tested
polycations with its IC50 values 5-10-fold higher than PG-BEN and PG-Nor in MDA-MB231 and 2-4-fold higher in B16F10. In HepG2 cells, the difference between IC50 (µM)
values of PEI and PG derivatives were negligible with the ratios between 0.6 and 1.1.
These results suggest that PG-BEN may have useful anticancer activity that cannot be
fully explained by its polycationic character. The results also emphasize the importance
of a proper selection of units when comparing toxicity of polycations with different
chemical structures.
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Figure 27. Effect of PG-BEN treatment on polyamine levels in MDA-MB-231 cells.
The cells were treated with 6 µg/mL PG-BEN or equivalent concentration of free
BENSpm (2.5 µg/mL) for 72 h, the cells were lysed in 5% perchloric acid and
polyamine levels in the lysate analyzed by LC-MS/MS. Results are shown as mean
polyamine levels in ng/5×106 cells ± SD (n=3).

4.3.5 Effect of PG-BEN treatment on cellular polyamine metabolism.
After confirming solid transfection activity of PG-BEN polyplexes with plasmid
DNA, we investigated whether the mechanism of the observed anticancer effect of PGBEN is through its effect on polyamine metabolism similar to the parent BENSpm.
BENSpm down-regulates natural polyamine pathway in many types of cancer cells and
that leads to cell growth inhibition and apoptosis. In order to analyze the effect of
BENSpm and PG-BEN on the cellular polyamine metabolism, an LC-MS/MS method
was developed to quantitatively analyze differences in the levels of different polyamines
in the polyamine metabolic pathway. LC-MS/MS does not require any pre-column
derivatization of the polyamines and provides superior sensitivity and reproducibility in
the analysis of structurally similar natural polyamines [176, 319, 320]. The linearity (r2 >
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0.96) of the method was confirmed in the concentration range from 16 ng/mL to 2 µg/mL
for all the analyzed natural polyamines, BENSpm, and norspermine.

Figure 28. BENSpm content in MDA-MB-231 cell lysate (right panel) and size
exclusion chromatography of PG-BEN and free BEN (left panel).
The effect of PG-BEN and BENSpm on polyamine metabolism was determined
in MDA-MB-231 cells. The cells were treated with BENSpm or PG-BEN for 72 h and the
levels of polyamines in cell lysate were analyzed by LC-MS/MS (Figure 27). The results
show that BENSpm (2.5 µg/mL) down-regulated all natural polyamines as expected. In
contrast, PG-BEN treatment had no effect on the levels of SPM and SPD and resulted
only in decreased levels of PUT. This finding suggests that BENSpm was probably not
efficiently released from PG-BEN. This hypothesis was confirmed when no detectable
amount of free BENSpm were observed in cells treated with PG-BEN, compared with
262 ng/5×106 cell of BENSpm in BENSpm treated cells (Figure 28). Moreover, no
BENSpm release was observed by SEC after incubation in both acidic and basic
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solutions, indicating negligible hydrolysis capability of the polymer (Figure 28). Our
results contradict previous report in which oligoamine was enzymatically released from
PG conjugates [302]. Most likely explanation for the discrepancy is the use of different
polyamine and insufficient levels of enzymes in MDA-MB-231 cells to cleave the
carbamate bond in PG-BEN.

4.4

Conclusions
We have conjugated anticancer agent BENSpm to dendritic PG and

demonstrated the utility of the conjugate for gene delivery. Compared with the lipid
based BENSpm prodrug Lipo-SS-BEN that we discussed in Chapter 3, PG-BEN
demonstrated ~10-75 fold increase in transfection efficiency in B16F10 cells. Because
the sizes and zeta potential of PG-BEN polyplexes are comparable to Lipo-SS-BEN
lipoplexes (sizes of polyplexes ~74-109 nm compared with ~ 99 nm of lipoplexes; zeta
potential of polyplexes ~26-44 mV compared with ~31 mV of lipoplexes), the increased
transfection capability of PG-BEN is most likely the result of improved extracellular
stability of the carbamate linker in PG-BEN, compared with the dithiobenzyl carbamate
linker in Lipo-SS-BEN. However, compromised drug function of polyamine depletion in
PG-BEN treated cells documented by LC-MS/MS analysis indicated inefficient release
of BENSpm from the PG-BEN vector. Therefore, alternative linker chemistry will have to
be developed to take full advantage of BENSpm anticancer activity in BENSpm-based
gene delivery vectors.
Moreover, PG-BEN showed favorable cytotoxicity profile by exhibiting selective
toxicity towards breast cancer cells relative to hepatocytes. The selective toxicity,
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however, was not fully related to the known mechanism of action of BENSpm through
its effects on polyamine metabolism. The mechanism of the selective toxicity of PGBEN towards cancer cells is also worth investigating.
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CHAPTER 5
POLYCATIONIC BENSPM PRODRUG USING SELF-IMMOLATIVE LINKER AS
DUAL DRUG/GENE DELIVERY SYSTEM

5.1

Introduction
Gene therapy shows promise for cancer treatment, however, this potentially

powerful therapeutic modality is greatly hampered by the lack of desirable drug delivery
systems that can accommodate various agent payloads and overcome multiple barriers
such as to prevent degradation, to limit susceptibility to serum, and to improve
bioavailability [321]. Polyplexes continue to gain strength as promising gene delivery
vectors but the relatively low transfection activity and high toxicity associated with
polycations hamper their success in clinical applications [322, 323]. Traditional ways to
address the problems include combining the therapeutic gene with small-molecule
drugs to enhance the therapeutic activity of the transgene [324-326]. For example,
Wang and colleagues developed a nanoparticle system for co-delivery of paclitaxel with
an interleukin-12-encoded plasmid. The authors demonstrated enhanced gene
transfection as well as superior tumor suppression both in vitro and in vivo in tumor
models [67]. A typical way to address the current problems with toxicity of polyplexes is
to design biodegradable polycations that degrade into less toxic byproducts [327, 328].
Incorporation of intracellular stimuli-triggered degradation is among the most favored
strategies in designing polycationic gene delivery system [329]. Examples include (i)
pH-sensitive polymers containing hydrolytically sensitive bonds such as esters, (ii)
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redox-responsive polymers containing disulfide bonds that are cleaved in the reductive
environment of the cytoplasm, and (iii) enzymatically cleavable polymers [330-334].
The field of combination drug/nucleic acid carriers is quickly developing, with
emerging novel designs of delivery vectors. Besides traditional polymeric delivery
systems, new concepts such as self-assembled nucleic acid nanostructures [335],
single nucleic acid encapsulation [336], multilayered polymer-nucleic acids nanocapsule
[337] as well as other multifunctional nanocarriers [338] are drawing increasing
attention. In order to achieve both drug/gene combination delivery and designing
biodegradable delivery vector, we proposed a novel design of dual delivery vectors that
not only deliver therapeutic nucleic acids but also utilizes pharmacologic effect of a
cationic drug to augment the activity of the nucleic acid. To achieve this, we synthesized
polycations based on a polyamine analogue BENSpm, which was originally developed
to treat cancer. BENSpm contains four secondary amines that can provide positive
charges under physiological conditions to bind with nucleic acids via electrostatic
interactions. Thus, conjugation of BENSpm with a lipid or a polymer by appropriate
linker can provide a prodrug gene delivery carrier, which can be engineered to release
free BENSpm under physiological conditions. In the previous chapters (Chapter 3 and
Chapter 4), Lipo-SS-BEN demonstrated satisfactory prodrug function, however, the
gene delivery function was compromised by the instability of the vector. We suspected
that the breakage of dithiobenzyl carbamate linker occurred before the cellular uptake.
Therefore, we explored a more stable linker strategy. PG-BEN with carbamate linker
between the PG core and BENSpm showed superior transfection efficiency, however,
the release of BENSpm was negligible in the intracellular space. In order to improve the
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dual function of the BENSpm base drug/gene delivery vector, a better linkage strategy
is further explored in this chapter. We decided to use bis(2-hydroxyethyl) disulfide as a
self-immolative linker to synthesize polymer prodrugs of BENSpm. The rationale behind
this design is that incorporating disulfide bond into the prodrug vector allows selective
degradation in the reducing intracellular space and that after the disulfide bond
cleavage, the intermediate will further undergo slow intramolecular cyclization to give
free BENSpm [339].

5.2

Materials and Methods

5.2.1 Materials
Plasmid DNA containing luciferase reporter gene (gWiz-Luc) was from Aldevron
(Fargo, ND). Dulbecco’s modified eagle medium (DMEM), Dulbecco’s phosphate
buffered saline (PBS), Hanks' balanced salt solution (HBSS), RPMI 1640 medium, fetal
bovine serum (FBS), L-glutamine, Penicillin-Streptomycin and Snakeskin dialysis
tubing (molecular weight cutoff = 3.5 kDa) were from Thermo Scientific (Waltham, MA).
G418 sulfate was from Mediatech, Inc. (Manassas, VA). Eagle's minimum essential
medium (EMEM) was from Corning (Manassas, VA). HepG2 cell line was purchased
from American Type Culture Collection (ATCC; Manassas, VA). MDA-MB-231 cell line
was a kind gift from Dr. Jing Li, Karmanos Cancer Institute (Detroit, MI). B16F10 cell
line was a kind gift from Dr. Rakesh Singh, University of Nebraska Medical Center
(Omaha, NE). HEK 293T cell line was a kind gift from Dr. Gensheng Wu, Karmanos
Cancer Institute (Detroit, MI). Human epithelial osteosarcoma U2OS cell line was
purchased from Thermo Scientific (Waltham, MA). DharmaFECT-4 siRNA transfection
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reagent, siGenome SMARTpool siRNAs: PLK-1 (polo-like kinase 1), sHH (sonic
hedgehog), Bcl-2 and negative control siRNA (ON-TARGET plus Non-targeting siRNA
#1) were purchased from Dharmacon (Lafayette, CO). SignalSilence® siRNAs: Akt-2,
survivin, PARP and Stat-3 were from Cell Signaling Technology (Beverly, MA). Hif-1α
siRNA was purchased from Santa Cruz Biotechnology (Santa Cruz, CA). 1,1’carbonyldiimidazole

(CDI),

bis(2-hydroxyethyl)

disulfide

(DSOH),

spermidine

trihydrochloride, putrescine dihydrochloride and polyethylenimine (PEI, 25 kDA,
branched) were purchased from Sigma-Aldrich (St. Louis, MO). Dichloromethane
(99.9%, extra dry, AcroSeal™), tetrahydrofuran (THF, 99.85%, extra dry, AcroSeal™),
5-sulfosalicylic acid dihydrate (SSA), 1,7-diaminoheptane (DAH), dansyl chloride (5dimethylamino-1-naphthalenesulfonyl chloride, 98%) and 1,6-hexanediol were from
Acros Organics (Fair Lawn, NJ). L-Proline was from Alfa Aesar (Ward Hill, MA).
Spermine (SPM) was from MP BiomedicalsTM (Santa Ana, CA). BENSpm was
synthesized as previously described [155]. Recombinant human TRAIL/Apo2L protein
was purchased from PeproTech (Rocky Hill, NJ). All other reagents and chemicals were
obtained from Fisher Scientific or VWR International unless otherwise stated.

5.2.2 Synthesis and characterization of polymeric BENSpm prodrugs
Polymer analysis. NMR spectra were recorded on 400MHz Bruker NMR
spectrometer and chemical shifts (δ) were expressed in ppm. The composition of the
polymers was determined by elemental analysis from N, S, H and Cl content (Atlantic
Microlab, Inc., Norcross, GA). Weight-average molecular weight (Mw) and polydispersity
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index (PDI) of polymers were determined by Size Exclusion Chromatography (SEC)
using Agilent Technologies 1260 Infinity GPC-SEC system Agilent 1260 Infinity
equipped with isocratic pump, degasser, variable wavelength detector, thermostated
column compartment and autosampler from Agilent Technologies, Inc. (Santa Clara,
CA). Wyatt miniDWANTM TREOS multi-angle light scattering detector and Optilab® TrEX™ differential refractometer (Wyatt Technology Corporation, Santa Barbara, CA)
were used to determine the molecular weights. The columns used were single-pore
AquaGelTM columns PAA-202 and PAA-203 from PolyAnalytik (London, ON, Canada).
Sodium acetate buffer (0.3 M, pH 5.0) was used as the mobile phase at a flow rate of
0.3 mL/min. Astra 6.1 software was used for chromatographic data processing.
Synthesis of disulfide-containing BENSpm carbamate prodrug (DSS-BEN).
Reactions were carried out under inert atmosphere with the exclusion of water. Briefly,
DSOH (403.2 mg, 2.6 mmol) was dissolved in the mixture of CH2Cl2 (3.3 mL) and THF
(0.7 mL). Then, a solution of CDI (887.5 mg, 5.5 mmol) in 3.5 mL CH2Cl2 was added
dropwise to the ice cold solution of DSOH under nitrogen, and the reaction was kept on
thawing ice for 1 h. A solution of BENSpm (2.6 mmol, 640 mg) in CH2Cl2 was then
added and the reaction was kept reflux for 18 h at 45 °C. The reaction mixture was then
allowed to cool down to room temperature and the final product was precipitated out in
ether (25 mL) and washed twice with 20 mL ether. The residual solvents were removed
under vacuum. Water (25 mL) was then added and 6 N HCl was added dropwisely until
the material dissolved completely. The product was further dialyzed in 3.5 L water using
dialysis tubing with molecular weight cutoff = 3.5 kDa. The solvent was changed three
times against water with pH adjusted to 4.0 using HCl and finally dialyzed against
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distilled water. The product was then freeze-dried. A total of 371.8 mg of DSS-BEN
hydrochloride was obtained (yield= 34.2%).
Synthesis of non-reducible BENSpm carbamate prodrug (DCC-BEN). Reactions
were carried out under inert atmosphere with the exclusion of water. To a solution of
1,6-hexanediol (437.3 mg, 3.7 mmol) in 15 ml CH2Cl2 and 1 mL THF, a solution of CDI
(1,260 mg, 7.77 mmol) in 5 mL CH2Cl2 was added dropwise under stirring. The reaction
was kept on thawing ice bath for 1 h and 10 mL solution of BENSpm (904 mg, 3.7
mmol) in CH2Cl2 was added. The reaction mixture was then refluxed for 96 h. The
reaction product was then precipitated out in ether and dissolved in 25 mL water with
addition of HCl. Polymer was isolated by freeze-drying after extensive dialysis against
distilled water acidified with HCl to pH 4.0 and a final dialysis against distilled water. The
product was then freeze-dried to afford the final product as HCl salt of 143.3 mg DCCBEN (yield= 10%).

5.2.3 Polymer degradation studies
Degradation studies of DSS-BEN and DCC-BEN were carried out following
published procedures [340]. Briefly, DSS-BEN or DCC-BEN (10 mg) was dissolved in
900 µL of 0.1 M phosphate buffered D2O:acetone-d6 (3:2) and the solution was purged
with argon for 10 minutes. DTT (15 mg, 0.097 mmol) was added to the solution of DSSBEN or DCC-BEN immediately before NMR acquisition and the solution was incubated
at 25 °C. The extent of depolymerization was monitored using 1H NMR spectrum.
Percentage of polymer degradation was quantified by the reduction of integrated
methylene peaks next to carbamate at the N end in the polymer (3.35-3.55 ppm for
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DSS-BEN; 3.23-3.50 ppm for DCC-BEN) relative to the solvent peak of D2O (4.8 ppm)
in the sample. The degradation of polymers was plotted using curve fitting of nonlinear
regression model with first-order kinetic using GraphPad Prism software.

5.2.4 Cell culture
Murine melanoma cell line B16F10 and human embryonic kidney cell line HEK
293T cells were cultured in DMEM supplemented with 10% FBS. MDA-MB-231 human
breast cancer cells were cultured in RPMI supplemented with 10% FBS. HepG2 cells
were cultured in EMEM supplemented with 10% FBS. Human epithelial osteosarcoma
U2OS cells were cultured in DMEM supplemented with 2 mM L-Glutamine, 10% FBS,
1% Pen-Strep and 0.5 mg/ml G418. All cells were kept at 37 °C in incubator with 5%
CO2.

5.2.5 Polyamine analysis
Cells were treated with BENSpm (2.5 µg/mL), DSS-BEN (5.7 µg/mL) or DCCBEN (5.7 µg/mL) for 24, 48, 72 h. Intracellular polyamines (SPM, SPD, PUT) and
polyamine analog BENSpm were then extracted from cell pellets with 5% SSA, modified
with dansyl, and analyzed by reverse phase HPLC as described previously [341].
Briefly, cell pellet was harvested and cells were counted after treatment. For every 107
cells, 200 µL of 5% SSA was added. Cell suspension was then sonicated for 30 s,
allowed to stand on ice for 60 min and mixed once at 30 min. Cell debris was then
centrifuged for 5 min at 12,000 g. Fifty µL of the supernatant was transferred to a new
1.7 mL centrifuge tube and mixed with 50 µL of internal standard (40 µM DAH stock
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solution in 0.1 N HCl). Two hundred µL of saturated sodium carbonate and 200 µL of
dansyl chloride (10 mg/mL in acetone) were then added. The reaction mixture was then
vortexed for 10 s and incubated at 70 °C for 10 min and kept in dark. The samples were
then allowed to cool to room temperature and 100 µL of freshly prepared proline
solution (250 mg/mL) was added. The sample was then kept in dark for additional 10
min and loaded onto a Bond-Elut C18 column (1 mL, with adapters, Agilent Technology).
After loading, column was washed with two column volumes of 35% acetonitrile.
Dansylated polyamine samples were then eluted with 100% acetonitrile. Fifty µL of
samples were injected onto Eclipse Plus C18, 4.6 x 150 mm column (5 µm particle size,
Agilent Technology, Santa Clara, CA) and eluted by a two-solvent gradient using 1260
Infinity Quaternary LC System (Agilent Technology, Santa Clara, CA). Solvent A was 10
mM phosphate buffer, pH 4.4. Solvent B was 100% acetonitrile. At 2 mL/min, the
gradient began at 45% solvent A and progressed linearly to 80% solvent B over 14 min
and increased to 90% solvent B at 15 min and the gradient was maintained until 20 min,
then the gradient of solvent A decreased linearly to 45% till 26 min. Compounds were
detected using 1260 Infinity Fluorescence Detector (Agilent Technology, Santa Clara,
CA) with an excitation wavelength of 340 nm and an emission wavelength of 515 nm.
The data were collected and analyzed using OpenLAB CDS Chemstation Edition
software (Agilent Technology). BENSpm and polyamine analogue levels were then
calculated based upon internal standard levels and external standard curves. The
results for natural polyamines were expressed as amount of polyamine (ng) per ten
million cells (ng/107 cells). The relative BENSpm release (%) was calculated as the
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amount of BENSpm detected ([M]) in DSS-BEN treated cells divided by [M] in free
BENSpm treated cells: [M]DSS-BEN/[M]BENSpm × 100%.

5.2.6 EtBr exclusion assay
The ability of DSS-BEN and DCC-BEN to condense gWiz-Luc plasmid DNA was
determined by EtBr exclusion assay by measuring the changes in EtBr/DNA
fluorescence. One mL DNA solution at a concentration of 20 µg/mL in 10 mM HEPES
buffer (pH 7.4) was mixed with EtBr (1 µg/mL) and fluorescence was measured and set
to 100% using an excitation wavelength of 540 nm and an emission wavelength of 590
nm

using

QuantechTM

Fluorometer

from

Thermo

Scientific

(Waltham,

MA).

Fluorescence readings were then taken following a stepwise addition of a polycation
solution, and the condensation curve for each polycation was constructed.

5.2.7 Gel retardation assay and release of DNA from polyplexes under reductive
environment
Twenty µL polyplexes of DSS-BEN and DCC-BEN at different w/w ratios with 20
µg/mL gWiz-Luc DNA were loaded onto a 0.8% agarose gel containing 0.5 µg/mL EtBr
and run for 60 min at 120 V in 0.5× Tris/Borate/EDTA (TBE) running buffer. For testing
the disassembly of polyplexes in reductive environment, DSS-BEN and DCC-BEN
polyplexes were prepared at w/w ratio of 8, and were incubated with different
concentration of heparin -/+ GSH (20 mM) for 30 min before loaded onto the gel. The
gels were visualized under UV illumination on a KODAK Gel Logic 100 Imaging System.
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5.2.8 Size and zeta potential of polyplexes
Hydrodynamic diameter and zeta potential of DSS-BEN/DNA and DCCBEN/DNA polyplexes were determined by dynamic light scattering (DLS) using a
ZEN3600 Zetasizer Nano-ZS Particle Size Analyzer (Malvern Instruments Ltd.,
Worcestershire, UK). Polyplexes were prepared at a desired weight-to-weight (w/w)
ratio of 2, 4, 6, 8 by adding a pre-determined amount of polymer to the solution of
plasmid DNA in 10 mM HEPES (pH 7.4) to achieve a final DNA concentration of 20
µg/mL (200 µL). The polyplexes were incubated for 30 min at room temperature and
then diluted to 1 mL for size and zeta potential measurement.

5.2.9 Cytotoxicity
Toxicity was evaluated by MTS assay. The cells were seeded in 96-well
microplates at a density of 10,000 cells/well. After 24 h, culture medium was replaced
by 200 µL of serial dilutions of DSS-BEN or DCC-BEN in serum-supplemented medium
and the cells were incubated for 24 h. Then the solutions were aspirated and replaced
by a mixture of 100 µL serum-free media and 20 µL of MTS reagent (CellTiter 96®
AQueous Non-Radioactive Cell Proliferation Assay, Promega). After 1.5 h incubation,
the absorbance was measured using SpectraMax® M5e Multi-Mode Microplate Reader
(Molecular Devices, CA) at a wavelength of 490 nm. The relative cell viability (%) was
calculated as [A]sample/[A]untreated × 100%. The IC50 were calculated as the polymer
concentration that inhibits growth of 50% of cells relative to untreated cells. The IC50
values were calculated using GraphPad Prism.
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5.2.10 Determination of maximum tolerated dose (MTD) in mouse
Animal experiment was performed under a protocol approved by the University of
Nebraska Medical Center Institutional Animal Care and Use Committee. Fifteen-weekold female BALB/c nude mice were administered by tail vein injection of DSS-BEN or
DCC-BEN polyplexes (w/w 4) in 200 µL solution of 0.27 M mannitol in 5 mM HEPES at
concentrations of 0.8, 1.6, 2.4 and 3.2 mg/kg body weight for the corresponding
polymer. Mice were monitored for 3 h after injection for acute toxicity. MTD was
considered the highest dose in which no mortality was observed.

5.2.11 Transfection of DNA polyplexes
All transfection experiments were conducted in 48-well plates following a
previously published protocol [342]. Cells were seeded at a density of 50,000 cells/well
for MDA-MB-231 cells and HEK 293T cells, 40,000 cells/well for B16F10 cells and
20,000 cells/well for U2OS cells 24 h prior to transfection. On the day of transfection,
cells were incubated with the polyplexes (DNA conc. 2.35 µg/mL) in 170 µL of media
with or without 10% FBS. After 4 h incubation, polyplexes were completely removed and
the cells were cultured in complete culture medium for 24 h prior to measuring
luciferase expression. The medium was discarded and the cells were lysed in 100 µL of
0.5x cell culture lysis reagent buffer (Promega, Madison, WI) for 30 min. To measure
the luciferase content, 100 µL of 0.5 mM luciferin solution was automatically injected
into each well of 20 µL of cell lysate and the luminescence was integrated over 10 s
using GloMax 96 Microplate Luminometer (Promega, Madison, WI). Total cellular
protein in the cell lysate was determined by the bicinchoninic acid protein assay using
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calibration curve constructed with standard bovine serum albumin solutions (Pierce,
Rockford, IL). Transfection activity was expressed as relative light units (RLU)/mg
cellular protein ± SD (n=4).

5.2.12 Combination of DSS-BEN and DCC-BEN with TRAIL protein
MDA-MB-231 cells were seeded in 96-well plates at a density of 3,000 cells/well.
After 24 h, culture medium was replaced by 200 µL of serial dilutions of BENSpm, DSSBEN, DCC-BEN, TRAIL protein or the combination of each reagent with TRAIL in
serum-supplemented medium. Cells were further incubated for 120 h and medium was
changed once with fresh medium containing the same concentration of agents at 48 h.
Cell viability was then measured by MTS assay as described above. Quantification of
synergistic effect was evaluated by CI value calculated using CompuSyn software
(ComboSyn, Inc., Paramus, NJ).

5.2.13 Combination of DSS-BEN and DCC-BEN with different siRNAs
Reverse transfection method was used for siRNA knockdown. For each well of
96-well plate, particles containing siRNA were prepared by mixing 10 µL siRNA solution
in HBSS (conc. 200 nM, 2 pmol per well) and 10 µL DharmaFECT4 solution (0.1 µL
DharmaFECT4 solution in 10 µL HBSS), the mixture was allowed to stand for 20 min at
room temperature, and the total amount of 20 µL of siRNA complexes was added to
each well. Eighty µL of U2OS cell suspension containing either fresh medium,
BENSpm, DSS-BEN or DCC-BEN was then added to each well (50,000 cells/mL, 4,000
cells/well). Final concentration of BENSpm, DSS-BEN, or DCC-BEN was 2.5 µg/mL, 5.7
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µg/mL, 5.7 µg/mL, respectively (the doses of DSS-BEN and DCC-BEN are equivalent to
2.5 µg/mL BENSpm as determined by elemental analysis). The cells were further
incubated for 72 h and cell viability was then measured using CellTiter-Blue® Cell
Viability Assay (Promega, Madison, WI). Twenty µL of CellTiter-Blue reagent was added
into each well and incubated for 1.5 h in the incubator before recording the fluorescent
intensity (560Ex/590Em). The relative cell viability (%) was calculated as the relative
fluorescence [F]sample/[F]untreated × 100%. Data were analyzed by Student’s t-test, and
statistical significant difference was determined as p < 0.02.

5.3

Results and Discussion

Scheme 8. Synthesis of DSS-BEN

In order to design a self-immolative prodrug/gene delivery vector with high
content of BENSpm and intracellularly selective drug release mechanism, we designed
a simple two-step reaction. Activation of DSOH with CDI was followed by polymerization
with BENSpm via carbamate bond to form DSS-BEN polymer (Scheme 8). As the nondegradable counterpart, control polymer DCC-BEN without the disulfide bond was also
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synthesized for this study (Scheme 9). The synthesized DSS-BEN was expected to
undergo intracellular reduction by reacting with intracellular reducing reagents such as
GSH. The resulting thiolated intermediate is subject to intramolecular cyclization, which
generates BENSpm and a small cyclic molecule 1,3-oxathiolan-2-one (Scheme 10).

Scheme 9. Synthesis of DCC-BEN

5.3.1 Synthesis and characterization of DSS-BEN and DCC-BEN
DSS-BEN and non-degradable control DCC-BEN were synthesized using 1: 1
ratio of BENSpm with activated DSOH or 1,6-hexanediol in dichloromethane (Scheme 8
and Scheme 9). The success of the synthesis was confirmed by 1H-NMR (Figure 29)
and elemental analysis (Table 6). The patterns of peak broadening in the NMR spectra
for both DSS-BEN and DCC-BEN proved the formation of polymers [343]. From the
NMR spectra of DSS-BEN, ratio between the integration of peak a to peak c and e
equals 1: 2, which indicates the molar ratio between DSOH and BENSpm in the
polymer is around 1: 1. This result was also confirmed by the elemental analysis (2 mol
S in 1 mol DSOH, 4 mol N in 1 mol BENSpm), where the molar ratio between BENSpm
and DSOH equals 1: 1.14. These results suggested that the structure of the polymer is
mostly linear, however, due to the similar reactivity of the four secondary amines in
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BENSpm, it is not possible to determine which two amines were conjugated with the
DSOH based on our current detection methods. Similar result was also obtained with
DCC-BEN. In the NMR spectra of DCC-BEN, ratio of peak a to the addition of peak e
and peak f equals 1: 2.01. It can be calculated from the elemental analysis that the ratio
between BENSpm and hexanediol is 1: 1.22 (6 mol C in 1 mol hexanediol, 4 mol N and
13 mol C in 1 mol BENSpm), indicating the structure of the polymer is mostly linear, with
most of the polymer molecules terminated with hexanediol. Moreover, both polymers
contain equal amount of 44% BENSpm in the total weight (Table 6).

Scheme 10. Intracellular release mechanism of BENSpm from DSS-BEN.
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Figure 29. 1H-NMR and SEC spectra (small figures) of DSS-BEN (upper panel) and
DCC-BEN (lower panel).
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SEC (Figure 29) showed that DSS-BEN has the molecular weight around 3.8
kDa, while the DCC-BEN has lower molecular weight around 2.8 kDa. The low
molecular weight of the DCC-BEN partially explained the low yield (10%), as the
polymer was purified by dialysis with the molecular weight cutoff of 3.5 kDa. The dn/dc
value was determined experimentally as 0.1693 g/mL using a serial dilution of DSSBEN. It can be calculated from the molecular weight of both polymers that the number
of repeating unit (n) in the polymers (as shown in the structure of DSS-BEN in Scheme
8 and DCC-BEN in Scheme 9) equals 8 and 7 for DSS-BEN and DCC-BEN,
respectively. The polymerizations for both DSS-BEN and DCC-BEN have been carried
out at different temperatures (60 °C in chloroform and 45 °C in dichloromethane) and
using different reaction times (24, 48, 72, 96 h). However, no significant increase in the
molecular weight was observed under either elevated temperature or prolonged
reaction time.
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Figure 30. 1H NMR spectra of DSS-BEN (a) immediately after DTT addition in 0.1 M
pH 7.4 phosphate buffered D2O:acetone (3:2) at 25 °C; (b) after 16 h under the same
conditions; (c) degradation kinetics of DSS-BEN and DCC-BEN as calculated from
the 1H NMR.

The synthesized DSS-BEN was expected to undergo intracellular reduction by
reacting with intracellular reducing reagents such as GSH (Scheme 10). In order to
verify the proposed degradation mechanism of DSS-BEN, we investigated the
degradation kinetic of DSS-BEN in comparison with non-reducible DCC-BEN by 1H
NMR spectroscopy. With the presence of reducing agent DTT, multiple changes of the
chemical shift were observed from the NMR spectrum for DSS-BEN after 16 h
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incubation (Figure 30a and 30b). Reduction of peak c and peak e in Figure 30a
compared with the corresponding peaks in Figure 30b indicated the cleavage of
carbamate bond in the polymer backbone. Peak a and peak b in Figure 30b
represented the methylene peaks of the 1,3-oxathiolan-2-one cyclic product in the
reaction mixture. These results proved the proposed mechanism of intramolecular
cyclization of the self-immolate linkage. Oppositely, no difference in the spectrum was
observed for DCC-BEN under the same condition (data not shown), therefore verified
the need of designing self-immolative linker to facilitate the carbamate cleavage in the
polymer backbone. The degree of polymer degradation was calculated as the
percentage of reduction in the integration of peak a and e (Figure 30a) relative to the
peak integration at time 0 (immediately after DTT addition). As shown in Figure 30c,
curve fitting of the degradation result demonstrated that DSS-BEN depolymerization
followed first-order kinetic, with a rate constant of 3.5 × 10-3 min-1 and a corresponding
half-life of 198 min. This result is in well agreement with former reports that the
degradation of several self-immolative polymers containing similar cyclizing spacers
followed the kinetics between zero and first order [340, 344]. Co-incubation of DCCBEN with DTT resulted in no change in the NMR spectrum, and the calculated degree
of depolymerization was lower than 0.7% within 48 h. In all, these results demonstrated
the success of designing DSS-BEN as an effective self-immolative BENSpm prodrug.
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Table 6. Elemental analysis and calculated BENSpm content in DSS-BEN and DCCBEN
Weight %

C

H

N

S

Cl

BENSpm

DSS-BEN

44.1

7.9

10.2

13.3

8.5

44.0

DCC-BEN

49.7

9.3

10.1

NA

11.3

43.9

5.3.2 Prodrug function of DSS-BEN and DCC-BEN in various cell lines
The prodrug function of DSS-BEN and DCC-BEN was evaluated using HPLC to
quantitatively determine the intracellular levels of BENSpm and their effect of depleting
natural polyamines. We first verified that BENSpm could be released from the DSSBEN. As shown in Figure 31, BENSpm was detected in all cell lines tested after the
treatment with DSS-BEN, the highest amount of BENSpm release (67.5%) was
observed in U2OS cells followed 72 h treatment with DSS-BEN. In comparison, in all
untreated groups and DCC-BEN treated groups, no detectable amount of BENSpm was
observed, and thus was not depicted in the figure. This result confirmed the success of
degradable design of DSS-BEN, and the cell line-dependence of BENSpm release may
be caused by the difference in intracellular redox potential of the different cell lines.
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Figure 31. BENSpm release after 72 h treatment of DSS-BEN in different cell lines
determined by HPLC analysis.
In order to test the drug effect of DSS-BEN and DCC-BEN in comparison with
BENSpm, we further evaluated the intracellular polyamine levels. As shown in Figure
32a, BENSpm treatment efficiently depleted all the natural polyamines in B16F10 cells
when treated for at least 24 h. Treatment with DSS-BEN resulted in less polyamine
depletion because less than 15% of BENSpm was released from DSS-BEN in B16F10
cells. It is reasonable to conclude that limited BENSpm release and insufficient time
were the major causes for the compromised drug effect. In contrast, significant downregulation of polyamines was observed in U2OS cells after 72 h treatment with DSSBEN (Figure 32b), suggesting that BENSpm release from DSS-BEN is strongly cell linedependent. DCC-BEN failed to down-regulate the polyamines in both B16F10 cells and
U2OS cells. Although in MDA-MB-231 cells, DCC-BEN showed moderate downregulation of polyamines, it was considered less relevant with the BENSpm drug effect,
as no BENSpm release was detected 72 h after DCC-BEN treatment. In all, these
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results demonstrated that DSS-BEN could release BENSpm in the intracellular
environment and exhibit the drug effect for polyamine depletion.

Figure 32. Polyamine concentration in different cell lines determined by
HPLC analysis. (a) Time dependence of polyamine production in B16F10
cells after treatment with BENSpm, DSS-BEN or DCC-BEN; (b) Cell line
dependence of polyamine production in B16F10, MDA-MB-231 and U2OS
cells after 72 h treatment.
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5.3.3 DNA condensation and polyplex characterization
In order to test the function of DSS-BEN and DCC-BEN as gene delivery vectors,
we first investigated the ability of DSS-BEN and DCC-BEN to condense DNA using EtBr
exclusion assay (Figure 33a). Results showed that the parent BENSpm could not
condense DNA, indicated by the decrease of fluorescence intensity by less than 30%. In
contrast, DSS-BEN could efficiently condense DNA at w/w ratio > 4, however, DCCBEN only showed partial DNA condensation ability with only 50% decrease in
fluorescence intensity at w/w 10. Gel retardation assay showed that both DSS-BEN and
DCC-BEN could confine DNA to the start of the gel at w/w ratio higher than 0.5 and 1,
respectively (Figure 33b). However, fluorescence was observed in the wells even at the
highest w/w ratio (w/w 16) used. Because the fluorescence emission is a result of
intercalation of DNA by EtBr, it can be concluded that both DSS-BEN and DCC-BEN
formed lose polyplexes structure with DNA. Therefore the partially condensed DNA
molecules could remain active to interact with EtBr.
The DSS-BEN/DNA and DCC-BEN/DNA polyplexes were further analyzed for
the size and zeta potential (Figure 33c and 33d). DSS-BEN efficiently condensed DNA
into positively charged nanoparticles, with small particle sizes ~70-100 nm for all the
tested w/w ratios. However, DCC-BEN could not condense DNA at w/w 2 and the
particle sizes were above 100 nm at higher w/w ratios, with zeta potential generally
smaller than DSS-BEN polyplexes. Despite the structural similarity between DSS-BEN
and DCC-BEN, possible explanation for the discrepancy in DNA condensation ability is
that the flexible disulfide-disulfide exchange between DSS-BEN polymer chains may
facilitate encapsulation of DNA molecule as well as stabilization of the polyplexes [345].
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Figure 33. Physiochemical characterization of DNA polyplexes of DSS-BEN and
DCC-BEN polyplexes. (a) EtBr exclusion assay in 10 mM HEPES (pH 7.4); (b) gel
retardation assay; (c) hydrodynamic particle size and (d) zeta potential of the
polyplexes at different w/w ratios.
The effect of disulfide reduction mediated by GSH on the polyplexes against
polyelectrolyte exchange with heparin was evaluated by agarose gel electrophoresis
(Figure 34). We hypothesized that disulfide reduction of DSS-BEN would not only
facilitate the BENSpm release from the polymer, but also result in the intracellular
release of DNA from the polyplexes. In the absence of a reducing agent, both the DSSBEN and DCC-BEN polyplexes showed the first sign of DNA release at a heparin
concentration of 120 µg/mL. However, in the presence of 20 mM GSH that mimic the
redox status in the cell nuclei [346], DNA release was observed even without the
involvement of heparin. On the other hand, DCC-BEN polyplexes showed only slight
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difference in DNA release with the presence of GSH. These results confirmed our
hypothesis that disulfide-containing polymer DSS-BEN possesses the advantage of
redox-responsive DNA release in the intracellular environment. Therefore, DSS-BEN is
expected to have better transfection capability over DCC-BEN.

Figure 34. DNA release from DSS-BEN (upper panel) and DCC-BEN (lower panel)
polyplexes after incubation with heparin -/+ GSH (20 mM). All polyplexes were
prepared at w/w ratio 8.

5.3.4 Cytotoxicity
Toxicity associated with the use of polycations remains a major hindrance for
polycation-based gene delivery systems. One of the most effective strategies to reduce
the vector toxicity is to incorporate degradable moiety into the polymer backbone [347350]. Because of the bioreducible nature of DSS-BEN, we expected it to have lower
toxicity compared with the non-degradable control DCC-BEN. As shown in Figure 35,
IC50 values of DSS-BEN were generally 1.5-2 fold higher than DCC-BEN, and 3-4 fold
higher than PEI. Interestingly, DSS-BEN showed selective toxicity in MDA-MB-231, with
the IC50 comparable to that of DCC-BEN and PEI, whereas no cell line dependence was
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observed for DCC-BEN (IC50 12-20 µg/mL) and PEI (IC50 6-12 µg/mL). We then also
determined the MTD of DSS-BEN and DCC-BEN in BALB/c nude mice after i.v.
injection. The determined MTD was 1.6 mg/kg body weight for DSS-BEN and 0.8 mg/kg
body weight for DCC-BEN. MTD values of both BENSpm polymers was lower than the
reported MTD of PEI [351]. The fact that PEI was more toxic in vitro, while less toxic in
vivo suggests that other factors play a role in in vivo toxicity that are not captured in the
simple in vitro assays.

Figure 35. IC50 values of DSS-BEN, DCC-BEN and PEI in various cell lines. Cell
viability was measured by MTS assay after 24 h treatment.
5.3.5 Transfection
Luciferase transfection assay was used to assess the capability of DSS-BEN and
DCC-BEN as gene delivery vectors in various cell lines. Cells were transfected with
DSS-BEN or DCC-BEN polyplexes prepared at different w/w ratios in the presence or
absence of serum (Figure 36). DSS-BEN polyplexes showed comparable transfection
with PEI in all tested cell lines. Interestingly, DSS-BEN polyplexes showed low
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sensitivity to w/w ratio and the presence of serum, especially in B16F10 and HEK 293T
cells. In contrast, transfection of DCC-BEN polyplexes showed strong dependence on
w/w ratio. The transfection efficiency of DCC-BEN was consistently lower than that of
DSS-BEN polyplexes in all cell lines tested. Compared with DCC-BEN, higher
transfection efficiency of DSS-BEN can be explained by the redox-responsive nature of
the polymer, which can reduce the vector cytotoxicity and facilitate intracellular DNA
release. This result verified the success of designing DSS-BEN as an efficient gene
delivery vector.

Figure 36. Transfection activity of DSS-BEN and DCC-BEN polyplexes in different
cell lines. Results are shown as mean relative light unit (RLU)/mg protein ± SD (n=4).
5.3.6 Combination of DSS-BEN with nucleic acids and proteins
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BENSpm was reported to act synergistically with different therapeutic agents
such as 5-FU, PTX, histone deacetylase inhibitor MS-275 and recombinant proteins
TNF or TRAIL [199, 265, 352, 353]. In order to utilize the synergistic effect of BENSpm
in DSS-BEN, it is important to evaluate the effectiveness of DSS-BEN in combination
with different therapeutic agents, including siRNA or proteins.

CI value
TRAIL (ng/mL)

BENSpm + TRAIL

DSS-BEN +

DCC-BEN +

(100: 1)

TRAIL (100:1)

TRAIL (50:1)

10

0.31

1.10

1.82

20

0.27

0.90

0.95

30

0.26

0.68

0.73

40

0.29

0.57

0.74

50

0.25

0.41

0.84

Figure 37. Combination treatment of (a) BENSpm; (b) DSS-BEN and (c) DCC-BEN
with TRAIL in MDA-MB-231 cells. Dose axis of DSS-BEN and DCC-BEN was
normalized to corresponding BENSpm content, results were shown as relative cell
viability compared with non-treated cells ± SD (n=3).
The synergistic effect of DSS-BEN and TRAIL combination was determined in
MDA-MB-231 cells and compared with BENSpm and DCC-BEN. The cells were treated
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with DSS-BEN, DCC-BEN, BENSpm or TRAIL protein alone, or in the combination with
TRAIL at fixed weight ratios (BENSpm: TRAIL 100:1; DSS-BEN: TRAIL 100:1 and
DCC-BEN: TRAIL 50:1) for 120 h (Figure 37). CI value analysis showed that for all the
doses tested, BENSpm showed strongest synergistic effect with TRAIL (CI < 0.32).
DSS-BEN also showed synergism at high doses (CI = 0.41-0.68), while additive effect
was observed at low doses (CI = 0.9-1.10). Compromised synergism may be owing to
the less amount of BENSpm presented in DSS-BEN (44% weight loading) in
combination with TRAIL, compared with the BENSpm free drug and TRAIL combination.
Nevertheless, the results provided evidence of the prodrug functionality of DSS-BEN,
which could maintain the enhancing potential of BENSpm. In contrast, DCC-BEN only
showed slight synergism with TRAIL at high doses, as indicated by the CI values higher
than 0.73, and additive effect or antagonism at low doses tested (CI = 0.95-1.82).

Figure 38. Combination of BENSpm, DSS-BEN and DCC-BEN with different siRNAs
in U2OS cells for 72 h. Result are shown as mean cell viability ± SD (n=3). *p  <  0.02
indicates significant difference of cell viability in comparison with the (-) BENSpm
groups.
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Effect of DSS-BEN in combination with a panel of siRNAs was also investigated
(Figure 38). U2OS cell line was used for the combination study because of the
sensitivity to various siRNAs. A panel of siRNAs was chosen based on documented
effectiveness of the target in cancer treatment, either alone or in combination with
different therapeutic agents [354-364]. Doses of BENSpm, DSS-BEN or DCC-BEN used
contained the equivalent amount of BENSpm (2.5 µg/mL). The results showed that
BENSpm achieved the strongest cell growth inhibition (37%). DSS-BEN treatment
showed compromised growth inhibition to U2OS cells (15%). It is possible that longer
time is needed for efficient BENSpm release from DSS-BEN in order to take the drug
action. As predicted, DCC-BEN alone at the equivalent BENSpm dose did not show any
cell growth inhibition. This result supports our hypothesis that efficient BENSpm release
is important for the drug function. When the cells were treated with 20 nM of different
siRNAs, the data demonstrated that PLK-1 knockdown was lethal to U2OS cells (less
than 10% viable cells detected). Significant cell killing could also be observed in cells
treated with siRNA against Bcl-2, sHH, Akt2, and survivin. Combination of these siRNAs
with BENSpm, DSS-BEN and DCC-BEN did not lead to any significant enhancement of
siRNA activity. In contrast, the activity of siRNAs against PARP and Hif-1α was
enhanced by the combination with BENSpm and DSS-BEN by almost 20%.
Combination of the same siRNA treatments with DCC-BEN showed no additional
induction of cell killing. To summarize, results from the combination experiments proved
that DSS-BEN could well-maintain the synergistic potential of BENSpm.
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5.4

Conclusions
We have successfully developed polymeric prodrug of anticancer drug BENSpm

and confirmed its dual functionality as a prodrug and a gene delivery vector. Presence
of free BENSpm in cells treated with DSS-BEN confirmed the success of our selfimmolative linker strategy. We have also demonstrated that DSS-BEN can act
synergistically with several therapeutic agents, making it a promising delivery platform
for combination therapy in cancer by co-delivering a variety of therapeutic agents.
Moreover, this kind of self-immolative linker can also be incorporated into prodrug
design for a growing number of other similar drugs that possess cationic amines, such
as difluoromethylornithine or AMD3100, and thus may be applied to other diseases:
such as Barrett's esophagus and myelokathexis [365-367], for which polyamine drugs
are promising therapeutics. In all, DSS-BEN is a promising dual delivery vector, and
development of this kind of dual delivery platform warrants further investigation.
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ABSTRACT
DUAL DELIVERY SYSTEMS BASED ON POLYAMINE ANALOG BENSPM AS
PRODRUG AND GENE DELIVERY VECTORS
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Combination drug and gene therapy shows promise in cancer treatment.
However, the success of such strategy requires careful selection of the therapeutic
agents, as well as development of efficient delivery vectors. BENSpm (N1, N11bisethylnorspermine), a polyamine analogue targeting the intracellular polyamine
pathway, draws our special attention because of the following reasons: (1) polyamine
pathway is frequently dysregulated in cancer; (2) BENSpm exhibits multiple functions to
interfere with the polyamine pathway, such as to up-regulate polyamine metabolism
enzymes and down-regulate polyamine biosynthesis enzymes. Therefore BENSpm
depletes all natural polyamines and leads to apoptosis and cell growth inhibition in a
wide range of cancers; (3) preclinical studies proved that BENSpm can act
synergistically with various chemotherapy agents, making it a promising candidate in
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combination therapy; (4) multiple positive charges in BENSpm enable it as a suitable
building block for cationic polymers, which can be further applied to gene delivery.
In this dissertation, our goal was to design dual-function delivery vector based on
BENSpm that can function as a gene delivery vector and, after intracellular degradation,
as an active anticancer agent targeting dysregulated polyamine metabolism. We first
demonstrated strong synergism between BENSpm and a potential therapeutic gene
product TRAIL. Strong synergism was obtained in both estrogen-dependent MCF-7
breast cancer cells and triple-negative MDA-MB-231 breast cancer cells. Significant
dose reduction of TRAIL in combination with BENSpm in MDA-MB-231 cells, together
with the fact that BENSpm rendered MCF-7 cells more sensitive to TRAIL treatment
verified our rationale of designing BENSpm-based delivery platform. This was expected
to be beneficial for overcoming drug resistance in chemotherapy, as well as boosting
the therapeutic effect of therapeutic genes.
We first designed a lipid-based BENSpm dual vector (Lipo-SS-BEN) capable of
intracellular release of BENSpm using thiolytically sensitive dithiobenzyl carbamate
linker. Similar activity on SSAT enzyme induction by Lipo-SS-BEN compared with
BENSpm free drug verified the success of this prodrug design. Biodegradability of LipoSS-BEN contributed to decreased toxicity compared with nondegradable control
LipoBEN. However, decreased enhancement of TRAIL activity was observed for LipoSS-BEN when compared with BENSpm, indicating that the lipid-related toxicity
diminished the synergism. In addition, compared with LipoBEN and DOTAP, decreased
transfection efficiency of Lipo-SS-BEN demonstrated instability of Lipo-SS-BEN in
extracellular environment.
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In order to design a dual delivery vector with reduced vector toxicity and
improved linker stability, we employed dendritic polyglycerol (PG) as a safe carrier
backbone, onto which BENSpm was conjugated through carbamate linkage (PG-BEN).
Polymers with norspermine (PG-Nor) shell and amine-terminated PG (PG-NH2) were
synthesized as controls. The BENSpm dual vector PG-BEN demonstrated superior
gene delivery function, and showed decreased toxicity compared with the control
polymers. However, compared with BENSpm, which depleted all natural polyamines,
PG-BEN only down-regulated intracellular putrescine levels. In addition, no free
BENSpm was detected in PG-BEN treated cells. These results suggested that in order
to take full advantage of BENSpm anticancer activity, alternative linker chemistry needs
to be further explored.
We then incorporated bis(2-hydroxyethyl) disulfide as a self-immolative linker to
synthesize polymer prodrugs of BENSpm (DSS-BEN). The proposed mechanism of
BENSpm release from DSS-BEN contains two steps: disulfide bond is first cleaved in
the reducing intracellular space, then the intermediate further undergoes slow
intramolecular cyclization to release free BENSpm. Cell line-dependent BENSpm
release after DSS-BEN treatment was observed using HPLC analysis, demonstrating
the success of our linker strategy. DSS-BEN showed comparable transfection efficiency
as polyethylenimine and showed decreased toxicity in several cell lines compared with
the nondegradable control DCC-BEN. We further demonstrated that DSS-BEN could
act synergistically with several therapeutic agents, making it a promising delivery
platform for combination therapy in cancer. In all, we have successfully developed a
dual delivery vector based on BENSpm, which fulfills its function as a gene delivery
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vector as well as a prodrug of BENSpm, and possesses synergistic potential to
augment the effect of the co-delivered agents.
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